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Mutation or functional inactivation of tumour suppressors represents a key event in the 
transformation of cells and contributes to the development of cancer. P300 and CBP 
constitute two histone acetyltransferases with tumour suppressor functions that are 
frequently mutated or functional inactivated in cancer. Accordingly, after chemotherapy-
induced DNA damage, for example, p300 and CBP can co-activate the key tumour 
suppressor proteins p53 and TAp73, thereby contributing to tumour cell apoptosis. 
Here we investigated the impact of the co-factor protein iASPP on p300 and TAp73 function, 
after treatment of tumourigenic cell lines with the chemotherapeutic drug cisplatin. iASPP 
belongs to the ASPP-family, another class of co-factors that contribute to p53-family-
mediated apoptosis induction. Direct interaction of iASPP with p300 and TAp73 has been 
revealed before; functional consequences of these interactions remain elusive though and 
are therefore subject of our analyses.  
By investigating the consequences of stable iASPP knockdown in tumourigenic cell lines, we 
found that direct interaction of iASPP and p300 in cisplatin-treated cells led to enhanced 
protein stability of p300 and TAp73. Correspondingly, iASPP depletion resulted in decreased 
protein amounts of p300, reduced induction of pro-apoptotic p73 target genes and impaired 
apoptosis.  
BRMS1 represents a recently discovered E3 ubiquitin ligase for p300. Hence, we observed 
that BRMS1 depletion rescued the degradation of p300 and CBP in cisplatin-treated, iASPP-
depleted cells. Therefore, we hypothesize that BRMS1 inhibition constitutes the molecular 
mechanism underlying the increased protein stability of p300 in the presence of iASPP. 
Furthermore, we discovered, that malignant melanoma are characterized by down-regulated 
iASPP expression level. Follow-up studies on melanoma cell lines revealed that low iASPP 
expression correlated with decreased protein levels of p300 in cisplatin-treated cells. BRMS1 
knockdown in some of these cell lines could up-regulate p300 protein level, suggesting that 
down-regulation of iASPP expression leads to functional inactivation of p300 in melanoma, 
by allowing BRMS1 activity on p300. Treatment of the cells with the MKP-1 inhibitor BCI, 
could re-establish p300 level and induce p300-dependent apoptosis by yet unknown 
mechanisms.  
Summing up, iASPP represents a regulator for p300 function. It contributes to p300-
dependent apoptosis induction by enhancing its protein stability after DNA damage. Re-
establishment of p300 levels in low iASPP-expressing melanoma might represent a novel 






1.1 Regulation and function of TAp73 in cancer 
 
1.1.1 The p53-family and its role in the prevention of cancer 
In 2008 approximately 7.6 million people died due to cancer (according to fact sheet No.297 
of World Health Organization, www.who.int). Therefore, cancer accounts for 13% of all 
deaths world-wide. In general cancer is mostly caused by accumulation of DNA mutations 
and following, uncontrolled proliferation of the cells. Mutations in the DNA arise from virus 
infections, bad nutrition, stroke or other environmental insults (Hanahan and Weinberg 
2000). Moreover, gene aberrations or other genomic cancer pre-dispositions can be inherited 
(Garber and Offit 2005). However, non-cancerous cells harbour proteins, the so called 
guardians of the genome that become activated upon DNA damage or DNA mutations. Upon 
activation, these proteins trigger DNA repair mechanisms or, in case DNA is too severely 
damaged, induce the programmed death of a cell. One major protein family that prohibits 
such an accumulation of DNA mutations or replication errors constitutes the p53-family. 
The p53-family, consisting of p53, p73 and p63 are tumour suppressor proteins that control 
cell cycle arrest and apoptosis induction by transcriptional regulation of cell-cycle related and 
pro-apoptotic target genes (Smeenk, van Heeringen et al. 2008; Allocati, Di Ilio et al. 2012). 
Moreover, the p53-family is also involved in a variety of other cellular processes such as 
differentiation, senescence or autophagy due to transcriptional regulation of different sets of 
target genes (Levrero, De et al. 2000).  
As primarily p53 represents such a crucial inhibitor of cell transformation, 50% of all solid 
tumours display mutations in the p53 gene which lead to a functional inactivation of wild-type 
p53 (Soussi and Wiman 2007). Interestingly, these mutations comprise point mutations in the 
DNA-binding domain of the protein. They result in the expression of dominant-negative 
mutant p53, thus leading to the inactivation of the remaining wild-type p53 allele 
(Blagosklonny 2000; de Vries, Flores et al. 2002). Moreover, other tumours that retain wild-
type p53 expression often harbour mutations in up-stream regulators of the p53 signalling 
pathway, thereby mediating a functional inactivation of wild-type p53 as well (Michael and 





1.1.2 The p53-family members TAp73 and TAp63 constitute tumour suppressors. 
The p53-family members p73 and p63 also constitute transcription factors that can partially 
regulate the same set of p53 target genes. Therefore, in case of inactive, deleted or mutated 
p53, both proteins can trigger tumour cell apoptosis as well (Rufini, Agostini et al. 2011; 
Allocati, Di Ilio et al. 2012).  
P73 and p63 exist in multiple isoforms due to usage of an internal promoter and alternative 
splicing that occurs at the C-terminus of both proteins (Figure 1.1). In general, p73/p63 
isoforms can be classified into two main groups. The first group of p73/p63 isoforms 
constitute the N-terminal truncated variants called ∆Np63 and ∆Np73. ∆Np73 and ∆Np63 
may act in an oncogenic fashion, as they can inhibit the transcription factor function of p53, 
TAp73 and TAp63. Molecular basis of this inhibition represents the formation of dominant-
negative hetero-tetramers and by blocking the DNA-binding sites of p53-family target genes 
(Muller, Schleithoff et al. 2006).  
The other main group comprises the full-length TAp73/TAp63 isoforms that may function as 
classical tumour suppressors due to their overlapping function with wild-type p53. 
Interestingly, studies of TAp73 knockout mice revealed an important role for TAp73 in the 
prevention of chromosomal instability, as TAp73 knockout mice displayed increased 
aneuploidy in oocytes (Tomasini, Tsuchihara et al. 2008). Thus, TAp73-mediated apoptosis 
of chromosomal instable cells represents another aspect of the presumed tumour 
suppressive functions of TAp73, which contribute to the prevention of cell transformation. 
Perhaps due to this dual role of tumour suppressor and proto-oncogene, the p73 and p63 
gene loci are rarely mutated in cancer (Rufini, Agostini et al. 2011). Therefore, classical 
chemotherapy such as treatment of tumour cells with the chemotherapeutic drug cisplatin, 
Etoposide or doxorubicin mostly leads to an activation of TAp73 (or wild-type p53, if present), 
followed by induction of apoptosis and regression of the tumour (Irwin, Kondo et al. 2003). 
 
1.1.3 Structure of the p73 and p63 gene locus 
P73 and p63 proteins were discovered in 1997 and 1998, over 30 years after the discovery 
of p53 (Kaghad, Bonnet et al. 1997; Yang, Kaghad et al. 1998). Both proteins consist of a 
transactivation domain (TA) and a central DNA-binding domain (DBD) at the N-terminus 
(Figure 1.1). The DNA-binding domains of p53, p73 and p63 share high sequence homology 
which partially explains the overlapping sets of target genes (Lokshin, Li et al. 2007; 




oligomerisation domain (OD) at the C-terminus, as the proteins bind to DNA as tetrameric 
complexes.  
Due to intensive splicing at the C-terminus, p73 and p63 exist in multiple isoforms that differ 
in their C-terminal structure. Therefore, full-length isoforms of p73/ p63, called p73α/ 
p63α and p73β/ p63β contain a unique SAM motif (sterile-α-motif) for mediation of protein-
protein interactions, as well as an extra, C-terminally located inhibitory domain (ID) that 
regulates their transcriptional activity (Luh, Kehrloesser et al. 2013).  
Instead of the N-terminal located transactivation domain of TA-isoforms, ∆N isoforms 
comprise a more internally localized transactivation domain. (Liu, Nozell et al. 2004; Toh, 
Logette et al. 2008). Therefore, ∆Np73 and ∆Np63 can actively regulate specific sets of 
target genes as shown for example for ∆Np63α in keratinocytes (King, Ponnamperuma et al. 
2003; Birkaya, Ortt et al. 2007).  
The composition of the p73 gene locus is depicted in Figure 1.1 (Deyoung and Ellisen 2007).  
 
 
Figure 1.1. Structure of the p73 gene locus. The gene locus of p73, including the exon 
structure as well as both promoter regions and the multiple splicing events at the C-terminus 
are displayed. Moreover the domain structure of TAp73 and ∆Np73 is illustrated. The exons 
which resemble the corresponding domains can be identified due to equal colouring. P1, P2 
= promoter region; TA = transactivation domain; DBD = DNA-binding domain; OD = 
oligomerisation domain; SAM = sterile-α-motif, ID = Inhibitory domain. 
Modified after DeYoung and Ellison, 2007
TA DBD OD SAMTAp73 ID







1.1.4 The expression pattern of p73 isoforms in cancer 
In-vitro experiments have elucidated a more pronounced role for p73 in cancer compared to 
p63. The expression of different p73 isoforms is highly variable in different tumour types, 
though. In detail, high expression of full-length TAp73 isoforms was found in breast cancer, 
hepatocellular carcinoma and prostate cancer so far (Tannapfel, Wasner et al. 1999; Zaika, 
Kovalev et al. 1999; Su, Ouyang et al. 2009). In leukemia, high expression of short TAp73 
isoforms (for example TAp73δ and TAp73ε) was commonly detected although functional 
consequences of this over-expression remain elusive (Tschan, Grob et al. 2000). In contrast, 
expression of the oncogenic splice variant ∆Np73 is often found to be up-regulated in 
neuroblastoma as well as in head and neck cancer (Guan and Chen 2005; Faridoni-Laurens, 
Tourpin et al. 2008). Interestingly, this over-expression of ∆Np73 isoforms can be correlated 
with increased chemoresistance in the respective tumours (Kovalev, Marchenko et al. 1998; 
Casciano, Mazzocco et al. 2002; Douc-Rasy, Barrois et al. 2002). However, most gene 
expression studies lack a differentiating analysis of the expression levels of single p73 
isoforms. Therefore, future analyses will have to dissect the expression patterns of the pro- 
and anti-apoptotic p73 isoforms in more detail. 
 
1.1.5 The role of TAp73 in classical chemotherapy 
TAp73 becomes active by treatment of the cells with classical chemotherapeutics such as 
cisplatin, Taxol, doxorubicin or Etoposide, leading to TAp73-dependent apoptosis induction 
(Irwin, Kondo et al. 2003). The underlying signalling pathway of chemotherapy-induced, 
TAp73-mediated apoptosis induction involves a cascade of different proteins (Figure 1.2). 
In summary, most of the TAp73-activating agents primarily cause DNA damage that is 
recognized then by the multiprotein complex MRN (protein complex of Mre11-Rad50-NBS1) 
(Uziel, Lerenthal et al. 2003; Adams, Medhurst et al. 2006). As a consequence, the kinases 
ATM and ATR are getting activated, leading to the phosphorylation and therefore activation 
of multiple down-stream kinases (Basu and Krishnamurthy 2010). Most importantly, the p73-
specific, tyrosine receptor kinase c-abl is activated by ATR/ ATM which in turn triggers a 
variety of phosphorylation events that ultimately lead to the accumulation and activation of 
TAp73 (Agami, Blandino et al. 1999; Gong, Costanzo et al. 1999). Next, TAp73 
transcriptionally up-regulates a panel of pro-apoptotic BH3-only genes, including puma and 
pig3 (Fontemaggi, Kela et al. 2002; Melino, Bernassola et al. 2004). Due to this accumulation 
of pro-apoptotic proteins, BAX and BAK proteins are released from inhibitory complexes with 




translocate to the mitochondria which in turn initiates the release of cytochrome C and 
therefore the induction of tumour cell apoptosis. Figure 1.2 summarizes TAp73-mediated 
apoptosis after DNA damage. 
 
Figure 1.2. Overview of TAp73-dependent apoptosis induction after DNA damage. 
After DNA damage, the MRN complex senses DNA lesions. Thereafter, a cascade of 
kinases, including ATM and c-abl are activated, leading to the transduction of the signal. 
Finally, TAp73 is activated by post-translational modifications, which subsequently mediates 
the transcriptional up-regulation of pro-apoptotic genes. Next, due to increased expression of 
pro-apoptotic proteins, BCL-2 is repressed and Bax and Bak can translocate to the 
mitochondria. Hence, cytochrome C is released, which induces apoptosis. 
 
Nevertheless, classical chemotherapy often confers high toxicity and patients frequently lack 

























2007; Galluzzi, Senovilla et al. 2012). Moreover, some tumours acquire chemoresistance 
during repeating cycles of chemotherapy. One of the causes for this acquired 
chemoresistance constitutes the functional inactivation of TAp73 due to an newly developed 
interaction of TAp73 with oncogenes such as mutant p53, or due to mutations of TAp73-
associated co-factors (Bergamaschi, Gasco et al. 2003; Rufini, Agostini et al. 2011). As 
TAp73-signalling pathways are not completely understood, new insights into the regulation of 
TAp73 function might provide the basis for new cancer therapies, thus circumventing 
chemoresistance that derives from an inactivation of TAp73 function.  
 
1.1.6 Regulation of TAp73 function by phosphorylation  
As the p53-family can mediate a variety of different cellular responses, the activity and 
specific functions of the proteins have to be tightly regulated. Two of the major mechanisms 
that regulate the function and activity of the p53-family comprise associating proteins (so 
called co-factors) and post-translational modifications. Post-translational modifications of the 
p53-family include phosphorylation, acetylation, ubiquitination, sumoylation and neddylation 
(Bode and Dong 2004; Conforti, Sayan et al. 2012). Some of the post-translational 
modifications are commonly found for all p53-family members, others are family-member 
specific.  
A variety of different post-translational modifications for TAp73 have already been described. 
As we investigated the effects of cisplatin on TAp73 function, we will only summing up the 
most relevant post-translational modifications of TAp73 that have been elucidated after 
cisplatin treatment (Figure 1.3). 
As shortly mentioned before, a major phosphorylation event of TAp73 is mediated by the 
tyrosine receptor kinase c-abl. Thus, active c-abl kinase represents a pre-requisite for TAp73 
protein accumulation, followed by activation of the protein and TAp73-mediated apoptosis 
induction (Agami, Blandino et al. 1999; Gong, Costanzo et al. 1999). In detail, upon DNA 
damage, especially after cisplatin treatment of primary and tumour cells, c-abl gets activated, 
thus leading to a direct interaction of c-abl and TAp73. Consequently, c-abl phosphorylates 
TAp73 at tyrosine residue 99 (Yuan, Shioya et al. 1999) which triggers activation and 
accumulation of the protein.  
In parallel, the p38 MAP kinase pathway is activated by c-abl as well, due to the 
phosphorylation and activation of the MKK3/ MKK6 kinases. In turn, MKK3 and MKK6 
activate p38 by its phosphorylation at threonine residue 180 and tyrosine residue 182 then 




Subsequently, p38 contributes to the induction and stabilization of TAp73 protein by 
phosphorylating its threonine residues 167, 442 and 482 (Sanchez-Prieto, Sanchez-Arevalo 
et al. 2002; Rufini, Agostini et al. 2011). Interestingly, inhibition of p38 is already sufficient to 
prevent accumulation and induction of TAp73 protein, even in the presence of active c-abl 
protein (Sanchez-Prieto, Sanchez-Arevalo et al. 2002). This validates again the importance 
of phosphorylation-mediated regulation of TAp73 activity. 
Furthermore, after previous phosphorylation of TAp73 by c-abl and p38, the TAp73 co-factor 
protein YAP-1 gets activated by c-abl-mediated phosphorylation as well, thereby inducing a 
complex formation of YAP-1 and TAp73 (Strano, Monti et al. 2005; Lapi, Di Agostino et al. 
2008; Levy, Adamovich et al. 2008). Due to this complex formation, the p73-specific ubiquitin 
ligase Itch cannot bind and hence proteasomally degrade TAp73 anymore. Thus, TAp73 
protein further accumulates due to an increase in its protein stability (Levy, Adamovich et al. 
2007).  
 
1.1.7 Regulation of TAp73 function by p300-mediated acetylation  
After phosphorylation-mediated activation of TAp73, the histone acetyltransferase (HAT) 
p300 can associate with YAP-1/ TAp73 complexes, followed by p300-mediated acetylation of 
TAp73 at lysine residues 321, 327 and 331 (Costanzo, Merlo et al. 2002; Mantovani, Piazza 
et al. 2004). Hence, acetylation of TAp73 represents another type of post-translational 
modification that further contributes to the enhanced protein stability of TAp73. The 
underlying molecular mechanism of acetylation-mediated stabilization of TAp73 protein 
comprises the dissociation of the ubiquitin ligase MDM2 from TAp73, as binding of MDM2 
and p300 to TAp73 is mutually exclusive (Zeng, Li et al. 2000). Furthermore, p300-mediated 
acetylation increases the DNA-binding affinities of TAp73. This partially explains the 
increased half-life of the TAp73 protein, as chromatin association of proteins anticipates their 
fast proteasomal degradation in general (Sakaguchi, Herrera et al. 1998; Martinez-Balbas, 
Bauer et al. 2000; Costanzo, Merlo et al. 2002). 
Apart from enhanced protein stability, acetylation of TAp73 also dictates which groups of 
target genes are regulated by TAp73, as p300-dependent acetylation of TAp73 promotes the 
transcriptional up-regulation of pro-apoptotic p73 target genes instead of cell-cycle related 
genes (Costanzo, Merlo et al. 2002). This can be partially explained by the fact that this 
multi-protein complex consisting of p300, YAP-1 and TAp73 is localized to genomic p73 
target sites. This causes p300-dependent acetylation of adjacent histones and formation of 




bridging factor for the basal transcription machinery with specific transcription factors, as well 
(Chen and Li 2011), chromatin localization of TAp73-YAP-1-p300 complexes also triggers 
the recruitment of RNA polymerase II to specific promoter regions. Consequently, 
transcriptional up-regulation of pro-apoptotic p73 target genes is initiated (Levy, Adamovich 
et al. 2008). Examples for genes that are transcriptionally up-regulated by TAp73-YAP-1-
p300 complexes comprise the pro-apoptotic target genes puma, pig3, bax, fas or noxa 
(Fontemaggi, Kela et al. 2002; Koeppel, van Heeringen et al. 2011). Figure 1.3 summarizes 
the TAp73/ p300-mediated apoptosis induction after cisplatin treatment (Lunghi, Costanzo et 
al. 2009). 
 
Figure 1.3. Activation of TAp73-mediated transcription after cisplatin treatment. A. 
Upon cisplatin treatment of cells, c-abl and p38 are activated to mediate phosphorylation and 
therefore activation of TAp73. Moreover, c-abl-mediated YAP-1 phosphorylation triggers 
TAp73-YAP1 complex formation in PML bodies, followed by the recruitment of p300 to the 
protein complex and subsequent acetylation of TAp73. B. Additionally, p300 acetylates 
adjacent histones of p73 target gene promoters. This leads to the DNA-binding of the TAp73-
YAP-1-complex to pro-apoptotic p73 target gene promoters as well as to the recruitment of 
the basal transcription machinery to pro-apoptotic p73 target gene promoters. (Ac = 
acetylation; P = phosphorylation, RNA Pol II = RNA polymerase II).  
 
Of note, TAp73-YAP-1-p300 complexes accumulate in distinct nuclear structures due to their 
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composed of various proteins that form distinct, metabolically stable, sub-nuclear domains. 
The localization of TAp73-YAP-1-p300 complexes to the so called PML-bodies further 
protects p300, TAp73 and YAP-1 from proteasomal degradation, thus contributing to active 
transcription of p73-target genes and the subsequent induction of apoptosis (Bernassola, 
Salomoni et al. 2004; Shima, Shima et al. 2008).  
Besides post-translational modifying enzymes, p73 as well as p53 and p63 can associate 
with other co-factor proteins that regulate distinct cellular responses of the p53-family as well. 
One important co-factor family constitutes the ASPP-family (apoptosis-stimulating proteins of 
p53 or ankyrin repeat-, SH3-domain- and proline-rich region-containing proteins). 
 
 
1.2. The ASPP-family  
 
1.2.1 Structure and interaction properties of the ASPP-family 
The ASPP-family consists of three proteins, called ASPP2, ASPP1 and iASPP (Figure 1.4). 
The first protein of the ASPP-family that has been associated with p53 function was the 
ASPP2-deriving fragment 53BP2. Interestingly, binding studies between 53BP2 and wild-
type p53 revealed that direct interaction of both proteins has a crucial impact on p53-
mediated apoptosis induction (Iwabuchi, Bartel et al. 1994; Iwabuchi, Li et al. 1998; Lopez, 
Ao et al. 2000). Furthermore, point mutations in the DNA-binding domain of the p53 gene, 
that result in the expression of mutant p53, often target residues that mediate the interaction 
between p53 and 53BP2 (Iwabuchi, Bartel et al. 1994; Tidow, Veprintsev et al. 2006; Ahn, 
Byeon et al. 2009). Therefore, it is assumed that loss of 53BP2-p53 interaction due to p53 
mutation contributes to the functional inactivation of wild-type p53 in respect to apoptosis 
induction. Follow-up analysis of the gene locus coding for 53BP2 (TP53BP2) revealed that 
53BP2 only represents the N-terminal truncated version of the full-length protein ASPP2 and 
that ASPP2 has similar impact on p53 function than 53BP2 has. 
Structural analysis discovered that all ASPP-family members are similarly composed of 
multiple ankyrin repeats, a SH3 domain and a proline-rich region at the C-terminus (Slee, 
Gillotin et al. 2004) (Figure 1.4). At the N-terminus, ASPP1 and ASPP2 harbour a unique α-
domain region that is thought to mediate ASPP1- and ASPP2-specific protein-protein 
interactions (Sullivan and Lu 2007). Hence, ASPP1 and ASPP2 share a higher sequence 





Interestingly, in lower vertebrates such as Caenorhabditis elegans only one ASPP-family 
member is present (encoded by the ape-1 gene) that displays high sequence homology to 
human iASPP (Bergamaschi, Samuels et al. 2003). Thus, the genes encoding for ASPP1 
and ASPP2 (PPP1R13B and TP53BP2) are likely to be evolved from the iASPP encoding 
gene PPP1R13L (Trigiante and Lu 2006). 
 
Figure 1.4. Structure of the ASPP-family (modified after Sullivan and Lu 2007). 
All ASPP-family members, ASPP1, ASPP2 and iASPP, comprise a proline-rich region (Pro), 
multiple ankyrin repeats (Ank) and a SH3-domain (SH3) at the C-terminus. Moreover, 
ASPP1 and ASPP2 harbour a specific α−domain (α) at the N-terminus. IASPP is an inhibitor 
of p53-mediated apoptosis whereas ASPP1 and ASPP2 are stated as enhancers of p53-
dependent apoptosis induction (the numbers left indicated the number of total amino acids 
and therefore size of the protein). 
 
The main function of the ASPP-family includes the mediation of protein-protein interactions, 
the formation of multi-protein complexes and sub-cellular re-localization as well as 
conformational changes of their interaction partners (Sullivan and Lu 2007). By yeast two 
hybrid screens, several interaction partners of the ASPP-family have been identified. Apart 
from interaction of ASPP with BCL2, p65/RelA and Protein phosphatase 1 (PP1) (Naumovski 
and Cleary 1996; Yang 1999; Llanos, Royer et al. 2011), all ASPP family members are able 
to interact with the p53-family (Iwabuchi, Bartel et al. 1994; Samuels-Lev, O'Connor et al. 
2001). Interestingly, binding studies of the ASPP- and p53-family members revealed that 
iASPP has a more potent binding affinity towards p63 and p73 than ASPP1 and ASPP2 
display, which indicates that iASPP possesses p63/p73-specific functions (Robinson, Lu et 
al. 2008). On the other hand, binding affinities of ASPP2, ASPP1 and iASPP to p53 are 
equally strong.  
 
1.2.2 The role of ASPP1 and ASPP2 as co-factors for the p53-family  
ASPP1 and ASPP2 interactions with p53 result in enhanced DNA-binding properties of p53 










(Samuels-Lev, O'Connor et al. 2001). Similar results were obtained from EMSA assays using 
recombinant ASPP1/2 proteins together with p73 and p63 (Samuels-Lev, O'Connor et al. 
2001). In contrast, cell-cycle regulated target genes such as p21 or Mdm2 remained 
unaffected from ASPP1 and ASPP2 over-expression.  
Moreover, a triple complex formation between ASPP1/2, p300 and p53 in untreated as well 
as doxorubicin-treated U2OS cells was discovered (Gillotin and Lu 2011). Luciferase assays 
using different combinations of these proteins showed that this triple interaction enhanced 
the transcriptional up-regulation of the pro-apoptotic gene pig3 whereas p21 expression 
remained unaffected. Therefore, ASPP1 and ASPP2 seem to promote the pro-apoptotic 
function of p53 by enhancing the interaction of p300 and p53.  
In line, likely due to the p53-dependent, pro-apoptotic function of ASPP1 and ASPP2, mRNA 
levels of both genes were also found to be frequently down-regulated in tumours deriving 
from breast cancer patients (Bergamaschi, Samuels et al. 2003; Sullivan and Lu 2007). 
Down-regulation of ASPP1/2 mRNA levels is caused by methylation events at the promoter 
sequences and might partially explain the frequently observed functional inactivation of wild-
type p53 in breast cancer beside the expression of mutant p53 (Mori, Ito et al. 2004; Liu, Lu 
et al. 2005; Zhao, Wu et al. 2010). 
 
1.2.3 The cellular function of iASPP 
In contrast to ASPP1 and ASPP2, iASPP is declared an inhibitor of p53-mediated apoptosis 
(Bergamaschi, Samuels et al. 2003). Originally, iASPP has been discovered as a smaller 
fragment called RAI (RelA-associated inhibitor) by using RelA/p65 as a bait in yeast two 
hybrid screens (Yang 1999). Follow-up studies depicted a role for RAI in the inhibition of the 
transcriptional activity of NF-κB (Takada, Sanda et al. 2002) (Figure 1.5). Four years later 
Bergamaschi and colleagues discovered that RAI only represents a small fragment of the 
full-length protein iASPP that is encoded by the PPP1R13L gene (Bergamaschi, Samuels et 
al. 2003). Of note, polymorphisms at the 19q13.2 gene locus (consisting out of PPP1R13L, 
ERCC1 and CD3EAP) have been previously associated with increased susceptibility for the 
development of lung, breast and rectal cancer (Nexo, Vogel et al. 2008; Chae, Kim et al. 
2013; Yin, Guo et al. 2013), thereby implicating a possible role of iASPP in the formation of 
cancer. 
Expression studies of various iASPP fragments revealed an overall cytoplasmic localization 
of iASPP due to a nuclear export signal that is located at the N-terminus (Slee, Gillotin et al. 




iASPP, likely due to the existence of a N-terminal truncated isoform of iASPP, called iASPP-
SV (Zhang, Diao et al. 2007). Besides, it is not clear yet, whether iASPP-SV constitutes a 
new isoform of iASPP or whether it is a cleavage-product of the full-length iASPP protein. 
Chikh and colleagues found a nuclear localization of iASPP in mouse keratinocytes as well, 
whereas in most of the analysed human cell lines iASPP localizes to the cytoplasm (Slee, 
Gillotin et al. 2004; Chikh, Matin et al. 2011). Interestingly, nuclear localization of iASPP 
could be clearly correlated with its inhibitory role on p53 and p63 function (Trigiante and Lu 
2006). Thus, sub-cellular localization of iASPP seems to have a crucial impact on its specific 
function. 
In U2OS and MCF-7 cells over-expression of full-length iASPP results in a complex 
formation of iASPP and wild-type p53 followed by inhibition of p53-dependent apoptosis after 
UV-radiation or treatment of the cells with cisplatin (Bergamaschi, Samuels et al. 2003) 
(Figure 1.5). Interestingly, it was recently discovered that a direct interaction of iASPP with 
PP1 seems to represent a pre-requisite for this inhibitory effects of iASPP, as mutation of the 
PP1 interacting phenylalanine residue 815 of the iASPP protein sequence prohibited the 
inhibitory effects of iASPP over-expression on p53 function (Llanos, Royer et al. 2011). 
Nevertheless, an over-expression of iASPP in breast cancer tissue and breast cancer cell 
lines is frequently detected (Bergamaschi, Samuels et al. 2003). Moreover, rat transformation 
assays using full-length iASPP constructs revealed that iASPP can enhance cell 
transformation by its co-operation with Ras, E1A or E7, thereby validating iASPP as a proto-
oncogene. Hence, the protein name iASPP can be also interpreted as the inhibitory form of 
apoptosis stimulating proteins of p53.  
To assess the cellular role of iASPP more closely, iASPP knockout mice were recently 
generated. As the most obvious phenotype, iASPP knockout mice display abnormalities in 
the formation of the skin (Notari, Hu et al. 2011). Closer analysis of different skin layers 
revealed a crucial role for iASPP in prevention of cellular senescence, as loss of iASPP 
yielded a higher rate of differentiated keratinocytes (Notari, Hu et al. 2011). Further analysis 
showed that the underlying mechanism of iASPP function in skin homeostasis resulted from 
its nuclear interaction with p63, thus revealing a new, p53-independent function of iASPP 
(Chikh, Matin et al. 2011). In the analysed keratinocytes and MEF cells, iASPP was able to 
interact with TAp63 and ∆Np63, thereby inhibiting the transcription factor function of both 
proteins (Chikh, Matin et al. 2011; Notari, Hu et al. 2011), which in turn inhibited the 




Interaction of iASPP with p53 and p63 suggests similar, functional interactions between 
iASPP and p73, as direct binding of both proteins has been elucidated before. (Robinson, Lu 
et al. 2008). However, consequences of iASPP expression on TAp73 function have not been 
addressed yet. Moreover, a complex formation of iASPP and the TAp73 co-activator p300 
has already been proven in untreated as well as doxorubicin-treated U2OS and H1299 cells 
(Gillotin and Lu 2011). The functional consequences of iASPP-TAp73 and iASPP-p300 
interaction remain elusive, though. Figure 1.5 summarizes the cellular functions of iASPP 
that have been described so far. 
 
Figure 1.5. Protein interactions and cellular functions of iASPP. iASPP interacts with a 
set of different proteins in the cell. One of the most important interactions represents the 
iASPP-p53 complex formation that leads to a functional inhibition of p53. The direct 
interaction of iASPP with PP1 represents a pre-requisite for this inhibitory function of iASPP 
on p53. In contrast, a fragment of iASPP (RAI) can also interact and inhibit RelA/ p65 and 
therefore NF-κB activity, which is likely to result in apoptosis induction. Additionally, in 
keratinocytes, iASPP binds to TAp63 and ∆Np63 which in turn leads to an inhibition of p63 
function and therefore iASPP-mediated regulation of skin homeostasis. Other interactions of 
iASPP comprise those with p73 and p300; however, functional consequences of such 
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1.3 Function and regulation of the KAT3-family members p300 and CBP 
 
1.3.1 P300 and CBP mainly function as histone acetyltransferases 
As stated before, p300 and CBP constitute another important co-factor family that modulates 
p53-family-dependent apoptosis induction (Costanzo, Merlo et al. 2002; Iyer, Chin et al. 
2004). P300 and CBP are involved in various cellular processes. However we will only 
summarize the most relevant functions in respect to this project. 
Originally, both proteins have been found as binding partners for the viral proteins E1A and 
E7 that cause the functional inactivation of p300 and CBP (Arany, Sellers et al. 1994; 
Eckner, Ewen et al. 1994). This at least suggests that CBP and p300 could be classified as 
tumour suppressor proteins. Moreover, aberrant CBP fusion products with other transcription 
factors are detected in haematopoietic malignancies due to chromosomal translocations 
(Blobel 2002; Chan, Hannah et al. 2011). Consequently, these aberrant fusion proteins (for 
example MOZ-CBP) induce the functional inactivation of wild-type CBP and constitute one of 
the main causes for the development of some subtypes of acute and chronic myeloid 
leukemia (Satake, Ishida et al. 1997; Crowley, Wang et al. 2005). P300, instead, lacks a 
significant role in the development of haematopoietic malignancies. However, mutations and 
truncations at the EP300 gene locus are frequently found in solid tumours of epithelial origin, 
which indicates a crucial role for p300 in tumour suppression as well (Gayther, Batley et al. 
2000; Goodman and Smolik 2000). 
P300 and CBP form the KAT3-family of histone acetyltransferases. Besides, they might 
possess additional, histone-acetylating independent functions (Shi, Pop et al. 2009).  
Acetylation of N-terminal lysine residues of histones is normally associated with 
transcriptionally active genes, as histone acetylation results in a relaxation of chromatin 
packaging. P300- and CBP-mediated histone acetylation comprises acetylation of all 4 core 
histones (H2A, H2B, H3 and H4). Especially acetylation of H3K14, H3K18, H4K5 and H4K8 
has been found to be solely mediated by p300 and CBP (Schiltz, Mizzen et al. 1999; Bedford 
and Brindle 2012) (Figure 1.6). Moreover, after DNA damage, p300 is likely to acetylate 
specific lysine residues, such as H3K56, thereby actively contributing to the recruitment of 
DNA repair complexes to DNA lesions (Das, Lucia et al. 2009; Ogiwara and Kohno 2012).  
Apart from their function as histone acetyltransferases, p300 and CBP mediate the 
acetylation of over 100 non-histone proteins (Goodman and Smolik 2000). Therefore, p300 




histone proteins is correlated with enhanced protein stability of the target protein as well as 
increased activity (Kalkhoven 2004). However, some single acetylation events, such as 
p300-mediated acetylation of the high mobility protein HMGI(Y), are functionally related to an 
inhibition of the respective target protein activity (Munshi, Merika et al. 1998). 
 
Figure 1.6. Overview of the main cellular substrates and functions of p300 and CBP. 
Main function of p300 and CBP constitutes histone acetylation of different N-terminal lysine 
residues, thereby influencing transcription processes. Interaction of p300/ CBP with different 
proteins, including p53, p73, E2F or NF-κB, induces acetylation of the respective target 
protein and therefore contributes to the regulation of cell survival, apoptosis and cell cycle 
events. Moreover, p300 and CBP are involved in the control of different processes such as 
embryonic development and cell differentiation. Another important aspect of p300/CBP 
function represents their indirect involvement in DNA repair mechanisms. Recruitment of 
DNA repair proteins to DNA lesions (through specific histone marks) as well as the 
transcriptional regulation of DNA repair genes (for example brca1 and rad51) constitutes the 
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1.3.2 In-vivo studies of p300 and CBP confirm their important role in development 
P300 and CBP knockout mice (p300-/- and CBP-/-) die around day E11.5 and are therefore 
embryonic lethal (Yao, Oh et al. 1998; Goodman and Smolik 2000; Kung, Rebel et al. 2000). 
One major cause for death of the embryos derives from severe developmental defects, such 
as open neural tubes. Moreover, an increased portion of heterozygous p300 knockout mice 
(p300+/-) die during development as well. This underscores the importance of the expression 
level of p300, as small changes in its expression are already likely to impair the full 
functionality of the p300 protein (Roth, Shikama et al. 2003; Shikama, Lutz et al. 2003).  
Furthermore, p300 and CBP heterozygous knockout mice display similar as well as unique 
phenotypes. P300+/- mice show defects in the development of the heart, while CBP+/- mice 
display retarded growth and craniofacial abnormalities (Oike, Takakura et al. 1999; Kung, 
Rebel et al. 2000; Shikama, Lutz et al. 2003). Thus, in-vivo studies confirm an indispensable 
role of p300 and CBP in development and differentiation, and studies of heterozygous mice 
uncover overlapping but also unique functions of p300 and CBP. Figure 1.6 summarizes the 
role of p300 in different cellular responses. 
 
1.3.3 P300 as a co-activator of the p53-family 
As already mentioned, P300 and CBP mediate the acetylation of the p53-family, as well. 
Acetylation of the p53-family leads to the inhibition of the proteasomal degradation as well as 
the promotion of the transcriptional activity of p53, p73 and p63. This enhanced activity of the 
p53-family derives from increased DNA-binding affinities of p300-acetylated proteins to their 
respective genomic target sites (Figure 1.6). Furthermore, due to a re-localization of p300-
p53 and p300-TAp73 complexes in metabolically stable PML bodies, p300-target protein 
complexes are fully protected from MDM2- and Itch-mediated degradation (Bernassola, 
Salomoni et al. 2004; Iyer, Chin et al. 2004), thus leading to a further increase of TAp73 and 
p53 protein levels.  
Apart from direct acetylation of the p53-family, p300 and CBP also contribute to their 
activation in an indirect way, as both histone acetyltransferases are involved in the 
acetylation of TAp73- and p53-modifying proteins as well. In detail, p300-mediated 
acetylation of the TAp73-activating kinase c-abl has been described to cause a nuclear 
translocation of the protein. Hence, this sub-cellular re-localization of c-abl triggers a 
functional turn-over from its anti-apoptotic role in normally growing cells to its pro-apoptotic 




TAp73 activation, through acetylation and re-localization of the TAp73-phosphorylating 
kinase c-abl.  
Moreover, p38 is acetylated by p300 and CBP, which promotes a prolonged stabilization and 
therefore activation of the p38 kinase, thereby subsequently contributing to p53-family 
dependent induction of apoptosis (Pillai, Sundaresan et al. 2011).  
Surprisingly, Zeng and colleagues reported that p300 is indeed crucial for TAp73 function; 
however, mutations in the HAT domain of p300 did not abolish its activating function of 
TAp73 (Zeng, Lee et al. 2001). Therefore, it is not clear yet, whether p300 needs to exhibit 
full HAT activity to display its effects on the p53-family.  
As p300 and CBP can also acetylate and therefore activate transcription factors that promote 
uncontrolled proliferation and tumour growth, such as NF-κB, Stat-1 or c-myc, the question 
remains how p300 and CBP function is specifically regulated (Chen, Williams et al. 2005; 
Faiola, Liu et al. 2005; O'Shea, Kanno et al. 2005). One regulatory mechanism comprise a 
panel of post-translational modifications of the p300 and CBP proteins that influence their 
activity, protein level and interacting partners. 
 
1.3.4 Regulation of p300 by post-translational modifications 
P300 and CBP are subjects to a high degree of post-translational modifications including 
phosphorylation, acetylation and ubiquitination (Chen and Li 2011). Although p300 and CBP 
level can also be regulated by various mechanisms, we will only summarize the most 
important post-translational modifications that are relevant for our project. 
As both proteins can regulate the acetylation and therefore the activity and protein stability of 
over 100 non-histone proteins, their specific function, cellular localization and expression 
levels have to be tightly regulated. Phosphorylation of p300 and CBP represents one of the 
major regulatory mechanisms.  
Phosphorylation of p300 is conducted by various kinases, including p38, Akt, ERK1/2 and 
PKC and mostly occurs on serine residues at the C-terminus (Chen and Li 2011). In general, 
phosphorylated p300 can be detected in quiescent and proliferating cells (Yaciuk, Carter et 
al. 1991). Moreover specific phosphorylation events of p300 can be detected in specific 
phases of the cell-cycle, as these modifications are mediated by cyclin-dependent-kinases 




Phosphorylation of serine residue 89 of p300 was shown to be mediated by protein kinase C 
(PKC). Interestingly, this PKC-mediated phosphorylation at the consensus sequence RXXS 
results in inactive p300 and CBP proteins (Yuan and Gambee 2000) (Figure 1.7). Apart from 
this inhibitory phosphorylation, all other phosphorylation events that have been elucidated so 
far support the HAT activity of p300 and CBP.  
One of the best-studied post-translational modification that enhances the HAT activity of 
p300 represents Akt- and p38-mediated phosphorylation at serine residue 1834 (Wang, Han 
et al. 2013) (Figure 1.7). Interestingly, phosphorylation of p300 by Akt kinase alone promotes 
the HAT activity of p300. This is followed by p300-mediated acetylation of NF-κB and 
subsequent transcriptional activation of NF-κB target genes (Huang and Chen 2005; Liu, 
Denlinger et al. 2006). Therefore, Akt-mediated phosphorylation of p300 results in the 
promotion of its pro-survival functions due to the activation of NF-κB signalling pathways. 
In contrast, after UV radiation or cisplatin treatment, p300 is simultaneously phosphorylated 
by Akt and p38 kinases at serine residue 1834, followed by the activation and later 
degradation of the p300 protein. However, this phosphorylation and degradation of p300 only 
occurs after the generation of DNA lesions that are substrates for nucleotide excision repair. 
Thus, Akt- and p38-mediated phosphorylation of p300 represents a mechanism for activation 
and recruitment of the nucleotide excision repair process (Wang, Han et al. 2013). Chemical-
based inhibition of one of these kinases is sufficient to inhibit p300 degradation. This is 
followed by impaired removal of UV-induced DNA lesions and diminished nucleotide excision 
repair.  
Moreover, Poizat and colleagues showed that p38-mediated phosphorylation of p300 
contributes to apoptosis induction in cardiac cells after doxorubicin treatment. This 
represents another cooperation of p38 and p300, thus controlling the level of p300-mediated 
apoptosis induction (Poizat, Puri et al. 2005).  
Another important phosphorylation event of p300 is mediated by nuclear ERK1/ ERK2 
(Gusterson, Brar et al. 2002). ERK1/ ERK2 is known to be activated after treatment of cells 
with DNA damaging agents such as Etoposide and cisplatin (Ley, Balmanno et al. 2003). 
Surprisingly, although activation of ERK1/ ERK2 is normally correlated with proliferation and 
cell survival, cisplatin treatment activates ERK1/ ERK2, which contributes then to the 
induction of apoptosis (Wang, Martindale et al. 2000; Pearson, Robinson et al. 2001). 
However, it is not elucidated yet under which conditions ERK1/ ERK2 phosphorylates p300 
at the C-terminal residues serine 2279, serine 2315 and serine 2366 (Chen, Wang et al. 




mediated phosphorylation of p300 will have and if the function of ERK1/ ERK2 in cisplatin-
dependent apoptosis induction is related to p300 at all.  
Besides phosphorylation as a regulatory mechanism of p300 and CBP activity, acetylation of 
both proteins promotes their HAT activity and elevates their expression levels. Auto-
acetylation of p300 and CBP occurs at multiple lysine residues in the HAT domain, including 
lysine 1499 (for p300) and lysine 1535 (for CBP) (Thompson, Wang et al. 2004; Stiehl, Fath 
et al. 2007; Bhatia, Tykodi et al. 2009) (Figure 1.7). As auto-acetylation was found to be 
indispensable for p300/ CBP co-activator function, detection of acetyl-p300/ CBP can be 
utilized as a read-out for active p300 protein.  
Figure 1.7 summarizes the most important post-translational modifications of p300 including 
localization of important interaction sites as well as the responsible kinase that mediates the 
specific post-translational modification (Teufel, Freund et al. 2007; Chen and Li 2011). 
 
 
Figure 1.7. Post-translational modifications of p300. The domain structure of p300 (N- to 
C-terminus) and the most important post-translational modifications are shown. The 
responsible enzymes that mediate these modifications are depicted above the respective 
residues. Below the domain structure and the most important interaction sites of some target 
proteins are displayed. (Ac = Acetylation, P = Phosphorylation, CH = cysteine-histidine-rich 
region, Q/P = glutamine-proline-rich region, TAZ = transcriptional adapter zinc binding 
domain, KIX = CREB-binding domain; ZZ = zinc finger domain, PHD = Plant homeo domain, 
Bromo = bromodomain; IBID = Interferon-binding domain) 
 
TAZ1 KIX Bromop300 PHD HAT ZZ TAZ2 IBID
332 417 566 646 1053 1156
2050 2096
1726 18061284 1517
1198 1278 1664 1705
CH2CH1 CH3 Q/P-rich region
Modified after Teufel et al, 2007



























1.3.5 The protein stability of p300 is mainly regulated by poly-ubiquitination. 
Poly-ubiquitination and therefore degradation of p300 and CBP represents another important 
post-translational modification that regulates the overall protein levels as well the stability of 
both proteins. Surprisingly, only a few studies discovered p300/CBP-specific E3 ubiquitin 
ligases yet. One such candidate ubiquitin ligase is Mdm2, which is one of the most important 
ubiquitin ligases of wild-type p53 (Haupt, Maya et al. 1997; Kubbutat, Jones et al. 1997). 
Mdm2 forms a complex with p300 (Grossman 2001), but this direct interaction does not 
trigger the proteasomal degradation of p300. Instead, Mdm2 is acetylated by p300, thereby 
preventing the degradation of p53 (Wang, Taplick et al. 2004). 
Another E3 ubiquitin ligase that has been implicated in mediating the proteasomal 
degradation of p300 constitutes SCFFbx3 (Shima, Shima et al. 2008). SCF E3 ligases are 
composed of Skp1, Cul1 and a F-box protein, the latter in this case Fbx3, dictating the 
substrate specificity of the respective SCF E3-ligase complex (Ahn, Byeon et al. 2009; 
Skaar, Pagan et al. 2013). Interestingly, association of p300 with PML in sub-nuclear 
structures inhibits the proteasomal degradation of p300 by SCFFbx3 (Shima, Shima et al. 
2008). Thereafter, when p300 completed its role in transcriptional regulation of specific 
cellular responses, it is subjected again to SCFFbx3-mediated proteasomal degradation in the 
nucleus. However, it is not clear yet which molecular signalling events lead to SCFFbx3-
mediated degradation of p300 then (Shima, Shima et al. 2008).  
As expected, phosphorylation of p300 indirectly regulates its protein stability and therefore its 
proteasomal degradation, as well. Chen and colleagues showed that over-expression of the 
protein phosphatase 2A (PP2A) subunit B56γ augments the proteasomal degradation of 
p300 (Chen, St-Germain et al. 2005). Hence, after treatment of cells with the histone 
deacetylase inhibitor valproic acid, B56γ directly binds to p300 and subsequently de-
phosphorylates the protein. Thereafter, p300 is proteasomally degraded, thus possibly 
contributing to the frequently observed teratogenic side effects of valproic acid treatment, as 
p300 represents a key factor in embryonic development (Chen, St-Germain et al. 2005; Lloyd 
2013). 
However, major evidence for p300/CBP-specific E3-ubiquitin ligases is missing. Very 
recently Liu and colleagues discovered that the breast cancer metastasis gene 1 (BRMS1) 
harbours specific E3 ubiquitin ligase activity towards p300, thus identifying a new regulatory 





1.4. BRMS1 as a candidate ubiquitin ligase for p300/CBP 
 
1.4.1 BRMS1 constitutes an E3 ubiquitin ligase for p300. 
Breast cancer metastasis gene 1, shortly termed BRMS1, is a recently discovered gene that 
plays a role in the inhibition of metastasis whereas it has nearly no effect on tumourigenesis 
(Seraj, Samant et al. 2000; Shevde, Samant et al. 2002). Over-expression studies of BRMS1 
in breast, lung and melanoma cell lines elucidated its crucial role in prevention of invasion, 
loss of cell adhesion and migration by transcriptional repression of metastatic genes 
(Robertson, Coleman et al. 1996; Shevde, Samant et al. 2002; Cicek, Samant et al. 2004). 
Molecularly, the BRMS1-mediated down-regulation of target genes is likely to derive from its 
interaction with the Sin3A-complex that can deacetylate histones and therefore silence gene 
expression (Hurst, Xie et al. 2013). However, further experiments still needs to prove that 
BRMS1-SIN3a complex formation indeed controls the transcriptional repression of pro-
metastatic target genes. 
In lung cancer cell lines, Liu and colleagues found that BRMS1 can also bind to p65, a 
subunit of the NF-κB complex, thereby leading to its transcriptional repression (Liu, Smith et 
al. 2006). It has been elucidated before that the transcriptional activity of NF-κB is mainly 
regulated through acetylation of p65 at lysine residue 310. P300 mediates this acetylation of 
p65, thereby inhibiting the IkBα-mediated cytosolic sequestration of NF-κB and thus 
positively regulating the transcription of NF-κb target genes (Chen, Williams et al. 2005). In 
contrast, BRMS1 was shown to mediate the deacetylation of lysine 310 due to recruitment of 
HDAC1 to p65 (Liu, Smith et al. 2006; Cicek, Fukuyama et al. 2009). Therefore, BRMS1 and 
p300 exhibit opposing roles in the regulation of NF-κB activity.  
Correspondingly, it was recently discovered that BRMS1 can poly-ubiquitinate and therefore 
proteasomally degrade p300 (Liu, Mayo et al. 2013). BRMS1 is likely to possess E3 ubiquitin 
ligase activity due a conserved CXD motif that is structurally related to the bacterial Ipah E3 
ligase family. Consequently, protein levels of p300 and BRMS1 are inversely correlated in 
lung cancer cell lines. Moreover, they also claimed that BRMS1-mediated degradation of 
p300 contributes to the suppression of metastasis, as mutation of the CXD motif is 
correlating with a higher migration potential of the cells. However, these observations did not 
correlate with a modulation in p300 activity, although some single reports proposed a role for 
p300 in the promotion of metastatic transformation before (Debes, Sebo et al. 2003; Li, Luo 




1.4.2 BRMS1 and its implication in melanoma development 
Expression studies of the BRMS1 substrate p300 in melanoma lack so far. However, the 
anti-metastatic protein BRMS1 has been investigated in melanoma before, as their 
metastatic potential constitutes one of the most critical features of malignant melanoma. 
Initially, an increased frequency of chromosome breakage, mutations or deletion of 
chromosome 11 was discovered in malignant melanoma samples (Robertson, Coleman et al. 
1996). Later, it was revealed that BRMS1 is encoded at chromosome 11q13 and that 
mutations at this genomic site might result in down-regulated BRMS1 expression. Analysis of 
the mRNA expression levels of BRMS1 revealed that BRMS1 expression is indeed 
dramatically down-regulated in the process of melanocyte transformation to primary tumours, 
followed by complete loss of BRMS1 expression in metastatic cell lines (Shevde, Samant et 
al. 2002). However, comparative analysis of protein and mRNA levels of BRMS1 in breast 
cancer cells revealed that mRNA level and protein level of BRMS1 do not always correlate, 
likely due to at least four different splice variants of BRMS1 (Hurst, Xie et al. 2009).  
Lately, Slipicevic and colleagues revealed a more differentiated role for BRMS1 in malignant 
melanoma due to its sub-cellular localization within the cell (Slipicevic, Holm et al. 2012). 
While cytoplasmic BRMS1 expression accounts for an increased disease-free survival and 
decreased metastatic potential, nuclear localization of BRMS1 in some melanoma correlated 
with increased invasion and migration potential as well as a poor survival rate.  
Concluding, it remains to be revealed whether BRMS1 constitutes an E3 ligase for p300 in 
melanoma as well. Therefore, it might be of therapeutical interest to investigate whether 
p300 expression in melanoma is altered, and whether changes in p300 expression correlate 










1.5 Scope of the thesis  
Although p300 and CBP are implicated in many different signalling pathways and cellular 
responses, dissection of the molecular mechanisms underlying the specific regulation of 
p300/CBP function remains largely elusive. It has been revealed that p300 is frequently 
inactivated in certain tumour types (Goodman and Smolik 2000; Kalkhoven 2004). Therefore, 
re-establishment of p300 function might contribute to a re-activation and therefore 
enhancement of p53-family-dependent apoptosis induction. However, the question remains 
which treatment strategies re-establish p300 function and which types of tumours might 
respond to these treatments then.  
Recently Gillotin and colleagues discovered a direct interaction of p300 with iASPP, another 
co-factor protein that can regulate p53-family dependent apoptosis induction (Gillotin and Lu 
2011). However, the functional consequences of this interaction still need to be understood. 
Moreover, direct interaction of iASPP and TAp73 has been shown before; nevertheless, the 
functional consequences of iASPP expression on TAp73 function remain elusive as well 
(Bell, Dufes et al. 2007; Robinson, Lu et al. 2008). 
Therefore, this project investigated the impact of iASPP-p300 interaction on the expression 
levels and acetyltransferase function of p300, in untreated as well as cisplatin-treated tumour 
cell lines. We hypothesized that iASPP might change the expression levels, sub-cellular 
localization or cellular function of p300 and that iASPP-p300 interaction might have 
implications for new therapy approaches in specific tumour types. Furthermore, we analysed 
the effects of iASPP expression on TAp73 expression levels and transcription factor function, 
as well as TAp73-mediated tumour cell apoptosis, as TAp73 constitutes an important 









2.1.1 Technical devices 
 
Table 2.1. Technical Devices 
Device Company 
Autoclave DX-200 Systec GmbH 
Blotting chamber Biozym, Hessisch Oldendorf, Germany 
Cell counting chamber Neubauer improved Brand, Wertheim, Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific, Waltham, MA, United States 
Chemiluminescence imager Chemocam HR 
16 3200 
Intas Science Imaging Instruments, 
Göttingen, Germany 
Electrophoresis system Mini Format 1D, for 
SDS-PAGE 
Bio-Rad Laboratories, Hercules, CA, United 
States 
FACS machine Guava PCA-96 Base System Millipore, Merck, Darmstadt, Germany 
Freezer -20°C Liebherr, Bulle, Switzerland 
Freezer -80°C Heraeus, Thermo Scientific 
Incubator for bacteria Memmert, Schwabach, Germany 
Incubator for cell culture Hera Cell 150 Heraeus, Thermo Scientific, Waltham, MA, United States 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Liquid nitrogen tank LS 4800 Taylor-Wharton, Theodore, AL, United States 
Magnetic stirrer MR Hei-Standard Heidolph, Schwabach, Germany 
Microscope Axovert 40C Zeiss, Oberkochen, Germany 
Microwave Cinex, Lippstadt, Germany 
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Mini Centrifuge MCF-2360 LMS, Tokyo, Japan 
PCR machine for qPCR CFX96, C1000 Bio-Rad Laboratories 
PCR machine Thermocycler T personal Biometra, Göttingen, Germany 
Personal computer Dell, Round Rock, TX, United States 
pH-meter WTW-720 WTW, Weilheim, Germany 
Pipets Eppendorf Research Series 2100 
(0.1-2.5 μL; 2-20 μL; 20-200 μL; 100-1000 
μL) 
Eppendorf, Hamburg, Germany 
Power supply unit Powerpack P25T Biometra 
Refrigerator 4°C Liebherr 
Roller RM5 V-30 CAT, Staufen, Germany 
Rotator PTR 300 Grant Instruments 
Scales Acculab ALC-6100.1 Sartorius, Göttingen, Germany 
Scales LE623S Sartorius, Göttingen, Germany 
Shaker PROMAX 2020 Heidolph 
Sonication device Bioruptor Diagenode, Liège, Belgium 
Spectrophotometer NanoDrop ND-1000 PeqLab, Erlangen, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Timer Oregon Scientific, Portland, OR, United States 
UV-transilluminator Intas UV system Gel Jet 
Imager Intas Science Imaging Instruments 
Vacuum pump IBS Integra Biosciences, Fernwald, Germany 
Vortex Genie 2 Scientific Industries, Bohemia, NY, United States 









Table 2.2. Consumables 
Product Company 
96-well plates for qPCR 4titude, Wotton, United Kingdom 
Bacteria culture dishes Sarstedt, Nümbrecht, Germany 
Bacteria culture vials (14 cm) Becton Dickinson 
Cell culture dishes (10 cm, 15 cm) Greiner, Frickenhausen, Germany 
Cell culture plates (6-well, 12-well) Greiner, Frickenhausen, Germany 
Cell scraper (16 cm, 25 cm) Sarstedt, Nümbrecht, Germany 
Cryo tubes Cryoline Nunc, Thermo Scientific 
Filter tips (10 µL) Starlab, Hamburg, Germany 
Filter tips (20 µL, 200 µL, 1000 µL) Sarstedt, Nümbrecht, Germany 
Parafilm Brand 
Pipet tips (10 µL, 20- 200 µL, 1000 µL) Greiner, Frickenhausen, Germany 
Protran nitrocellulose transfer membrane Whatman, Dassel, Germany 
Reaction tube (0.2 mL) Sarstedt, Nümbrecht, Germany 
Reaction tube (0.5 mL, 1.5 mL, 2.0 mL) Eppendorf, Hamburg, Germany 
Falcon reaction tube (15 mL, 50 mL) Greiner, Frickenhausen, Germany 
Safe-lock reaction tube (1.5 mL) Eppendorf, Hamburg, Germany 
Sterile filter (0.2 µM and 0.45 µM) Millipore, Merck 
Syringe, 1 mL, 5 mL, 10 mL, 50 mL Henke-Sass, Wolf, Tuttlingen, Germany 
Syringe canules (23G) B.Braun, Melsungen, Germany 
Transparent sealing foil for 96-well plate 4titude, Wotton, United Kingdom 
Whatman paper Whatman, Dassel, Germany 
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2.1.3 Chemicals and reagents 
 
Table 2.3. Chemicals and reagents 
Substance Article No. Company 
Albumin Fraction V (Bovine Serum Albumine, 
BSA) for molecular biology 80763 Roth 
Ammonium persulfate (APS) p.a. 9592.1 Roth 
Ammonium sulphate ((NH4)2SO4) >99.5%, 
p.a. 3746.1 Roth 
Ampicillin K029.1 Roth 
Bromophenol blue B0126 Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) 
>99%, p.a., ACS 52391 Roth 
Chloroform, Rotipuran 3313.1 Roth 
Complete Mini Protease Inhibitor EDTA free 11836170001 Roche, Basel, Schweiz 
Dimethyl sulfoxide (DMSO) A3672 AppliChem 
Dithiotreitol (DTT) 6908.3 Roth 
deoxynucleotide triphosphates (dNTPs) Cat 1201,1202, 1203, 1204 Primetech 
Ethanol 99.8% K928 Roth 
Ethanol 99.9% p.a. (EtOH) 1009672500 Merck 
Sodium Ethylene diamine tetraacetatic acid 
(Na-EDTA) 80432 Roth 
Ethylene glycol tetraacetic acid (EGTA) 3054.2 Roth 
Formaldehyde, 37% solution 4979.1 Roth 
Glucose X997.2 Roth 
Glycerol, >99%, p.a. 3783.2 Roth 
Glycerophosphate (ß-) dissodium salt 
hydrate G5422 Sigma-Aldrich 
Glycine, >99%, p.a. 3908.3 Roth 
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Glycogen, molecular biology grade HP51.2 Roth 
Guava ICF Cleaning Solution 4200-0140 Millipore, Merck 
HEPES Pufferan >99%, p.a. 3908.3 Roth 
Hydrogen chloride (HCl) 0992.1 Roth 
Igepal (NP-40), Ca-630 I3021 Sigma-Aldrich 
Isopropanol 6752.4 Roth 
Lithium chloride P007.1 Roth 
Lipofectamine 2000 11668-019 Invitrogen, Life Technologies 
Magnesium chloride hexahydrate (MgCl2 x 
6H2O) 
2189.1 Roth 
Methanol >99% (MetOH) 4627.2 Roth 
Milkpulver, blotting grade T1454 Roth 
Nonidet P-40 substitute (NP-40) 74385 Fluka 
Phenol solution (pH 8.0) for ChIP P4557 Sigma-Aldrich 
Phenol solution (pH 4.3) for RNA P4682 Sigma Aldrich 
Potassium chloride (KCl) A1362 Applichem 
Potassium hydrogenphosphate (KH2PO4) 3904.1 Roth 
Prestained Protein Ladder 26616 Fermentas, Thermo Scientific 
Propidium iodide solution (PI), 1 mg/mL in 
water P4864 Sigma-Aldrich 
Protein-G-Sepharose,4 Fast Flow 17-0618-01 GE healthcare 
Protein A/G Agarose Sc2003 Santa Cruz 
Puromycin P9620 Sigma-Aldrich 
Random Hexamer Primer (0.2 µg/µL) SO142 Thermo Scientific fisher 
Rotiblock 10x concentrate A151.1 Roth 
Rotiphorese Gel 30 3029.1 Roth 
Sodium acetate (NaAc) 6773.1 Roth 
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Sodium hydrogen carbonate (NaHCO3), 
>99,5%, p.a., ACS, ISO 6885.1 Roth 
Sodium chloride (NaCl) 3957.2 Roth 
Sodium deoxycholate 30970 Applichem 
Sodium dodecyl sulphate (SDS) 161-0302 Biorad 
Sodium hydrogenphosphate monohydrate 
(NaHPO4 x H2O), p.a. 
K300.2 Roth 
Sodium (di-) hydrogenphosphate dihydrate 
(Na2HPO4 x 2H2O) >99%, p.a. 
4984.1 Roth 
Sodium hydroxide (NaOH), pellets 221465 Sigma-Aldrich 
SYBR green S7567 Invitrogen, Life Technologies 
Tetramethylethylenediamine (TEMED) 11.073.100.100 Merck 
Trehalose dihydrate 22515 Usb corporation, Cleveland 
Trisamine (Tris) Pufferan, >99% p.a. 4855.3 Roth 
Triton X-100, molecular biology grade A4975 Applichem 
Trizol 15596-018 Invitrogen, Life Technologies 
Tryptone 8952.2 Roth 
Tween 20 A4974.0500 Applichem 
Yeast extract 2363.2 Roth 
 
Table 2.4. Chemotherapeutics and inhibitors 
Name Target/ Function Article No. Company 
SB203580 P38 EI-286 Biomol 
MG132 Proteasome 474791 Merck-Calbiochem 
BCI MKP-1, MKP-3 B4313 Sigma-Aldrich 
CTB P300, CBP C6499 Sigma-Aldrich 
Cisplatin (CDDP) DNA intra/  Teva 




Cycloheximide Proteinsynthesis inhibitor C1988 Sigma 
Etoposide Topoisomerase II inhibitor E1283 Sigma 
z-VAD-FMK Caspases ALX-260020M005 Enzo 
 
 
2.1.4 Buffer and Solutions 
 
Table 2.5. Buffer and Solutions 
 
6x Laemmli buffer 




Bromophenol blue 0.02% 
dissolved in H2O   
 
Western blot washing buffer 
(PBST) 
NaCl 24.00 mM 
KCl 0.27 mM 
Na2HPO4 x 7H2O 0.81 mM 
KH2PO4 0.15 mM 
Tween-20 0,10% 




Phosphate buffered saline 
(PBS), pH 7.4 
NaCl 24.00 mM 
KCl 0.27 mM 
Na2HPO4 x 7H2O 0.81 mM 
KH2PO4 0.15 mM 
dissolved in H2O   










Western blot blocking solution 
milk powder 5% 
dissolved in PBS  
 
Western blot buffer, for proteins 
< 130kDa 
Tris 25 mM 
Glycin 192 mM 
Methanol 20% 
dissolved in H2O  
 
Cell lysis buffer 
TRIS-HCl (pH 7.5) 20 mM 
NaCl 150 mM 
Na2EDTA 1 mM 
EGTA 1 mM 
Triton-X 100 
1% 
ß-glycerophosphate 1 mM 
Urea 2 M 
Protease Inhibitor 




qPCR reaction buffer, 10x 
Tris (pH 8.8) 750 mM 
(NH4)2SO4 200 mM 
Tween 20 0.1% 
dissolved in H2O   
qPCR reaction mix, 25x 
10x qPCR reaction 
buffer 1x 
SybrGreen 0,001620 
MgCl2 3.0 mM 
Trehalose in 10 mM 
Tris (pH 8.5) 300.0 mM 
dNTPs 0.2 mM 
Triton X-100 0.25% 
Taq polymerase 20 U/mL 
dissolved in H2O  
Western blot buffer, for 
proteins > 130kDa 
Tris 25 mM 
Glycin 192 mM 
Methanol 10% 
SDS 0,01% 
SDS running buffer 
Tris 25.0 mM 
Glycin 86.1 mM 
SDS 3.5 mM 
dissolved in H2O   
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NET buffer (IP lysis buffer) 
NaCl 150 mM 
TRIS-HCl (pH 8.0) 50 mM 
EDTA 1 mM 
NP-40 1% 
Protease Inhibitor 
Cocktail (PIC) 1x 
 
Buffer B for chromatin 
fractionation 
EDTA, pH 8.0 3 mM 
EGTA, pH 8.0 0.2 mM 
DTT 1 mM 
Protease Inhibitor 
Cocktail (PIC) 1x 
dissolved in H2O   
 
Buffer B for chromatin harvest 
(for ChIP) 
Triton X-100 0.25% 
EDTA, pH 8.0 10 mM 
EGTA, pH 8.0 0.5 mM 
HEPES pH 7.6 20 mM 
dissolved in H2O   
 




NaCl 0.15 M 
EDTA, pH 8.0 1 mM 
EGTA, pH 8.0 0.5 mM 
HEPES pH 7.6 20 mM 
dissolved in H2O  
Buffer A for chromatin 
fractionation 
HEPES pH 7.9 10 mM 
KCl 10 mM 
MgCl2 1.5 mM 
Sucrose 0.34 M 
Glycerol  10% 
DTT 1 mM 
Protease Inhibitor 
Cocktail (PIC) 1x 
dissolved in H2O   
Buffer A for chromatin harvest 
(for ChIP) 
NaCl 0.1 M 
EDTA, pH 8.0 1 mM 
EGTA, pH 8.0 0.5 mM 
HEPES pH 7.6 50 mM 
dissolved in H2O   
Buffer C for chromatin harvest 
(for ChIP) 
NaCl 0.15 M 
EDTA, pH 8.0 1 mM 
EGTA, pH 8.0 0.5 mM 
HEPES pH 7.6 50 mM 
dissolved in H2O   
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NaCl 0.5 M 
EDTA, pH 8.0 1 mM 
EGTA, pH 8.0 0.5 mM 
HEPES pH 7.6 20 mM 
dissolved in H2O  
 




NaCl 0.75 M 
EDTA, pH 8.0 5 mM 






2.1.5 Enzymes and Kits 
 
Table 2.6. Enzymes and Buffer 
Reagent Company 
DNase I (50 u/µL) Thermo Scientific fisher 
DNase I buffer Thermo Scientific fisher 
RT Buffer, 5x Thermo Scientific fisher 
Revert Aid Reverse transcriptase (RT) (200 u/µL) Thermo Scientific fisher 
RiboLock RNAse Inhibitor (40 u/µL) Thermo Scientific fisher 
Washbuffer 3 for ChIP 
LiCl 0.25 M 
NaDOC 0.5% 
NP-40 0.5% 
EDTA, pH 8.0 1 mM 
EGTA, pH 8.0 0.5 mM 
HEPES pH 7.6 20 mM 
dissolved in H2O   
Washbuffer 4 for ChIP 
EDTA, pH 8.0 10 mM 
EGTA, pH 8.0 5 mM 
HEPES pH 7.6 200 mM 
dissolved in H2O   
Elutionbuffer for ChIP 
SDS 1% 
 NaHCO3 0.1 M 
dissolved in H2O   
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RNase A (100 mg/mL) Qiagen, Venlo, Netherlands 
Taq polymerase Primetech 
 
Table 2.7. Kits 
Name Company 
Guava Check Kit Millipore, Merck 
Immobilon Western HRP Substrate Peroxide Solution Millipore, Merck 
Pierce BCA Protein assay kit Thermo Scientific fisher 
PureYield Plasmid Midiprep System Promega 
SuperSignal West Femto Maximum Sensitivity 





Table 2.8. Primary antibodies 





(WB), ChIP or Co-IP 
Company 
actin ab8227 rabbit WB: 1/20000 Abcam, Cambridge, UK 
BRMS1 (MO-1) 2D4-2G11 mouse WB: 1/500 Abnova GmbH 
CBP (A-22) sc-369 rabbit WB: 1/500 Santa Cruz Biotechnology 
cleaved Caspase 3 
(Asp175) 9664 rabbit WB: 1/500 
Cell Signaling 
Technology 
GAPDH ab8245 mouse WB: 1/20000 Abcam, Cambridge, UK 
Hsc70 B-6 mouse WB: 1/2000 Santa Cruz Biotechnology,  
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iASPP A4605 mouse WB: 1/1000 Sigma-Aldrich  
IgG, ChIP grade ab46540 rabbit ChIP: 2 µg Abcam, Cambridge, UK 
Lamin B1 ab16048 rabbit WB: 1/2000 Abcam, Cambridge, UK 
p21 WAFI AB (Ab-
1,EA10) OP64 mouse WB: 1/500 Calbiochem 
p300 (N-15) sc-584 rabbit 
WB: 1/500, 
Co-IP: 1 µg 
Santa Cruz 
Biotechnology 
p300 (N-15X) sc-584X rabbit ChIP: 5µg Santa Cruz Biotechnology,  
p38 9212 rabbit WB: 1/1000 Cell Signaling Technology 
p53 (DO-1) 554293 mouse WB: 1/1000 BD Pharmingen 
p73 ab14430 rabbit WB: 1/1000, ChIP: 2 µg 
Abcam, Cambridge, 
UK 
PARP 9542 rabbit WB: 1/2000 Cell Signaling Technology 
Phospho-HSP27 
(Ser82) 
2401 rabbit WB:1:1000 Cell Signaling Technology 
Phosho p38 MAPK 




Term P4618 rabbit WB: 1/500 
Sigma-Aldrich 
Germany 
TBP SL30 mouse WB: 1/250 self-made 
 
Table 2.9. Secondary antibodies 
Antibody Cat. Number Company 
HRP-coupled AffiniPure F(ab')2 
fragment, anti mouse IgG (H+L)  711-036-152  Jackson Immunoresearch,  
HRP-coupled AffiniPure F(ab')2 
fragment, anti rabbit IgG (H+L)  715-036-150  Jackson, Immunoresearch  
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2.1.7 Eukaryotic cell culture 
 
 
Table 2.10. Cell lines 
cell lines origin 
A375 malignant melanoma 
Brown malignant melanoma 
GH testicular carcinoma 
HCT116  colon adenocarcinoma  
HCT116 -/-p53  colon adenocarcinoma, isogenic p53 knockout 
HEK293T 
human embryonic kidney 
cells, harbouring SV40 
antigen 
HMB-2 malignant melanoma 




background gifted by 
Yvonne Begus-Nahrmann 
Mel2a malignant melanoma 
Mewo malignant melanoma 
MSM malignant melanoma 




Table 2.11. Media and reagents for eukaryotic cell culture 
Reagent Company 
Dulbecco’s Modified Eagle 
Medium (DMEM), powder Gibco, Life Technologies 
Fetal Calf Serum (FCS) Gibco, Life Technologies 
L-Glutamine Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Trypsin/EDTA Gibco, Life Technologies 
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Table 2.12. Culture medium for eukaryotic cells 
DMEM (dissolved in 
H2O) 
DMEM, powder 10.0 g 
NaHCO3 3.7 g 





Table 2.13. Bacteria strains 
Strain Description Company 
TOP10 competent E.coli Invitrogen, Life Technologies 
 
Table 2.14. Bacteria culture media 
2YT medium 
Tryptone 1.6% 




2.1.9 Oligonucleotides and plasmids 
 
Table 2.15. Primer for human gene expression studies 
Primer Sequence 5`-3` target gene 
BAX_ forward CCGGGTTGTCGCCCTT Bax 
BAX_reverse AGGGCCTTGAGCACCAGTT Bax 
BRMS1_forward GGCAGCTCTCAGGGAATCTC BRMS1 
BRMS1_reverse TCTTTGCTTGGAGGCTGGAC BRMS1 
CBP_forward CATTGTCAGGCTGGGAAAGC CBP 
2YT agar 
YT agar 15% 
2YT medium 100% 
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CBP_reverse CAGGATGGTTTGTTGGTTTCG CBP 
cyclinE_forward GACGGGGAGCTCAAAACTGA CyclinE 
cyclinE_reverse CATGGCTTTCTTTGCTCGGG CyclinE 
Fas_forward AGGAATGCACACTCACCAGC Fas (CD95) 
Fas_reverse TGGAGATTCATGAGAACCTTGG Fas (CD95) 
HPRT1_forward ATGCTGAGGATTTGGAAAGG HPRT1 
HPRT1_reverse TCATCACATCTCGAGCAAGAC HPRT1 
IASPP_forward ACAGCGAGGCATTCCAGAG iASPP (PPP1R13L) 
IASPP_reverse TGCTTGGTCAGTTCATCCAC iASPP (PPP1R13L) 
Noxa_forward GCCGCGGGTCGGGAGCGTGT Noxa (PMAIP1) 
Noxa_reverse GCCCCTGTCCCCGCCCCTGT Noxa (PMAIP1) 
P21_forward CTTTCTGGCCGTCAGGAACA P21 (CDKN1A) 
P21_reverse CTTCTATGCCAGAGCTCAACATGT P21 (CDKN1A) 
P300_forward GCGGCCTAAACTCTCATCTC P300 (EP300) 
P300_reverse TGGTAAGTCGTGCTCCAAGTC P300 (EP300) 
PIG3_forward ATGTTAGCCGTGCACTTTGACA PIG3 (TP53I3) 
PIG3_reverse CACGTAGAGGTTTTCCGGTCC PIG3 (TP53I3) 
Pml_forward CCGCAAGACCAACAACAT PML 
Pml_reverse ACTGTGGCTGCTGTCAAG PML 
PUMA_forward GAAACGGAATGGAAAGCTATGAGA Puma (bbc3) 
PUMA_reverse GCAGACCCCATGCCAAATT Puma (bbc3) 
rad51_forward GAGAAGTGGAGCGTAAGCCA Rad51 
rad51_reverse GCTGCATCTGCATTGCCATT Rad51 
 
Table 2.16. Primer for mouse gene expression studies 
Primer Sequence 5`-3` target gene 
mHPRT1_forward CGTCGTGATTAGCGATGATGAAC HPRT1 
mHPRT1_reverse CATCTCGAGCAAGTCTTTCAGTC HPRT1 
miASPP_forward ATCTTCGCCACCACTCTCAG iASPP (ppp1r13l) 
miASPP_reverse ACAACGCCATTGTGCATCAG iASPP (ppp1r13l) 
mNoxa_forward GCGAAAGCTAACACGCAGAG Noxa (PMAIP1) 
mNoxa_reverse GGAGTGGGACAGCTGGATTT Noxa (PMAIP1) 
mP300_forward CCTCGGTTGTATCTCCGAAAG P300 
mP300_reverse TCCAGGTCAAACAGTGAACC P300 
mPuma_forward TTCTCCGGAGTGTTCATGCC Puma (bbc3) 
mPuma_reverse ATACAGCGGAGGGCATCAGG Puma (bbc3) 
 
Table 2.17. Primer for ChIP analysis 
Primer Sequence 5`-3` target gene 
ChIPpuma_forward CTTGCTAACTGGCCCACTG BBC3 
ChiIPpuma_reverse CGGAATGGAAAGCTATGAGAC BBC3 
ChIPFas_forward AGGGCTTGTCCAGGAGTTC CD95 
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ChIPFas_reverse ACAGGAATTGAAGCGGAAGT CD95 
ChIPmyo_forward CTCATGATGCCCCTTCTTCT MB 
ChIPmyo_reverse GAAGGCGTCTGAGGACTTAAA MB 
ChIPp21_forward GCAGATGTGGCATGTGTCC CDKN1A 
ChIPp21R_reverse AGTGACTGCACGACCTTGG CDKN1A 
ChIPPIG3_forward CCCTGGGTACCTGCATTAAG TP53I3 
ChIPPIG3_reverse TAGCCGTGCACTTTGACAAG TP53I3 
 
Table 2.18. siRNA 
All siRNA samples were purchased from Ambion (Silencer Select). 
Target (No.) ID sequence 
BRMS1 (kd1) S24632 
Sense: GGAAUAAGUACGAAUGUGAtt 
Antisense: UCACAUUCGUACUUAUUCCtg 










iASPP (kd1) S21296 
Sense: GCCUUAAAUUUAGUAAUCUtt 
Antisense: AGAUUACUAAAUUUAAGGCtg 




Table 2.19. shRNA 
All shRNA constructs were purchased from Sigma Aldrich. 



















































Table 2.20. Plasmids 





Expression vector for the exogenous expression of proteins 
under the control of a CMV promoter in eukaryotic cells; 





from Xin Lu, 
Oxford 
pcDNA3.1 vector with open reading frame coding for iASPP. C-
terminal tagged with V5. Extra neomycin resistance for 
generation of stable cell lines; harbours ampicillin resistance 





Lentiviral vector encoding for viral envelop proteins; ORF is 







Viral vector for the production of lentivirus. Encodes for gag, 
pol and rev genes under the control of a CMV promoter. 
Contains ampicillin resistance.   
M420 from AG Dietrich, GSH Frankfurt  
Vector with coding sequence for GFP under the control of a 
CMV promoter. Contains a RNA packaging signal, LTR 
sequences for genomic insertion of the target sequences and a 
3`SIN/LTR for production of replication deficient virus. 
Harbours an ampicillin resistance cassette for amplification in 
E.coli. 









Vector with coding sequence for luciferase gene under the 
control of a CMV promoter. Contains a RNA packaging signal, 
LTR sequences for genomic insertion of the target sequences 
and a 3`SIN/LTR for production of replication deficient virus. 
Harbours an ampicillin resistance cassette for amplification in 






Vector with coding sequence for iASPP or p73 gene under the 
control of a CMV promoter (see Table 2.19. for clones). 
Contains a RNA packaging signal, LTR sequences for genomic 
insertion of the target sequences and a 3`SIN/LTR for 
production of replication deficient virus. Harbours an ampicillin 
resistance cassette for amplification in E.coli and a puromycin 





Table 2.21. Software 
Name Company 
Adobe Photoshop CS5 Adobe Systems, San Jose, CA, United States 
AxioVision 3.0  Zeiss 
CFX Manager Software for 
qPCR cycler  Bio-Rad 
Excel Microsoft, Redmond, WA, United States 
Guava Express Software  Millipore, Merck 
INTAS lab ID  Intas Science Imaging Instruments 












2.2.1 Cultivation of adherent cells 
All cell lines were cultured in full DMEM medium (supplemented with 10% FCS, 50 U/mL 
penicillin/streptomycin and 200 µM L-glutamine) at 37°C and 5% CO2 in a moistly incubator. 
For stable knockdown cell lines, full DMEM medium was freshly supplemented with 0.1% 
puromycin solution. 
Cells were regularly split for 2-3 times per week. Hence, old medium was sucked off the 
plates, cells were gently washed with pre-warmed PBS (with MgCl2) and finally detached by 
incubation with 0.1% pre-warmed trypsin/ EDTA solution. Trypsination was stopped by 
adding new, pre-warmed, medium. Finally, a portion of trypsinized cells was transferred to a 
new petridish and supplemented with fresh pre-warmed medium. 
 
2.2.2 Freezing/Thawing of adherent cells 
To secure low passage cultivation of the cell lines, cells were regularly frozen and kept at      
-80°C or in liquid nitrogen. For freezing, cells were trypsinized, centrifuged (5 min, 1000 rpm 
at RT) and subsequently dissolved in freezing medium containing 90% FCS and 10% 
DMSO. One full 10 cm plate was normally resuspended in 2 mL freezing medium and 
divided into 2 aliquots. The aliquots were placed in a freezing unit containing isopropanol, 
and placed for 24 h at -80°C, before the tubes were transferred to a storage tank containing 
liquid nitrogen. 
For thawing of the cells, frozen aliquots were quickly warmed up and cells were added to a 
10 cm dish containing 18 mL pre-warmed medium. 24 h after thawing, medium was changed 
to remove the toxic DMSO from growing cells. 
 
2.2.3 Treatment of the cells with chemotherapeutic drugs and inhibitors 
Cells were mostly treated with the chemotherapeutic drug cisplatin or Etoposide. Cisplatin 
solution was applied as an aqueous solution of 1 mg/mL. Final concentration of cisplatin 
ranged from 10-40 µM depending on the cell line and experiment. Etoposide, that had been 
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dissolved in DMSO before was applied in a concentration of 30 µM. All other chemicals and 
inhibitors that were used for treatment of the cells as well as the solvent and final 
concentration are listed in table 2.22. 







10-40 µM 1 mg/mL water 
Etoposide 30 µM 10 mM DMSO 
zVad 40 µM 40 mM DMSO 
MG132 20 mM 10 mM DMSO 
CTB 10 µM, 20 µM 100 mM DMSO 
BCI 10 µM 10 mM DMSO 
SB203580 10 µM, 20 µM 10 mM DMSO 
CHX 100 µg/mL 100 mg/mL Ethanol 
 
For the control reactions, cells were always treated with the same concentration of the 
solvent as used for the treatment with the respective drug. Generally, for treatment of the 
cells, medium was removed and substituted by a master mix of the drug or chemicals pre-
dissolved in fresh pre-warmed medium. 
 
2.2.4 Transfection of cells using Calcium-phosphate  
Transient over-expression of iASPP as well as the transfection of HEK293T cells for the 
production of lentivirus was conducted using Calcium-phosphate (Graham and van der Eb 
1973). Therefore an appropriate amount of cells was seeded 24 h before transfection. For 
transient over-expression of iASPP, cells of a 10 cm plate were transfected with 10 µg 
plasmid. DNA, 500 µL 2x HBS buffer and 440 µL sterile water were mixed. Then 60 µL 2 M 
CaCl2 solution was quickly added to the mix, followed by virtuously shaking and incubation 
for 30 min at 37°C. Finally the transfection mix was drop-wise pipetted on the cells and 
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incubated with the cells over night or at least for 8 h at 37°C. The next day, the medium of 
the transfected cells was exchanged. 48 h post transfection, cells were harvested or treated 
with chemotherapeutic drugs. For generation of control cells, same amount of cells were 
transfected with 5 µg pcDNA (empty vector) and 5 µg GFP-plasmid. 
For the transfection and therefore production of lentivirus in HEK293T cells, 1x106 cells were 
seeded 24h before and subsequently transfected with 2.5 µg shRNA construct for the 
respective gene, 1.6 µg 8.91 plasmid and 1 µg VSV-G plasmid (Naldini, Blomer et al. 1996; 
Stewart, Dykxhoorn et al. 2003). Concentration of CaCl2 and 2x HBS buffer as well as the 
transfection protocol remained the same as for the transient over-expression of iASPP. For 
control, lentivirus with shRNA containing a siRNA sequence against the luciferase gene was 
generated as well as a virus expressing GFP. 
 
2.2.5 siRNA mediated knockdown of cells 
BRMS1, p300 and partially also iASPP were transiently knocked down in various cell lines 
using commercial available siRNA (Sequences see table 2.18). For transfection of a 6-well, 
50pmol siRNA was added to 250 µL DMEM without FCS, Pen-Strep or glutamine (= DMEM 
(-)). In another tube 5 µL Lipofectamine 2000 (Invitrogen) was incubated with 250 µL DMEM 
(-) for 5 minutes at RT. Next DMEM with siRNA and DMEM with Lipofectamine were mixed 
and incubated for 20 minutes at RT. In the meantime, cells were trypsinated and counted. 
SiRNA/ Lipofectamine mix was spread on the dish and 20-40x105 cells/ per 6-well were drop-
wise added to the plate. The number of transfected cells depended on the cell line. Each well 
was filled up to 2.5 mL with full DMEM medium and incubated over night in the incubator at 
37°C. Next day, medium was exchanged. 48 h-72 h post transfection, cells were treated and 
subsequently harvested for further analysis. For chromatin fractionation, 10 cm plates were 
transfected with 3 µL 50 pmol siRNA and 20 µL Lipofectamine 2000 in 2x 500 µL DMEM (-) 
medium. 
 
2.2.6 Lentivirus mediated generation of stable knockdown cell lines 
Stable knockdown cell lines were generated using lentivirus-mediated transduction, because 
lentivirus renders a high transfection efficiency and genomic integration rate of the 
constructs. As lentivirus belongs to the safety class 2 (S2) organisms, all following work was 
conducted under S2 safety rules. In general, lentivirus was produced in HEK293T cells, 
followed by transduction of the target cell lines with the virus containing supernatant 
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(modified after the protocol from www.sigma-aldrich.com). As the transduced shRNA-
constructs contain a sequence encoding for a puromycin resistance gene, stably transduced 
cells were selected by cultivation of the cells with puromycin-containing medium. Once 
selected, cells were cultured with a medium containing low concentrated puromycin to 
maintain the knockdown. 
For production of the lentivirus, HEK293T cells were transiently transfected with lentiviral 
packaging plasmids and the respective shRNA constructs using Calcium-phosphate (see 
table 2.19). Two control viruses were generated and transfected in parallel. One control 
represented a shRNA against the luciferase gene (= control knockdown cells) and the other 
control constituted a transducable GFP-plasmid that monitored the transduction efficiency.  
48h post transfection, the supernatant including the lentivirus was collected and passed 
through a 0.45 µm filter. Polybrene (8 mg/ml) was added to the supernatant in a dilution of 
1:1000 and the mix was finally placed on the target cells. Following, virus and target cells 
were incubated for 24 h in the incubator at 37°C. Virus incubation was stopped by sucking off 
the supernatant and supplementation of target cells with fresh full DMEM medium. 
24 h-48 h post-transduction, transduction efficiency was controlled by detection of the green 
fluorescence of GFP-expressing control cells using the Zeiss fluorescence microscope. 
When GFP was broadly expressed, selection for stably knocked down cells was started by 
adding puromycin to a final concentration of 0.1%. In general, puromycin was always freshly 
supplemented to the medium as it is not stable for a longer time. When the cells stopped to 
die from incubation with puromycin, analysis of the cells was started and cells were frozen in 
parallel. 
For transduction of MEFs, cells were not selected with puromycin but directly harvested after 
4 days of transduction, as MEFs enter a senescence status if they are cultivated too long. 
 
2.2.7 Cell cycle analysis of cells 
Cell cycle analysis as well as the quantification of the apoptosis rate as the number of cells in 
subG1 phase was assessed by FACS (Tounekti, Belehradek et al. 1995). In general fixed 
cells were stained with Propidium iodide which specifically stains the DNA. Thus the DNA 
content and following also the number of cells in subG1, G1, S and G2/M are countable. 
For preparation of the samples, cells were harvest by collection of the supernatant and 
trypsinized cells in 15 mL Falcon tubes. After centrifugation of the cells (5 min, 1500 rpm at 
RT) cell pellets were resuspended in 0.6mL 3% FCS/PBS. As the staining solution cannot 
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cross the cell membrane, cells had to be fixed. Therefore 1.4 mL 96% Ethanol was drop wise 
added to the resuspended cells by gentle agitation of the cells. Cells were fixed in Ethanol for 
at least 24 h at -20°C.  
For subsequent analysis, fixed cells were centrifuged (5 min, 1500 rpm at RT) and washed 
with 5 mL PBS (with MgCl2). After an additional centrifugation step (5 min, 1500 rpm at RT), 
cells were resuspended in 400-750 µL PBS (depending on the cell pellet) and 40 U RNAse A 
was added, followed by a brief incubation of the samples for 20 min at RT. Incubation with 
RNAse A is a crucial step, as FACS analysis with Propidium iodide-stained samples cannot 
discriminate between RNA and DNA. 
Next, 200 µL sample was mixed with 6 µL Propidium iodide solution (Sigma) and cell number 
was assessed by FACS analysis using the Express Pro software (Guava System, Millipore). 
Of note, samples were pre-diluted with PBS to retrieve equal cell numbers between 300-500 
cells/µL. For analysis, gates were set only once and same gate settings were applied for all 
samples of one series.  
For assessment of the apoptosis rate, cells in subG1 phase were counted. As late apoptotic 
cells display fragmentation of the DNA, all signals that run lower than the G1 phase (after 





2.2.8 Transformation of E.coli 
Plasmids used for over-expression experiments and lentivirus production were transformed 
and amplified in TOP10 E.coli cells (Invitrogen). Hence, 0.5 µg Plasmid DNA was incubated 
with 50 µL competent E.coli cells for 30 minutes on ice followed by a heat-shock 
transformation of the cells for 45 sec at 42°C. After heat-shock, cells were placed for 1.5min 
on ice followed by the addition of 950 µL pre-warmed YT medium. After another incubation 
time of the cells in a gently shaking thermoblock at 37°C for 1 h, cells were plated on YT 
plates containing 100 µg/mL ampicillin. E.coli cells were usually seeded in 1:100, 1:1000 and 
1:10000 dilution to retain single colonies. Plates were subsequently incubated at 37°C over 
night. A single colony was picked and expanded by an overnight culture in 50 mL YT medium 
containing 100 µg/mL ampicillin. Finally, the plasmid DNA was extracted using the Midi-prep 
System (Promega). 
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2.2.9 Midi-preparation of plasmid DNA 
Midi-preparation of plasmid DNA from a 50 mL over night culture was performed using the 
midi-prep kit from Promega. Plasmid DNA was extracted according to the manual. Of note, 
binding and washing of the columns was performed under vacuum. Finally, the plasmid DNA 
was eluted with 200 µL nuclease-free water. The concentration was measured with the 
Nanodrop (Peqlab). Plasmid DNA was then stored at -20°C until it was used for transfection 
of eukaryotic cells. 
 
2.2.10 Primer design 
ChIP-primers were designed with the Primer3 software (http://frodo.wi.mit.edu/primer3). 
Criteria for primer design were the following: 
Template size: 50-150 bp, Primer size: 18-24, GC content: 40-60%, Melting temperature tm: 
58.0-62.0°C, Max. Poly X: 5.00, Max. self complementary: 3.00, CG clamp: 1 
As the basis for the design of ChIP primers served genomic DNA sequences that were 
retrieved from the UCSC genome browser (genome.ucsc.edu). For p73/p300 ChIP-Primer, 
self-made p73 ChIPseq tracks (Koeppel et al, 2011) were uploaded at the UCSC genome 
browser site. After zoom in to the respective p73 binding site, the corresponding genomic 
sequence was retrieved and served as the input sequence for the Primer3 software.  
For gene expression primer, the Primer blast program of the NCBI website was used 
(www.ncbi.nlm.nih.gov/tools/primer-blast/). Basis for this platform is the Primer3 software 
that was also used for the design of ChIP primer. The same criteria for primer design were 
applied as stated above. Additionally, primers were design as intron-spanning to avoid 
amplification of probably contaminating genomic DNA.  
The resulting oligonucleotides were ordered at Biomers (www.biomers.net) and Metabion 
(www.metabion.com). Lyophilized primers were resuspended with nuclease-free water to a 
final concentration of 100 µM and stored at -20°C. For real-time PCR analysis, forward and 
reverse primer were mixed at a concentration of 10 µM and kept as working solutions.  
 
2.2.11 Quality control of primer 
Primers were validated for their efficiency and specificity prior to standard usage. Therefore 
dilution series of cDNA or genomic DNA (1:20, 1:40 and 1:80) served as templates for real-
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time PCR analysis for each new primer pair. Composition of the real-time PCR reactions is 
depicted in Table 2.23. PCR was performed with the standard thermocycler program (table 
2.24). 





Sybr green mix (self-made, see table 2.5) 14 µL 
Primer working solution (10 µM) 1 µL 
Nuclease-free water 5 µL 
cDNA (1:20 diluted)/ ChIP sample 5 µL 
 
Table 2.24. Standard thermocycler program for real-time PCR 
Temperature Time Cycles 
95°C 3 min  
95°C 15 sec  
58°C 45 sec     40x 






From the resulting Ct values, the primer specificity as well as primer efficiency was 
calculated. Due to the theoretical basis that a 2-fold diluted cDNA (input) sample should give 
a 1.00 higher Ct value compared to the 2-fold higher concentrated cDNA (input) sample, a 
good primer efficiency was judged by plotting the log2 of the cDNA (input) dilutions (x-axis) 
against the Ct value (y-axis). A good primer pair should show a linear correlation between Ct 
values and dilution factor with an approximately slope of 1.00 and a regression higher than 
0.95. Specificity of the primer was judged by looking at the respective melting curves of the 
primer pair. Specific primers always display one sharp melting curve of the PCR product; 
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unspecific primers result in multiple melting curve peaks or astringent curves. Nonspecific or 
inefficient primer were newly designed and replaced. 
 
2.2.12 Isolation of total RNA  
Basically RNA extraction was done according to the TRIZOL extraction protocol from Sigma-
Aldrich.  
Prior to RNA extraction, cells were harvested by trypsination and transferred to a 1.5 mL 
Eppendorf tube. After pelletation of the cells by centrifugation (1 min, 3800 rpm, at RT), cells 
were dissolved in 1mL TRIZOL and subsequently incubated for 2 minutes at RT. 200µL 
chloroform was added and the mix was virtuously shaked for 15 sec to separate the RNA 
from proteins and genomic DNA. After 2 minutes of additional incubation, the mix was 
centrifuged (for 5 min, 13000 rpm at 4°C) and the upper RNA-containing phase was 
transferred to a new 1.5 mL Eppendorf tube. 
Next 0.5 mL Isopropanol was added and the mix was thoroughly vortexed. For precipitation 
of the RNA, the RNA-Isopropanol mix was incubated for 10 minutes on ice and afterwards 
centrifuged again (for 30 min, 13000 rpm at 4°C). After removal of the supernatant, the pellet 
was washed one time with 150 µL 70% EtOH (short vortexing and centrifugation for 1 min, 
13000 rpm at 4°C) followed by removal of all liquid and short air drying of the RNA. Finally, 
the pellet was resuspended in 100 µl nuclease free water. 
 
2.2.13 DNAse I digest of RNA samples 
To ensure the total removal of any possible contaminating genomic DNA, a DNAse I digest 
was subsequently performed. Therefore the RNA was mixed with 20 µL DNAse I mix (table 
2.25) and incubated at 37°C for 30 minutes, shaking. 
Table 2.25. Composition of DNAse I mix (per reaction) 
Compound Volume 
10x DNAse I Buffer 12 µL 
DNAse I, hc 0.25 µL 
RNAse inhibitor 1 µL 
Nuclease-free water 6.75 µL 
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After incubation, samples were purified by Phenol-chloroform extraction. Therefore 120 µL 
Phenol-chloroform mix (5:1; pH 4.3) was added to each RNA sample and vortexed for 10 
seconds. After short centrifugation of the tubes (for 1 min, 13000 rpm at 4°C) the upper 
aqueous phase was transferred to a new tube and the Phenol-chloroform extraction was 
repeated once. Following the Phenol-chloroform purification, the RNA-containing, upper 
phase was transferred to a new tube and mixed with 375 µL 96% EtOH and 17 µL NaAc for 
precipitation of the RNA. Next, the samples were either incubated over night at -20°C or for 1 
h at -80°C followed by centrifugation of the samples for 30 minutes, 13000 rpm at 4°C. After 
removal of the supernatant, the resulting RNA pellet was washed again with 150 µL 70% 
EtOH (short vortexing and centrifugation for 1 min, 13000 rpm at 4°C). Following, the pellet 
was shortly air dried again and resuspended in 10-30 µL nuclease free water.  
RNA samples were stored at -80°C or directly used for cDNA synthesis.  Prior to reverse 
transcription the concentration of the RNA was determined with the Nanodrop (Peqlab). 
Therefore 2 µL RNA was measured at a wavelength of 260 nm and subsequently diluted to 
400 ng RNA/µL. 
 
2.2.14 cDNA synthesis 
cDNA synthesis was principally done according to the manual of MMulV reverse transcription 
kit (Thermo Scientific Fisher). 2.5 µL (1 µg) of total RNA was incubated with 2 µL random 
hexamer primers (Thermo Scientific fisher) and 7.5 µL nuclease-free water for 5 min at 70°C. 
After short centrifugation of the samples, 8 µL of master mix (table 2.26) was added and 
reverse transcription was performed for 1 h at 42°C, followed by 10 minutes of heat 
inactivation at 65°C.  
Following cDNA samples were 1:20 diluted with nuclease-free water and stored at -20°C. 
Table 2.26. Master mix for cDNA synthesis 
Compounds Volume 
5x RT Buffer 4 µL 
20 mM dNTPs 1 µL 
RNAse inhibitor (40 u/µL) 1 µL 
MMulV RT enzyme 1 µL 
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2.2.15 Quantification of relative gene expression 
For determination of the relative gene expression, real-time PCR was performed using the 
C1000 CFX96 real-time PCR thermocycler (Biorad). Low-profile PCR plates in 96-well format 
with an optical covering were used (4-titude). 
Generally, gene expression values were obtained from three independently extracted RNA/ 
cDNA samples (biological replicas). Technical replicas were included in the biological 
replicas. Reactions were pipetted according to table 2.23. After sealing of the plate with 
optical foil, the whole plate was vortexed and shortly centrifuged (1 min, 1400 rpm, RT). All 
PCR plates were freshly prepared and directly analysed. The same thermocycler program as 
used for primer validation was applied (table 2.24). 
For calculation of the relative gene expression the ∆∆Ct method was applied. Therefore the 
threshold was manually set and the relative Ct values for target and reference genes were 
obtained. To account for variation of pipetting and independent runs, a reference gene 
(HPRT1) was always analysed in parallel to the target genes. 
For calculation of the ∆Ct value, Ct values of the target gene were normalized against the Ct 
values of the reference gene via subtraction. Next the ∆∆Ct value was calculated by 
subtraction of the Ct value of the control knockdown or untreated sample from treated or 
iASPP, BRMS1 or p73 knockdown samples. Hence the ∆∆Ct value of the control sample was 
set as 0 (= fold change). As Ct values resemble logarithmic values to the basis of 2, the 
mean log ratio was calculated with the following formula: - 2(-∆∆Ct). Control or untreated 
samples are therefore set as 1 whereas up-regulation is represented by a mean log ratio >1 




2.2.16 Protein harvest 
For preparation of total cell lysates, cells were scraped with medium. Scraped cells and 
medium were collected in 15 mL Falcon tubes and centrifuged for 5 minutes, 1500 rpm at 
RT. Following the cell pellet was washed with 1 mL PBS, centrifuged again (3800 rpm, 5 
minutes, RT) and dissolved in cell lysis buffer, containing ¼ volume 8 M Urea and 1x 
protease inhibitor complete (PIC). Cells from one 6-well were usually lysed in 100-200 µL 
buffer volume depending on the cell line.  
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Subsequently cell lysates were kept on ice. After virtuous pipetting, all samples were shortly 
sonicated to disrupt bulky genomic DNA. Sonication was performed with the Bioruptor 
(Diagenode) for 10 minutes at high power (30 sec on/off interval) in ice cold water. After 
sonication, the concentration of the cell lysates was determined using the BCA method.  
 
2.2.17 Determination of the protein concentration- BCA assay 
To ensure equal loading amounts of the protein samples, the concentration of the cell lysates 
was assessed using a BCA assay kit (Thermo Scientific Fisher). Basically 5 µL of each 
sample was incubated with 100 µL BCA-buffer at 37°C, 30 minutes, shaking. Afterwards 
relative protein concentration was determined using the Nanodrop (Peqlab). For calculation 
of the absolute protein concentration, a standard curve with defined standard concentrations 
of Albumin was measured in parallel. 
Next, cell lysates were denatured by boiling of the samples with ¼ volume Laemmli buffer for 
5 minutes at 95°C. For subsequent analysis of the protein samples, SDS-PAGE combined 
with Immunoblotting was performed. Therefore 20-40 µg of protein was loaded on SDS-
PAGE gels, depending on the abundance of the proteins that had to be detected. 
 
2.2.18 SDS-PAGE 
For separation of proteins according to their size, denatured samples were analysed using 
SDS-PAGE gels. SDS is masking the charges of proteins thereby allowing the separation of 
cell lysates according to their size. Basically, SDS-PAGE is performed by two layers of gels: 
a stacking and a running gel (Table 2.27). The stacking gel (5% acrylamide at pH 6.8) is 
concentrating the samples leading to sharpened protein bands whereas the separation of 
proteins is performed by varying concentrations of the running gel (6-12% acrylamide at pH 
8.8). For analysis of small proteins, small pore-gels were generated (12%) thereby allowing 
the standard detection of proteins ranging from 10-100 kDa, whereas 6% polyacrylamide 
gels were applied for separation of relatively big proteins (e.g. p300 and CBP, migrating at 
around 270 kDa). In general, for separation of the protein mixtures, the pre-casted gels were 
placed in a tank with 1x running buffer and samples were loaded in the pre-formed gel 
pockets together with a pre-stained protein marker. Next, power (constant voltage of 90-140 
Volt) was applied which led to a separation of the samples by migration of the proteins from 
the cathode towards the anode. 
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Table 2.27. Composition of gels for SDS-PAGE 
Compound Stacking gel Running gel  
Acrylamide-bisacrylamide 5% 6-12% 
Tris-HCl, pH 6.8 (0.5 M) 126 mM - 
Tris-HCl, pH 8.8 (1.5 M) - 375 mM 
SDS (10%) 0.1% 0.1% 
APS (10%) 0.05% 0.05% 
TEMED 0.1% 0.4% 
Glycerol - 10% 
 
After appropriate separation of the samples, the proteins in the gels were transferred on 
nitrocellulose membranes by applying the Immunoblotting technique. 
 
2.2.19 Immunoblotting 
Proteins in polyacrylamide-gels are difficult to assess for any antibody staining. Therefore 
proteins are usually transferred to a nitrocellulose membrane and stained with a primary 
antibody against the desired protein. To visualize the protein of interested, staining with a 
secondary horse radish peroxidase (HRP)-conjugated antibody is performed that recognizes 
the first bound antibody (Renart et al., 1979, Towbin et al., 1979). Of note, sequential 
incubation and detection using two antibodies leads to an amplification of the signal, thereby 
allowing the detection of low protein amounts. 
Finally the membrane is incubated with a chemiluminoscence reagent that is only activated 
at the sites of pre-antibody bound HRP enzyme. The emitted light of the bands can then be 
detected using the Chemocam HR 16 3200 imager (Intas). 
Starting, the proteins that were previously separated by SDS-PAGE were transferred to 
nitrocellulose membranes by application of a transfer buffer (Table 2.5)) and power. For 10-
100 kDa proteins a transfer buffer with 20% Methanol was used, for bigger proteins (>100 
kDa) a transfer buffer with only 10% Methanol and 0.01% SDS was applied, as big proteins 
are difficult to extract from the gels. 
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The transfer was accomplished in a cassette composed of two outer layers of sponges, two 
layers of Whatman-paper (that keeps gel and membrane wet) and an inner layer of 
membrane and the gel itself. The gel was placed at the site of the cathode and the 
membrane was placed at the site of the anode. Positively charged proteins were transferred 
then to the membrane by applying a constant voltage (2 h 100 V for 10-100 kDa proteins; 
over night at 25 V for proteins >100 kDa). As the blotting generates a lot of heat, the tank 
containing blots and transfer buffer, was put on ice in the cold room for the duration of the 
transfer. 
After finishing of the transfer, the membrane (or so called blot) was blocked in 5% milk/PBS, 
1 h at RT, rotating, to avoid any unspecific background staining. Next, the blot was incubated 
with dilutions of primary antibody (in 5% milk/PBS) either over night at 4°C or at least 4 h at 
RT. After extensive washing (3x for 10 minutes with PBST), the blot was incubated with 
secondary antibody (in 5% milk/ PBS) for 1 h at RT, rotating. Finally, after additional washing 
for 3x 10 minutes with PBST, the membrane was stained with Millipore staining solution and 
analyzed using the chemiluminoscence detection machine Chemocam HR 16 3200 imager 
(Intas). For proteins that were weakly expressed, Femto staining solution from Thermo 
Scientific Fisher was applied. 
 
2.2.20 Co-Immunoprecipitation (Co-IP) 
To validate the direct interaction of two proteins, co-immunoprecipitation was performed. In 
principle total cell lysates are incubated with an antibody against the protein of interest or IgG 
as a control. To precipitate antibody-protein complexes, protein G coupled Sepharose beads 
are added to the mix, followed by intensive washing of the beads and elution of the bound 
protein-antibody complexes. These precipitated protein-protein complexes are then 
denatured by short boiling with Laemmli buffer and finally analyzed by Immunoblotting. 
For precipitation of endogenous proteins, a relatively large amount of cells was needed as 
starting material. Therefore cells from one 15 cm petridish were used for 1 Co-IP reaction. 
Supernatant was sucked off and the plates were washed with 5 mL PBS by gently moving of 
the plate. After the liquid was sucked off again, cells were lysed with 750 µL NET lysis buffer 
+ 1x PIC for 30 minutes at 4°C. Next the cell lysates were scraped from the plates and 
passed 5 times through a 23G syringe to ensure total cell lysis. Of note, all following steps 
were conducted on ice to avoid any protein degradation. After 5 minutes of sonication with 
the Bioruptor (30 sec on/off, high power), cell lysates were shortly centrifuged (13000 rpm, 1 
min at 4°C).  
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After preparation of the cell lysates, the resulting supernatants were further pre-cleared by 
adding 30 µL Sepharose G beads (50% slurry in PBS) per 750 µL cell lysate and subsequent 
rotation of the reaction mix at 4°C for 1 h on a rotating wheel. This pre-clearing reaction is 
important as it reduces unspecific binding of proteins to the beads. Before Sepharose beads 
were added, storage buffer was removed from the beads by washing of the beads for 3 times 
with 800 µL PBS (inverting and 2 min centrifugation at 4000 rpm and 4°C).  
An additional batch of Sepharose G beads, which were later used for the IP reaction, were 
washed in parallel and finally supplemented with blocking solution (Blocking solution from 
Roth, 1:10 in PBS). Blocking of the beads was performed on a rotating wheel at 4°C for 1 h 
together with the pre-clearing reaction. After the incubation time, blocked beads were shortly 
centrifuged (4000 rpm, 2 min, 4°C) and supernatant was removed. Finally beads were 
resolved in appropriate amounts of NET buffer to retrieve a 50% bead slurry. 
After incubation of the cell lysates with beads, the pre-cleared samples were shortly 
centrifuged (4000 rpm, 2 min, 4°C) and the supernatants were united in a falcon tube. For 
the input sample, 100 µL of the pre-cleared cell lysate was mixed with ¼ volume Laemmli 
buffer and boiled for 5 minutes at 95°C. 
For the IP reaction 30 µL of pre-blocked Sepharose G beads was added to 750 µL pre-
cleared cell lysate together with 2 µg antibody against iASPP or p73. For the control reaction 
2 µg of ß-Galactosidase antibody was applied with the same amount of cell lysate and 
beads. Next, all IP reactions were incubated on a rotating wheel at 4°C over night. The next 
day, the IP reactions were shortly centrifuged (4000 rpm, 2 min at 4°C) and supernatant was 
removed. Following the remaining beads with captured protein-antibody complexes were 
washed 4 times with NET buffer. Therefore 1 mL NET buffer was added to the beads, the 
mix was 4 times inverted, centrifuged (4000 rpm, 2 min at 4°C) and the supernatant 
discarded. After the last washing round, the beads were mixed with 25 µL Laemmli buffer 
and boiled for 5 minutes at 95°C. After short centrifugation, the resulting supernatants were 
transferred to a new tube and subsequently analyzed by SDS-PAGE/ Immunoblotting. 
 
2.2.21 Chromatin fractionation 
Basically chromatin fractionation was done after the protocol from Mendez and Stillman 
(Méndez and Stillman 2000).  
Starting, approximately 1x107 cells (one 10 cm plate, 60-70% confluence) were used for one 
chromatin fractionation. Medium was sucked off and cells were washed with 5 mL PBS. After 
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removal of the PBS, cells were scraped with the remaining liquid and transferred to an 
Eppendorf tube. After short centrifugation (1000 rpm, 2 min at RT) supernatant was 
discarded and cell pellet was washed again with 1 mL PBS (resuspension and centrifugation 
for 1000 rpm, 2 min at RT). From here on all steps were performed on ice and with pre-
cooled buffers. After removal of the PBS, the cell pellet was thoroughly resuspended in 200 
µL Buffer A. Next 1 µL 20% Triton-X 100 solution was added to start the lysis of the cell. After 
8min of incubation on ice, cells were centrifuged for 5 min, 2000 rpm at 4°C to separate 
supernatant (S1) from Pellet (P1). The supernatant (S1) was transferred to a new tube and 
clarified by centrifugation on maximal speed (13000 rpm, 5 min at 4°C). The resulting clear 
supernatant (S2) constituted the cytosolic, non-chromatin bound fraction. 
The Pellet (P1) was washed once with 200 µL Buffer A to remove rests of contaminating 
non-chromatin bound proteins. Therefore cells were resuspended and centrifuged (2000 
rpm, 5 min at 4°C). The supernatant was discarded. Afterwards the pellet (P1) was lysed by 
resuspension in 100 µL Buffer B and subsequently incubated for 30 minutes on ice. After 
additional centrifugation (3000 rpm, 5 min at 4°C), the resulting supernatant (S3) was added 
to the supernatant (S2) as this liquid contains proteins that are localized in the nucleus but do 
not bind on the chromatin (nuclear, non-chromatin bound fraction). S2 + S3 (approx. 300 µL) 
were mixed with 100 µL Laemmli buffer and finally boiled for 5min at 95°C. 
The resulting pellet (P3) was resuspended in 100 µL Buffer B and 100 µL Laemmli buffer and 
boiled for 20 minutes at 95°C. This fraction P3 constituted the triton-insoluble, chromatin 
bound protein fraction. From both fractions 20 µL was loaded on SDS-PAGE gels and 
analysed by Immunoblotting. 
 
2.2.22 Chromatin harvest for chromatin-immunoprecipitation (ChIP) 
For ChIP, chromatin was harvested from 10 cm plates. After removal of the medium and 
washing with 5 mL PBS, all liquid was removed from the plates. Next crosslinking was 
performed by gently adding 1mL formaldehyde-Buffer A-PBS solution (0.5 mL 37% 
formaldehyde + 1.18 mL Buffer A + 15 mL PBS) to the cells. After 30 minutes of incubation at 
RT, crosslinking reaction was stopped by adding 100 µL 1.25 M Glycine. Glycine solution 
was distributed by gently shaking of the dish and following incubation for 5 min at RT. 
Next all liquid was sucked off and the fixed cells on the dish were carefully washed 2 times 
with 5 mL PBS. After removal of all remaining liquid, cell lysis was performed by adding 1 mL 
of Buffer B (virtuous distribution and incubation for 10 min at 4°C). Following the cells were 
scraped from the dish and transferred to a 2 mL Eppendorf tube on ice. After centrifugation 
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for 5 minutes, 3000 rpm at 4°C, supernatant was discarded and the cell pellet was washed 
with 2 mL Buffer C. Therefore cells were thoroughly resuspended by pipetting up and down 
and subsequently centrifuged for 5 minutes, 3000 rpm at 4°C. Finally the resulting cell pellet 
was estimated by eye and resuspended in sufficient sonication buffer (1x incubation buffer + 
0.23% SDS and 1x PIC). For ChIP using HCT116 cells, a cell pellet deriving from a 80% 
confluent 10 cm dish was usually resuspended in 750 µL sonication buffer. Then, chromatin 
was sonicated for 2x 10 min and 1x 5 min using the Bioruptor (30 sec on/off interval, high 
power in ice cold water) to shear the chromatin. Finally, the sheared chromatin was 
centrifuged for 5 min, 13000 rpm at 4°C to pellet remaining unsheared chromatin. The 
supernatant was transferred to a new tube and stored at -80°C until ChIP was performed.  
For analysis of the chromatin by Immunoblotting, 100 µL chromatin together with 50 µL 6x 
Laemmli buffer was boiled for 20 minutes. Usually, 20 µL of the denatured chromatin 
samples was loaded on SDS-PAGE gels and immunoblotted with the same antibodies that 
were used for ChIP, in order to validate equal amounts of the different chromatin samples as 
well as the presence of iASPP knockdown. 
 
2.2.23 Chromatin immunoprecipitation 
Chromatin immunoprecipitation detects the relative binding of a protein to a specific genomic 
site. The protein of interest can either bind to DNA itself (like p73) or localizes in a multi-
protein complex that binds to DNA then (like p300). The specific binding of a protein to a 
single genomic locus can be detected by combining ChIP with real-time PCR analysis of the 
precipitated DNA. In principle a previously published protocol was applied and modified for 
the respective cell lines and antibodies (Denissov, van Driel et al. 2007). 
Starting, 50 µL/ reaction protein A/G plus beads were washed 2 times with 100 µL/reaction 
beads washing buffer (1x incubation buffer with 0.2% BSA). Washing was performed by 
inversion and centrifugation of the beads for 2 min, 4000 rpm at 4°C. Finally, the washed 
beads were dissolved in 25 µL/ reaction beads wash buffer and stored on ice.  
Next ChIP reaction was set up according to table 2.28. 
Antibodies were pipetted as the last step (p73-ChIP: ab14430, abcam; p300-ChIP: N-15X, 
Santa Cruz; control ChIP: polyclonal rabbit IgG, ab46540, abcam). ChIP reactions were 
incubated on a rotating wheel at 4°C over night. In parallel 12 µL of chromatin was kept at 
4°C as the input sample. 
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Table 2.28. Set-up of ChIP reactions 
Compound Volume 
BSA (5%) 6 µL 
25x PIC 12 µL 
5x Incubation buffer (without SDS) 36 µL 
Chromatin 120 µL 
Protein A/G beads 25 µL 
Antibody 2 µg 
Water (for total volume of 300 µL) 99 µL 
 
The next day ChIP reactions were washed with a series of washing buffers. Each washing 
step comprised centrifugation of the samples for 2 min, 4000 rpm at 4°C, removal of the 
supernatant and finally addition of 400 µL of the respective washing buffer. Then tubes were 
4x4 times inverted on ice and centrifuged again. Washing was performed for 2 times with 
cold washbuffer 1, 1x with cold washbuffer 2, 1x time with cold washbuffer 3 and 2x with cold 
washbuffer 4. After the last washing step, the supernatant was completely removed and 
beads were supplemented with 400 µL elution buffer. 
From this point on the input samples were included. 12 µL input sample was mixed with 388 
µL elution buffer as well. For elution of the Protein-DNA complexes all samples, ChIP and 
input reactions, were incubated on a rotating wheel for 20 minutes at RT. Next samples were 
shortly centrifuged and supernatant was transferred to a new eppendorf tube. Subsequently 
de-crosslinking was performed by adding of 16 µL 5 M sodium chloride and shaking of the 
samples in a heating block for 4 h at 65°C and 1300 rpm.  
After the de-crosslinking step, the DNA was purified using Phenol-Chloroform. First 400 µL 
Phenol-Chloroform (pH 8.0; 5:1 dilution) was added, samples were vortexed and afterwards 
centrifuged for 1 min, 13000 rpm at 4°C. The upper, aqueous phase was transferred to a 
new tube and supplemented with 400 µL Chloroform. After vortexing and centrifugation 
(1min, 13000 rpm at 4°C), the resulting upper phase was transferred again to another new 
tube. For precipitation of the DNA, 20 µg glycogen together with 1 mL 96% Ethanol and 44 
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µL 3 M Sodium acetate was added, samples were mixed and finally incubated over night at -
20°C. 
Final purification of the samples was conducted by centrifugation (30 min, 13000 rpm, 4°C) 
followed by removal of all liquid and subsequent washing of the pellet with 400 µL 70% 
Ethanol (vortexing and centrifugation for 1 min, 13000 rpm at 4°C). All liquid was sucked off 
and the DNA pellets were shortly air dried before they were resuspended in 100 µL 
nuclease-free water. Afterwards, to secure a homogenous resuspension of the DNA, 
samples were incubated in a heating block (30 min at 50°C, 1000 rpm shaking). Importantly, 
ChIP samples were always stored at 4°C and shortly pre-warmed before real-time PCR 
analysis was conducted. 
 
2.2.24 Analysis of ChIP samples 
ChIP samples were analyzed with the real-time PCR, using the thermocycler program and 
master mix as described for the analysis of RNA/ cDNA (Table 2.23 and Table 2.24). Instead 
of gene expression primers, specific ChIP-primers were used that anneal to genomic DNA 
fragments. 5 µL of each ChIP sample and 5 µL of 1:10 diluted input sample were mixed with 
20 µL of master mix for one reaction. Input, IgG-ChIP and p73/p300-ChIP reactions were 
always analysed in parallel on one plate, to exclude analysis errors due to varying real-time 
PCR conditions. 
After finishing of the real-time PCR analysis, the recovery as the percentage of input was 
calculated. Therefore the Ct value of the ChIP sample was subtracted from the input sample 
for each primer pair and ChIP reaction, followed by the calculation of the logarithm to the 
basis of 2 (as Ct values represent logarithmic values) and the dilution factor of the input 
(normally 100). The following formula was applied for the calculation of the recovery: 
Recovery (% of input) = log2 (Ct value input-Ct value sample)/100*100 
Partially, the relative binding was calculated. As ChIPs of biological replicas can vary in their 
absolute percentages of input (due to the different chromatin preparations), the calculation of 
the relative binding ensures the correct calculation of the p-value. Therefore, the fold 
enrichment of each ChIP was calculated (recovery p73/ p300-ChIP vs. recovery IgG-ChIP) 
followed by the comparison of the fold enrichment of ChIP with control knockdown cells to 
the fold enrichment of ChIP with iASPP knockdown cells. ChIP of control knockdown cells 
was set to 100%, and the relative loss of binding in iASPP knockdown cells (compared to the 






3.1. P300 can directly interact with iASPP and p73 in cisplatin-treated cells.  
It is well known that iASPP represents a crucial inhibitor of p53-dependent apoptosis 
induction as it directly binds to p53 and blocks its transcriptional regulation of pro-apoptotic 
target genes (Bergamaschi, Samuels et al. 2006). The currently prevalent view is, that iASPP 
is also capable of forming complexes with the p53-family member TAp73 and with the 
histone acetyltransferase p300, although functional consequences of both interactions 
remain elusive (Robinson, Lu et al. 2008). Therefore, we wanted to find out, which impact 
endogenous expression of iASPP will have on p300 and TAp73 function.  
The functional interaction of TAp73 and p300 in cisplatin-mediated apoptosis has been 
intensively investigated before, especially in the adenocoloncarcinoma cell line HCT116 
(Mantovani, Piazza et al. 2004; Levy, Adamovich et al. 2008). Due to the fact that this cell 
line expresses relatively high amounts of endogenous TAp73 and p300, we decided to use 
HCT116 cells for our analysis. Moreover, an isogenic p53 knockout cell line of HCT116 was 
investigated (HCT-/-p53 cells), which offered the possibility to confirm our findings to be 
independent from the expression of p53. Of note, we analysed the expression levels of 
TAp73 and ∆Np73 isoforms in HCT116 cells by using isoform-specific primers and real-time 
PCR. As we could not detect any expression of ∆Np73, we can state that our results are 
TAp73-specific.  
We started to validate the interaction of iASPP with p300 and TAp73 in untreated as well as 
cisplatin-treated HCT116 cells. Under normal growing conditions of tumourigenic cells, we 
failed to detect any direct interaction of iASPP with p300 or TAp73 (Figure 3.1A). However, 
we could clearly validate the presence of iASPP-p300 as well as p300-TAp73 protein 
complexes in cisplatin-treated cells (Figure 3.1B). Of note, in both tested conditions, we 
could not detect an interaction between iASPP and TAp73, which might have been due to 
sub-optimal co-immunoprecipitation conditions though.  
As we could show that p300 and iASPP form a protein complex with each other in cisplatin-
treated HCT116 cells, we were interested in the functional consequences of iASPP depletion 
on p300 expression levels. Therefore, we generated stable iASPP knockdown cells by using 
two different shRNAs against iASPP. To exclude any off-target effects due to lentivirus-
mediated knockdown or due to the selection of the transduced cells with the antibiotic 




shRNA targeting the luciferase gene was utilized. Following, lentiviral transduced cells were 
cultured under the same conditions.  
 
Figure 3.1. P300 directly interacts with TAp73 and iASPP in cisplatin-treated HCT116 
cells.  
For co-immunoprecipitation experiments, total cell lysates were prepared from untreated (A.) 
and cisplatin-treated (20 µM, 16 h) (B.) HCT116 cells. Immunoprecipitation was performed 
using an iASPP- or p73-specific antibody. As control, an independent immunoprecipitation 
reaction was performed using a ß-galactosidase antibody. After extensive washing, 
precipitated were extracted from the beads, and co-bound p300, p73 or iASPP was detected 
by immunoblotting. (Ctrl = control) 
 
3.2. IASPP expression augments the protein levels of p300 and TAp73 after cisplatin 
treatment. 
After establishment of HCT116 and HCT-/-p53 cells with stable iASPP knockdown, protein 
levels of p300 and its closely related homologue CBP were detected in total cell lysates from 
untreated as well as cisplatin-treated cells. CBP staining was included, as it was shown 
before, that p300 and CBP exert overlapping functions in various cellular responses. Thus, 
p300 and CBP could be similarly affected by iASPP depletion. 
Interestingly, as untreated cells remain unaffected, cisplatin-treated iASPP knockdown cells 
displayed reduced protein levels of p300 (Figure 3.2A). Moreover, we obtained similar results 
from cisplatin-treated HCT-/-p53 cells, thereby excluding any influence of p53 on the 
observed effects (Figure 3.2B). Of note, protein levels of CBP were also decreased, although 
we could detect this effect in cisplatin-treated and untreated, iASPP-depleted HCT116 cells 


















































cells confirmed that the decreased protein amounts of p300 and CBP derived from changes 
on protein level rather than from changes on mRNA level (Figure 3.2C). 
 
Figure 3.2. iASPP depletion leads to a decrease in p300 and CBP protein levels. 
Stable iASPP knockdowns of HCT116 and HCT-/-p53 cells were generated using 2 
independent shRNA constructs against iASPP. To exclude off target effects, control cells 








































































































A. iASPP depletion leads to a decrease in p300 and CBP protein level in cisplatin-
treated HCT116 cells. Cells were treated for 24 h with 20 µM cisplatin prior to preparation of 
total cell lysates. P300 and iASPP levels were detected by immunoblotting. HSC70 staining 
served as loading control. 
B. Decrease of p300 protein level in iASPP knockdown cells is independent of the 
presence of p53. P300 protein level were analysed in cisplatin-treated, knockdown HCT-/-
p53 cells. Cells were treated for 24 h with 20 µM cisplatin prior to preparation of protein 
lysates. P300 and iASPP level were detected by immunoblotting. GAPDH staining served as 
the loading control. 
C. iASPP knockdown does not affect the mRNA levels of p300 and CBP. Total RNA was 
extracted from HCT116 knockdown cells. For cisplatin treatment, cells were incubated with 
20 µM cisplatin for 12 h. Ct values were normalized to the reference gene HPRT1. To 
calculate the relative mRNA level (mean log ratio), untreated control knockdown cells were 
set to 1. (n.s. = not significant) 
 
3.3. iASPP regulates the protein stability of p300 and TAp73. 
Concluding, we hypothesized that iASPP depletion seemed to reduce the protein stability of 
p300 and CBP. To validate our hypothesis, we performed a cycloheximide pulse chase 
experiment in cisplatin-treated HCT116 cells (Figure 3.3A). Cycloheximide inhibits protein 
de-novo synthesis, thereby displaying a tool for the analysis of protein turn over. Actually, we 
could observe a faster degradation of p300 in cisplatin-treated, iASPP knockdown cells 
compared to control knockdowns. Therefore, we conclude that iASPP enhances the protein 
stability of p300 in cisplatin-treated cells.  
 
Figure 3.3. IASPP depletion decreases the protein stability of p300 and TAp73 in 
cisplatin-treated cells.  
HCT116 knockdown cells were treated with 20µM cisplatin, prior to preparation of total cell 
lysates. Protein levels were detected by immunoblotting. Actin staining controlled equal 
loading of the samples. (CHX = cycloheximide, MG132 = proteasome inhibitor, kd = 
knockdown) 
A. Cycloheximide pulse chase reveals faster degradation of p300 and TAp73 in iASPP 
knockdown cells. HCT116 cells were treated for 20 h with 20 µM cisplatin followed by 
0h 1h 2h 4hCHX:
controlkd iASPPkd






















incubation with 100 µg/mL cycloheximide (CHX) for 1 h, 2 h or 4 h. As a control the 0 h 
sample was treated with the CHX solvent Ethanol.  
B. Low protein levels of p300 and TAp73 can be rescued by treatment with the 
proteasome inhibitor MG132. Cells were treated for 20 h with cisplatin followed by 4 h of 
treatment with 20 µM MG132 or DMSO as control. 
 
As it is well known that p300 can acetylate TAp73 after exposure of cells to cisplatin, which in 
turn enhances the protein stability of TAp73 (Costanzo, Merlo et al. 2002; Mantovani, Piazza 
et al. 2004), we included TAp73 staining of cycloheximide-treated samples. Similar to the 
effects of iASPP depletion on p300 protein stability, iASPP knockdown resulted in a faster 
degradation of TAp73 in cisplatin-treated cells (Figure 3.3A). However, we could not detect a 
direct interaction of iASPP and TAp73 in untreated or cisplatin-treated HCT116 cells. Hence, 
we suggest that the diminished stability of TAp73 protein results from the decreased protein 
levels of p300 and CBP.  
Apart from proteasomal degradation processes, proteins can be degraded by alternative 
pathways. To prove the influence of iASPP on the proteasomal degradation process of p300 
and TAp73, we investigated the level of both proteins in cells that were treated with the 
proteasome inhibitor MG132 (Figure 3.3B). Actually, MG132 treatment re-established the 
protein levels of p300 and TAp73 in cisplatin-treated iASPP knockdown cells. Concluding, 
iASPP expression is likely to inhibit the proteasomal degradation process of p300, TAp73, 
and probably also CBP after treatment of the cells with cisplatin. 
 
3.4. iASPP depletion affects the chromatin localization of p300 and TAp73.  
Next, we were interested in further consequences of iASPP depletion on p300 function. As 
p300 is mainly involved in the acetylation of histones, we performed chromatin fractionation 
as well as chromatin immunoprecipitation (ChIP) of p300 in HCT116 cells. In fact, less p300 
protein localized to the chromatin fraction in cisplatin-treated, iASPP knockdown cells (Figure 
3.4A). Consequently, ChIP experiments using a p300-specific antibody revealed diminished 
binding of p300 to known p300 target sites (e.g. puma and pig3 promoter), again in cisplatin-
treated HCT116 cells (Figure 3.4B).  
As we detected reduced protein stability of TAp73 in iASPP-depleted cells as well (Figure 
3.3A), we were also interested in functional consequences on TAp73 as a downstream target 
of p300. We hypothesized that the impaired chromatin localization of p300 in cisplatin-
treated, iASPP-depleted cells should also affect the localization and DNA-binding affinities of 




proved a diminished recruitment of TAp73 protein to the chromatin (Figure 3.4C). Moreover, 
ChIP experiments using a TAp73-specific antibody validated a strong reduction of TAp73 
































































































Figure 3.4. iASPP modulates the DNA-binding affinities of p300 and TAp73 in cisplatin-
treated HCT116 cells. 
A. Lower amounts of p300 protein localizes to the chromatin fraction. Cells were 
treated for 16 h with cisplatin prior to chromatin fractionation of cells (separation of cells into 
triton-soluble and triton-insoluble fractions). GAPDH staining served as control for unbound 
chromatin, lamin B1 staining controls the purity of the chromatin fraction. 
B. Diminished localization of p300 to genomic target sites in iASPP-depleted HCT116 
cells. For analysis of p300 level, that are bound to genomic target sites (puma, pig3), cells 
were treated for 8 h with cisplatin prior to chromatin preparation. Following, chromatin 
immunoprecipitation was performed using an IgG- or p300-specific antibody. To reveal the % 
of bound p300 protein on single target sites, real-time PCR was performed using specific 
primers. The relative binding was calculated by setting the fold enrichment (of p300 over IgG) 
to 100% in control knockdown cells. The significance was calculated by using the student`s t-
test. 
C. In iASPP-depleted cells, less TAp73 is recruited to the chromatin fraction. Cells were 
left untreated or incubated for 16 h with 20 µM cisplatin prior to separation of the cells in 
triton-soluble and triton-insoluble fractions. Similar controls were used as described under A. 
D. IASPP knockdown results in diminished DNA-binding of TAp73 while p53 remains 
unaffected. HCT116 control and iASPP knockdown cells were treated for 24 h with 10 µM 
cisplatin prior to chromatin harvest. Chromatin immunoprecipitation was performed using a 




































































time PCR analysis. Myo primers detect a region in the heterochromatin thereby serving as an 
internal negative control. To visualize protein levels in ChIP inputs, a fraction of chromatin 
was denatured with Laemmli buffer, boiled and analysed by immunoblotting. TBP staining 
served as loading control. 
 
Besides TAp73, p300 is also known to elevate the DNA-binding properties of p53 as well. 
Therefore, we included p53 in our analysis. Interestingly, we did not observe diminished 
recruitment of p53 to the chromatin in iASPP-depleted HCT116 cells, as seen for TAp73 
(Figure 3.4C). In line, we also failed to detect a similar loss of p53 binding to common p53 
and p73 target sites in ChIP experiments using a p53-specific antibody (Figure 3.4D).  
Therefore we state, that iASPP depletion mainly affects the function of p300 and CBP. 
Following, the consequences of diminished protein levels of p300 (and CBP) on TAp73 or 
p53 function might then be dependent on the cellular context and treatment of the cells. In 
HCT116 cells though, TAp73 seems to be mainly affected by the diminished p300 protein 
level after iASPP knockdown 
 
3.5. iASPP depletion leads to an overlapping loss of p300 and TAp73 to promoters of 
pro-apoptotic TAp73 target genes. 
Next, additional p73- and p300-ChIPs were repeated in parallel using the same chromatin 
batches of cisplatin-treated HCT116 knockdown cells. As shown for the puma promoter 
(Figure 3.5), as well as for the fas and p21 gene locus (Appendix Sup-1), we could validate 















































Figure 3.5. After cisplatin treatment, iASPP depletion leads to an overlapping loss of 
p300 and p73 binding to promoters of p73 target genes. 
For chromatin immunoprecipitation HCT116 knockdown cells were treated for 8 h with 20 µM 
cisplatin prior to chromatin harvest. ChIP input derived from an aliquot of chromatin that was 
denatured with Laemmli buffer, boiled and analysed by immunoblotting. TBP staining served 
as a loading control. Chromatin immunoprecipitations (ChIP) were performed using a p73- as 
well as p300-specific antibody. For control, an IgG reaction was performed in parallel. The 
data is represented as the % of input sample of the respective target site. Puma is presented 
as an example of a co-bound promoter region of p73 and p300. The promoter region of 
myoglobulin (myo) served as an internal negative control to exclude any unspecific binding of 
the antibodies to DNA. 
 
 
3.6. IASPP depletion counteracts the accumulation of pro-apoptotic p73 target genes 
in DNA-damaged cells. 
TAp73 constitutes a transcription factor that is known to induce the gene expression of pro-
apoptotic target genes after cisplatin treatment (Irwin, Kondo et al. 2003; Strano, Monti et al. 
2005). Thus, we were interested in the functional consequences of iASPP depletion on the 





















































target genes in iASPP-depleted HCT116 and HCT-/-p53 cells. As shown by the analysis of 
the mRNA levels of puma and pig3, pro-apoptotic target genes were significantly less 
induced in DNA-damaged, iASPP-depleted HCT116 cells compared to control knockdown 
cells (Figure 3.6A and Appendix Sup-2A). These effects were reproducible in HCT-/-p53 
cells, thereby confirming that the observed effects were independently of the presence of p53 
(Figure 3.6B). Moreover, we could confirm the role of TAp73 in the transcriptional up-
regulation of the analysed target genes analysis, by gene expression studies of TAp73 
knockdown cells (Appendix Sup-2B).  
Furthermore, we investigated the total protein levels of the p73 targets puma and p21. 
Immunoblot detection of both proteins revealed that a diminished induction of p73 target 
genes also resulted in an impaired accumulation of these effector proteins in cisplatin-treated 



















































































































































































Figure 3.6. iASPP knockdown leads to a decreased induction of pro-apoptotic p73 
target genes in cisplatin-treated cells. 
For RNA extraction, cells were treated for 8 h (pig3) or 12 h (puma) with 20 µM cisplatin. For 
immunoblotting, 24 h of treatment with 20 µM cisplatin was applied. Significance was 
calculated using student`s t-test. 
A.+B. Relative gene expression of puma and pig3 in stable iASPP and control 
knockdown cells. A. Analysis of untreated and cisplatin-treated HCT116 cells. B. Analysis 
of untreated and cisplatin-treated HCT-/-p53 cells. 
C. iASPP or p73 depletion leads to diminished puma and p21 protein level in cisplatin-
treated cells. Total cell lysates of HCT116 knockdown cells were immunoblotted. Actin 
staining controlled equal loading of the samples. 
 
As we were only able to detect any effects of iASPP knockdown after treatment of the cells 
with cisplatin, we were interested if cisplatin treatment is a pre-requisite for the observed 
effects. Therefore we repeated gene expression analysis of the same pro-apoptotic target 
genes in Etoposide-treated HCT116 knockdown cells (Appendix Sup-3A). Etoposide is a 
topoisomerase II inhibitor that is known to activate the p53-family and therefore triggering 
p53-family dependent apoptosis induction (Irwin, Kondo et al. 2003; Codelia, Cisterna et al. 
2010). Indeed, Etoposide treatment of iASPP knockdown and TAp73 knockdown HCT116 
cells resulted in a similar impaired induction of pro-apoptotic p73 target genes as shown for 
cisplatin treatment before. Concluding, as cisplatin and Etoposide treatment resulted in the 
same diminished induction of p73 target genes in iASPP-depleted cells, we suggest that the 
observed effects are dependent on the activation of DNA damaging pathways rather than 
































3.7. iASPP depletion counteracts p300- and p73-mediated apoptosis.  
Subsequently, we wanted to investigate which consequences iASPP knockdown and 
following diminished induction of p73 target genes would have on apoptosis induction. It 
have been revealed that puma among other pro-apoptotic p73 target genes plays a crucial 
role in the induction of apoptosis after cisplatin treatment (Melino, Bernassola et al. 2004). 
Therefore, we studied the effects of iASPP depletion on the level of apoptosis induction after 
cisplatin (Figure 3.7) or Etoposide (Appendix Sup-3B) treatment.  
Detection of cleaved caspase 3 fragments using a specific cleaved caspase 3 antibody 
represents a reliable marker for the level of apoptosis induction (Fernandes-Alnemri, Litwack 
et al. 1994; Nicholson, Ali et al. 1995). Therefore we investigated the level of cleaved 
caspase 3 in cisplatin-treated HCT116 knockdown cells (Figure 3.7A). As expected, cisplatin-
treated, iASPP knockdown HCT116 cells displayed lower levels of cleaved caspase 3 than 
control knockdown cells. In parallel, we performed transient knockdown of p300 and CBP to 
validate the pro-apoptotic role of both proteins in cisplatin treatment-induced apoptosis in 
HCT116 cells. Interestingly, transient knockdown of p300 (but not of CBP) resulted in a 
similar reduction of cleaved caspase 3 levels compared to control knockdown cells, thereby 


































Figure 3.7. iASPP knockdown in HCT116 cells leads to diminished apoptosis induction 
after cisplatin treatment. 
A. Lower levels of cleaved caspase 3 accumulate in cisplatin-treated iASPP and p300 
knockdown cells. P300 and CBP were transiently knocked down in control knockdown cells 
using siRNA. As control, stable, shRNA-transduced control and iASPP knockdown cells were 
transfected with scrambled siRNA. 48 h post-transfection, cells were treated with 40 µM 
cisplatin for 24 h prior to protein harvest. Knockdown efficiency was validated by 
immunoblotting. As a marker for apoptosis induction, cleaved caspase 3 levels were 
detected using a specific antibody. 
B. Cell cycle profiles of cisplatin-treated iASPP knockdown cells reveal a lower portion 
of cells in subG1 phase. Control and iASPP knockdowns were treated for 24 h with 20 µM 
or 40 µM cisplatin. Cells were harvested, fixed with Ethanol and stained with propidium 
iodide. Cell cycle profiles were generated by FACS analysis. Same gate settings were 
applied for all samples. As an example of the analysed cell cycle profiles, one example for 
cisplatin-treated control knockdown cells and one example for cisplatin-treated, iASPP 
knockdown cells are shown. The significance of the FACS analysis was calculated using the 
student`s t-test. 
 
In addition, we performed cell cycle analysis of HCT116 cells by applying propidium iodide 
staining of previously fixed cells. As apoptotic cells display DNA fragmentation, quantification 
of the number of cells in subG1 phase can be used as an indicator for the percentage of 
dead cells in a cell population (Tounekti, Belehradek et al. 1995). Quantification of the subG1 

















































apoptosis in iASPP-depleted cells compared to control knockdowns (Figure 3.7B). Moreover 
we could confirm a similar, pro-apoptotic role for iASPP after Etoposide treatment by similar 
FACS analysis of HCT116 knockdown cells (Appendix Sup-3B).  
 
3.8. iASPP regulates the protein levels of p300 in mouse embryonic fibroblasts. 
To generalize our findings, we tested the effects of iASPP depletion in several cell lines 
including non-tumourigenic mouse embryo fibroblasts (MEFs). Indeed stable knockdown of 
iASPP in wild-type MEF cells led to a reduction of p300 protein levels (Figure 3.8A). 
Interestingly, we could observe this effect in untreated as well as cisplatin-treated cells, 
thereby indicating that primary cells might display a slight different mechanism of iASPP-
mediated regulation of p300 levels.  
Moreover, we analysed the mRNA levels of p300 in iASPP-depleted MEF cells (Figure 3.8B). 
Actually, gene expression analysis of p300 revealed, that the decreased p300 protein levels 
in untreated MEF cells seemed to partially result from a transcriptional repression of p300. In 
cisplatin-treated MEF cells though, we could not detect any transcriptional changes in the 
gene expression of p300. Thus, we suggest that iASPP regulates the protein stability of p300 
in cisplatin-treated MEF cells, similar to the findings we obtained for HCT116 cells.  
Furthermore, we analysed the expression of pro-apoptotic target genes in iASPP-depleted 
MEF cells to validate a pro-apoptotic role of iASPP and subsequently also p300 in primary 
cells (Figure 3.8C). However, we failed to detect any significant changes in the expression of 
several pro-apoptotic genes (like Puma and Noxa) due to iASPP depletion. Therefore, iASPP 























Figure 3.8. iASPP depletion in mouse embryonic fibroblasts results in reduced p300 
levels. 
Mouse embryonic fibroblasts (MEF) were transduced with shRNA against iASPP. For control 
cells, MEFs were transduced in parallel with shRNA against luciferase. Four days after 
transduction cells were treated with 20 µM cisplatin. Significance was calculated using the 
student`s t-test. 
A. P300 levels decrease in iASPP-depleted MEFs. For immunoblotting, MEF cells were 
treated for 12 h with 20 µM cisplatin prior to cell lysate preparation. P300 protein levels were 
detected by immunoblotting. Knockdown efficiency was controlled by staining for iASPP. 
HSC70 staining served as loading control. 
B. P300 mRNA levels are repressed in untreated, iASPP-depleted cells. MEF cells were 
treated for 8 h with 20 µM cisplatin prior to RNA extraction. Relative gene expression was 
analysed by real-time PCR. Ct values were normalized to HPRT1. Depicted is the mean log 
ratio as the relative gene expression (untreated control knockdown cells are set to 1). 
C. iASPP depletion does not alter the transcription of pro-apoptotic target genes. To 
monitor any changes in the expression of pro-apoptotic genes, Puma and Noxa mRNA levels 
were analysed in control and iASPP knockdown cells. (n.s. = not significant) 
 
This might be caused by differential protein expression patterns of MEF cells compared to 






























































iASPP mRNA level 
untreated +cisplatin untreated +cisplatin






























Nevertheless, iASPP is likely to regulate the protein levels of p300 in cisplatin-treated 
primary cells. 
 
3.9. P300 levels are regulated by iASPP in cisplatin-treated melanoma cell lines. 
Apart from analysis of MEF cells, we investigated the effects of transient iASPP knockdown 
in 4 different tumourigenic melanoma cell lines (Figure 3.9A). In fact, all cell lines displayed a 
similar reduction of p300 protein levels in iASPP-depleted, cisplatin-treated cells compared to 
control knockdowns. 
 
Figure 3.9. Melanoma cell lines show a decrease in p300 levels in cisplatin-treated, 
iASPP knockdown cells. 
IASPP was transiently depleted in 4 different melanoma cell lines (Mel2a, Mewo, Lox and 
MV3 cells) using 2 different siRNA and a scrambled siRNA as control. 48 h after transfection, 
cells were treated for 24 h with 20 µM cisplatin. Total cell lysates were prepared and 
immunoblotted. HSC70 staining served as a loading control.  
 
Probably due to a long half-life of iASPP protein, siRNA-mediated, transient knockdown of 
iASPP was difficult to apply in untreated cells. Thus, iASPP protein levels did not significantly 





















































































detect any effects on p300 protein levels in untreated iASPP knockdown cells. We cannot 
exclude though, that iASPP knockdown affects p300 levels in untreated cells as well, due to 
this problems with siRNA-mediated knockdown of iASPP. We will have to repeat this 
experiment using stable shRNA-mediated iASPP knockdowns of melanoma cell lines. 
In summary, iASPP depletion affected p300 protein levels in cisplatin-treated melanoma cell 
lines as well. Therefore, iASPP represents a common regulator for p300 protein stability in 
several tumourigenic cell lines. 
 
3.10. BRMS1 is required for p300 degradation in HCT116 cells. 
As we already proved, that iASPP depletion leads to an accelerated proteasomal 
degradation of p300 in HCT116 cells (Figure 3.3A and Figure 3.3B), we were interested in 
the responsible E3 ubiquitin ligase mediating this effects. Up to now, little is known about 
p300- and CBP-specific ubiquitin ligases. Recently Liu and colleagues discovered that the 
breast metastasis suppressor 1 (BRMS1) protein can poly-ubiquitinate and therefore 
degrade p300 in lung cancer cell lines (Liu, Mayo et al. 2013). Therefore, we decided to test 
if BRMS1 is also involved in the proteasomal degradation of p300 and CBP in untreated as 
well as cisplatin-treated HCT116 cells. BRMS1 was transiently knocked down using two 
different siRNA against BRSM1 and a scrambled siRNA for generation of control knockdown 
cells (Figure 3.10). Indeed knockdown of BRMS1 resulted in an accumulation of p300 and 







































































Figure 3.10. BRMS1 regulates the protein levels of p300 and CBP in untreated and 
cisplatin-treated HCT116 cells. 
BRMS1 was transiently knocked down in HCT116 cells using two different siRNA against 
BRMS1 or scrambled siRNA as a control. 48 h post transfection cells were treated for 24 h 
(for protein) or 8 h (for RNA) with 20 µM cisplatin prior to cell harvest. 
A. BRMS1 knockdown leads to an accumulation of p300 and CBP protein in HCT116 
cells. Protein levels of p300 and CBP were detected via immunoblotting. HSC70 served as 
the loading control. 
B.+C. BRMS1 knockdown does not affect the mRNA levels of p300 and CBP. Efficiency 
of BRMS1 knockdown (B.) as well as mRNA levels of p300 and CBP (C.) were analysed by 
real-time PCR using gene-specific primer. All Ct values were normalized to HPRT1 and 
untreated control knockdown cells were set to 1 (calculation of the mean log ratio).  
 
Analysis of the mRNA levels of p300 and CBP in BRMS1-depleted cells proved that the 
observed effects were not deriving from transcriptional changes in p300 and CBP levels 
(Figure 3.10B and Figure 3.10C). Thus, BRMS1 can proteasomally degrade p300 and CBP 
in HCT116 cells. 
 
3.11. BRMS1 knockdown compensates for diminished p300 level in cisplatin-treated 
iASPP knockdown cells. 
Next we transiently knocked down BRMS1 in control as well as iASPP knockdown HCT116 
cells (Figure 3.11). If BRMS1 is mediating the proteasomal degradation of p300 and CBP in 
iASPP-depleted cells, additional knockdown of BRMS1 should re-establish the protein levels 
of p300 and CBP.  
We already showed that iASPP does not have an effect on p300 level in untreated cells. 
Thus, as expected, additional knockdown of BRMS1 in untreated control and iASPP 




















































































CBP mRNA level in HCT116 cells





However, knockdown of BRMS1 in cisplatin-treated iASPP knockdown cells was able to 
abrogate the diminished protein levels of p300 and CBP. Concluding we claim, that iASPP, 
maybe due to its direct interaction with p300, seems to inhibit the BRMS1-mediated 
proteasomal degradation of p300 and CBP in cisplatin-treated HCT116 cells. 
 
 
Figure 3.11. Effects of iASPP knockdown on p300 and CBP protein levels depend on 
the presence of BRMS1. 
BRMS1 was transiently knocked down in HCT116 control and iASPP knockdown cells using 
a BRMS1-specific siRNA or scrambled siRNA as a control. 48 h post transfection cells were 
treated for 24 h with 20 µM cisplatin prior to harvest of the cells. Protein levels of p300 and 
CBP were detected via immunoblotting. The presence of iASPP knockdown was controlled 
by detection of iASPP. Knockdown efficiency of BRMS1 knockdown was determined by 




























































Following, we also analysed the effects of BRMS1 knockdown on p73 and p300 target genes 
(Appendix Sup-4). If BRMS1 degrades p300, we hypothesized that BRMS1 depletion should 
indirectly elevate the expression of the previously described p73/ p300 target genes (for 
example puma, fas or pig3) due to increased p300 protein level. Nevertheless, we could only 
detect an increase in the mRNA levels of some p73 and/or p300 target genes in untreated as 
well as cisplatin-treated HCT116 cells. Therefore, we hypothesize that iASPP does not only 
affect p300 and TAp73 protein levels by inhibition of BRMS1-mediated degradation of p300. 
Likely, yet unidentified post-translational modifications of p300 might be affected by iASPP 
knockdown as well, thus contributing to the observed, impaired function of p300 and TAp73 
in iASPP-depleted cells. 
 
3.12. Malignant melanoma are characterized by down-regulated iASPP expression. 
iASPP-depleted HCT116 cells showed a significant reduction in the pro-apoptotic response 
to cisplatin and Etoposide. Therefore, we argued that there have to be tumour types that 
display low iASPP expression. Hence, down-regulation of iASPP might also correlate then 
with a down-regulation and therefore functional inactivation of the pro-apoptotic protein p300, 
thus promoting chemoresistance as well. 
To address this question, we scanned the gene expression atlas of the EMBL institute 
(www.ebi.ac.uk/gxa/ ) for microarray data sets of various tumour types. Interestingly, a study 
in 2005 revealed a significant down-regulation of iASPP mRNA levels in a panel of 45 
malignant melanoma samples compared to benign nevi and normal skin samples (Talantov, 
Mazumder et al. 2005). Statistical evaluation of this data set (Figure 3.12, conducted by Dr. 
Annalen Bleckmann and Michaela Bayerlova) confirmed a strong decrease of iASPP mRNA 
levels in tissue of malignant melanoma. Additionally, the same data set also revealed a 
statistical significant up-regulation of BRMS1 mRNA levels in the same set of malignant 
melanoma samples compared to benign nevus and normal skin cells. 
Moreover, two other gene expression studies that analysed melanoma tissue, normal skin 
and benign nevi, validated a significant down-regulation of iASPP mRNA levels in malignant 





Figure 3.12. Microarray analysis reveals a down-regulation of iASPP and up-regulation 
of BRMS1 in malignant melanoma. 
Microarray data was retrieved from the gene expression atlas of the EMBL institute 
(www.ebi.ac.uk/gxa). The data set was published by Talantov and colleagues in 2005 
(Talantov, Mazumder et al. 2005). In brief, 7 normal skin samples, 18 benign nevi and 45 
melanoma samples were analysed using the Affymetrix Gene CHIP A-AFFY-33. Analysis of 
the gene expression study for iASPP expression and evaluation of the statistical significance 
was conducted by Dr. Annalen Bleckmann and Michaela Bayerlova. 
 
3.13. Cisplatin-treated melanoma cell lines are show low protein levels of iASPP,p300 
and CBP 
Based on these findings, we further investigated the role of iASPP, p300 and CBP in 
malignant melanoma. Analysis of 8 untreated melanoma cell lines (Figure 3.13A) confirmed 
low expression levels of iASPP in 6 out of 8 melanoma cell lines compared to HCT116 cells 
or the osteosarcoma cell line U2OS. However, we failed to detect a correlating down-
regulation of p300/ CBP protein levels in the same, untreated melanoma cell lines.  
Cisplatin and its derivatives are a commonly used for a variety of different tumour types 
(Basu and Krishnamurthy 2010). As we only revealed a significant role for iASPP (and 
BRMS1) in the regulation of p300 level after cisplatin treatment, we investigated the protein 
levels of iASPP, p300 and CBP in cisplatin-treated melanoma cell lines, as well (Figure 
3.13B).  
Surprisingly, in cisplatin-treated melanoma cell lines, we could detect correlating low 
expression levels of iASPP and p300 in at least 5 out of the 7 analysed cell lines (compared 
to HCT116 und U2OS cells). Therefore, we suggest that p300 protein is degraded in 
ciASPP expression BRMS1 expression




cisplatin-treated melanoma cell lines, and this might be dependent on the low iASPP 
expression levels. Moreover, some of the melanoma cell lines also expressed BRMS1, 
thereby raising the possibility that BRMS1-mediated degradation could be responsible for the 
low protein levels of p300 in cisplatin-treated melanoma cell lines.  
PARP1 is normally cleaved during the process of apoptosis induction. Hence, detection of 
PARP1 cleavage products serves as a marker for the level of apoptosis (Satoh and Lindahl 
1992). We stained for PARP1 cleavage in cisplatin-treated melanoma cells (Figure 3.13B). 
However, we failed to reveal a correlation between the level of apoptosis induction and the 
expression levels of p300, iASPP and BRMS1. Thus, other factors might determine the 
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Figure 3.13. Cisplatin-treated melanoma cells are characterized by low expression 
levels of iASPP and p300/CBP, independently of the mutation status of the cells. 
A. Expression level of p300, CBP and iASPP in untreated cell lines. Total protein lysates 
of 8 different melanoma cell lines as well as GH, HCT116 and U2OS cells were prepared. 
For immunoblotting, 30 µg protein of each sample was analysed. Actin staining served as a 
loading control. 
B. Expression level of p300, iASPP and BRMS1 in cisplatin-treated cell lines. 7 different 
melanoma cell lines as well as GH, HCT116 and U2OS cells were treated for 24 h with 20 
µM cisplatin prior to preparation of total cell lysates. 30 µg protein of each sample was 
immunoblotted and stained for iASPP, p300 and BRMS1. Detection of PARP1 cleavage 
served as a control for the level of apoptosis induction. HSC70 staining controlled equal 
loading of the samples. 
C. Characteristics of melanoma cell lines (according to literature). Shown is the 
mutational status of p53, B-RAF and N-RAS in the analysed melanoma cell lines. Information 
about Brown cells could not be retrieved (therefore not listed). The table also states the origin 
of the cells. 
 
Malignant melanoma are characterized by mutations that frequently occur during the process 
of melanocyte transformation. 50% of all melanoma display mutations in the kinase B-RAF. 
Other commonly observed mutations include activating mutations of N-RAS (~15%) or 
upstream mutations in the p53 signalling pathway, thus resulting in inactive p53 protein 
(Pollock and Meltzer 2002; Kelleher and McArthur 2012; Tsao, Chin et al. 2012). However, 
current melanoma therapies targeting B-RAF, N-RAS, or those therapy approaches that are 
aiming at a re-activation of p53, show a low response rate or a high rate of tumour re-
occurrence due to acquired chemoresistance. Therefore, new candidates for melanoma 
therapy are urgently needed. Interestingly, low levels of iASPP or p300 expression did not 
correlate with any of these mutations, as revealed by the analysis of the mutation status of 
the investigated cell lines (Figure 3.13C). Our analysis indicates, that iASPP and p300 
expression might constitute new biomarkers for certain therapy approaches of malignant 





A375 wt V600E wt Primary tumor Giard et al 1973
HMB-2 mutant? V600E metastasis Poser et al 2004
Lox wt V600E wt metastasis Fodstad et al 1988
Mel2a mutant V600E metastasis Bruggen et al 1981
Mewo wt wt wt metastasis Bean et al 1975





melanoma, as diminished expression of both proteins occurs independently of the most 
commonly found mutations. 
 
3.14. BRMS1 mediates the degradation of p300 and CBP in a set of cisplatin-treated 
melanoma cell lines. 
Subsequently, we investigated if BRMS1 is responsible for p300/CBP degradation in low 
iASPP-expressing melanoma cell lines. We performed transient knockdown of BRMS1 in 
those cell lines, in which we previously monitored a reduction of p300 levels after knockdown 
of iASPP (Figure 3.9). We hypothesized that BRMS1 knockdown should recover p300 and 
CBP protein levels in cisplatin-treated cells, at least to some extent. Truly, transient depletion 
of BRMS1 in A375, Lox and MV3 cells partially re-established p300 and CBP protein levels 
in cisplatin-treated cells (Figure 3.14). In line to our previous findings, BRMS1 knockdown did 
not significantly increased p300/ CBP level in untreated cells.  
However, we failed to validate BRMS1-mediated degradation of p300/CBP in all of the 
analysed cell lines. In Mel2a and MeWo cells for example, BRMS1 knockdown did not 
elevate the protein levels of p300 or CBP (data not shown). Concluding, BRMS1-mediates 




















































Figure 3.14. BRMS1 contributes to the proteasomal degradation of p300 and CBP in 
cisplatin-treated melanoma cell lines. 
Lox, MV3 and A375 cells were transiently transfected with 2 different BRMS1 siRNA or a 
scrambled siRNA for the control knockdown. 48 h after transfection, cells were treated with 
20 µM cisplatin, before total cell lysates were prepared. Knockdown efficiency was controlled 
by detection of BRMS1 protein level. Of note BRMS1 level in MV3 cells were not detectable. 
HSC70 staining controlled the equal loading of the samples (n = 1). 
 
3.15. Treatment of MEF cells with the p300 activator CTB can re-establish the protein 
level and function of p300. 
Recently a substance from the cashew nut shell liquid anacardic acid, called CTB, was 
extracted, that was shown to modulate p300 activity (Balasubramanyam, Swaminathan et al. 
2003). CTB is a trifluoromethyl-phenyl-benzamide that binds to p300 and therefore enhances 
the HAT activity of p300. As this substance is commercially available, we tried to re-establish 
p300 levels in low iASPP-expressing cells by treatment of the cells with CTB. As a first 
experiment wild-type mouse embryonic fibroblasts were treated with CTB, cisplatin or a 
combination of CTB and cisplatin (Figure 3.15).  
Indeed, incubation of cells with CTB alone or in combination with cisplatin resulted in a 
strong accumulation of p300 protein (Figure 3.15A). Interestingly, combinational treatment 
with CTB and cisplatin also led to an elevation of iASPP protein levels, though we do not 
have an explanation for this observation. Moreover combinational treatment of cells with CTB 
and cisplatin induced higher level of apoptosis, as shown by the different amounts of cleaved 




























CTB treatment did not only resulted in an accumulation of p300 protein, but also led to a 




Figure 3.15. Treatment of mouse embryonic fibroblasts (MEF) with CTB leads to 
increased p300 levels and a stronger induction of apoptosis. 
Wild-type MEFs were treated with DMSO, 10 µM CTB, 20 µM cisplatin or a combination of 
10 µM CTB and 20 µM cisplatin. (CTB = p300-activating substance) 
A. CTB treatment leads to a stabilisation of p300 protein levels and subsequently to a 
higher rate of apoptosis. For immunoblotting, cells were treated for 16 h with CTB and 
cisplatin before cells were harvested and analysed. Total levels of p300, iASPP and cleaved 
caspase 3 were detected by immunoblotting. Actin staining served as loading control. Of 
note a slight but significant increase of p300 mRNA levels was detected in CTB and cisplatin-
treated MEF cells. 
B. CTB treatment causes a transcriptional up-regulation of pro-apoptotic target genes. 
For RNA extraction cells were harvested after 9 h of incubation with CTB and cisplatin. Gene 






























































































































and real-time PCR. Ct values were normalized to HPRT1. The graphs display the mean log 
ratio as the relative mRNA levels. DMSO-treated samples were set to 1 (mean log ratio). 
 
Moreover, we found a dramatic increase in the gene expression of pro-apoptotic p73 target 
genes, such as Puma and Noxa, in CTB and cisplatin-treated MEF cells. Thus, CTB does not 
only lead to an accumulation of p300 protein but also triggers its activation (Figure 3.15B). 
Following p300 is likely to mediate apoptosis by transcriptional up-regulation of pro-apoptotic 
target genes. 
 
3.16. CTB treatment cannot re-establish the protein levels of p300 in low iASPP 
expressing melanoma cell lines or iASPP knockdown cells.  
Due to these promising results we treated melanoma cell lines with CTB or a combination of 
CTB and cisplatin (Figure 3.16). As exemplarily shown for Lox and MV3 cells (Figure 3.16A), 
CTB treatment, alone or in combination with cisplatin, neither elevated p300 protein levels 
nor did it significantly increase the level of apoptosis induction, as shown by detection of 
PARP1 cleavage. We argue, that melanoma cells seem to have multi-facetted impairments 
in the regulation of p300 expression that cannot be rescued by sole re-activation of p300. In 
line with these findings, treatment of iASPP-depleted HCT116 cells with CTB and cisplatin 
could neither rescue the diminished p300 protein levels, nor overcome the observed defects 
in apoptosis induction (Figure 3.16B). Therefore, we state, that CTB does not represent a 
suitable drug for re-activation of p300 in low iASPP-expressing cells. 
 



























Figure 3.16. CTB treatment cannot re-establish the protein levels of p300 in low iASPP-
expressing cells. 
Lox, MV3 and HCT116 iASPP knockdown cells were treated for 24 h with DMSO, 20 µM 
CTB, 20 µM cisplatin (CDDP) or a combination of 20 µM CTB and 20 µM cisplatin (CDDP). 
(CTB = p300-activating substance, kd = knockdown) 
A. CTB treatment of low iASPP-expressing cells does not recover the protein levels of 
p300. Protein lysates were analysed by immunoblotting. Samples of treated Lox and MV3 
cells were stained for p300 and iASPP. Detection of PARP1 cleavage served as an indicator 
for the level of apoptosis induction. HSC70 staining validated equal loading of all samples. 
B. CTB treatment of iASPP-depleted HCT116 cells can neither rescue the protein 
levels of p300 nor defects in apoptosis induction. HCT116 control and iASPP knockdown 
cells were immunoblotted for p300 and iASPP. Actin staining was performed as a loading 
control. Detection of proteins in CTB and cisplatin-treated HCT116 control and iASPP 
knockdown cells was conducted by Viola Meyer-Pannwitt. To measure the level of apoptosis 
induction, cisplatin-treated or CTB and cisplatin-treated cells were Ethanol-fixed, stained with 
propidium iodide and assessed by FACS analysis. The graph displays the percentage of 
cells in subG1 phase. All samples were analysed using the same gate settings. 
 
3.17. P38 activity influences iASPP-mediated regulation of p300 level. 
Following, we thought of analysing additional signalling pathways that might regulate the 
expression levels of p300. Therefore, we investigated protein levels and activity of known 
p300-modifying proteins (p38, c-abl and Akt), that had been previously described to 
contribute to cisplatin-dependent apoptosis induction (data not shown). We suggest that 
these proteins might be affected by iASPP knockdown, as well. As p300 cannot be directly 
re-activated through application of CTB, modulation or re-establishment of the activity of 
these p300-modifying proteins might result in an elevation of the protein levels and activity of 



















































Phosphorylation level at threonine residue 180 and tyrosine residue 182 of p38 is a marker 
for the activity of p38. Surprisingly, we found decreased phosphorylation level of p38 (p-p38) 
in untreated and cisplatin-treated, iASPP knockdown MV3 cells (Figure 3.17A). Thus, iASPP 
depletion is likely to decrease the activity of p38. Vice versa, transient over-expression of 
iASPP in MV3 cells resulted in increased p38 activity as detected by phosphorylation level of 
p38 again (Figure 3.17B). 
 
Figure 3.17. P38 activity is modified by iASPP expression, thus contributing to 
diminished level of p300 in cisplatin-treated, iASPP knockdown cells. 
MV3 cells






























































A. P38 activity is decreased in MV3 iASPP knockdown cells. IASPP was stably knocked 
down in MV3 cells using shRNA. Control knockdown cells were generated using shRNA 
against the luciferase gene. Cells were treated for 24 h with 20 µM cisplatin prior to protein 
harvest and analysis by immunoblotting. IASPP knockdown efficiency was controlled by 
staining for iASPP. The level of p38 activity was detected by staining for phosphorylated p38 
(p-p38). P38 staining controlled equal levels of the total protein; HSC70 staining served as a 
loading control. 
B. Transient over-expression of iASPP increases p38 activity in MV3 cells. Cells were 
transiently transfected with equal amounts of empty vector or a plasmid encoding for iASPP. 
48 h after transfection, cells were treated for 24 h with 20 µM cisplatin. Total cell lysates were 
prepared and immunoblotting. Protein detection was similar as for A. 
C. Inhibition of p38 in cisplatin-treated iASPP knockdown cells amplifies diminished 
protein levels of p300 and TAp73. Stable HCT116 knockdown cells were treated for 24 h 
with 20 µM cisplatin and DMSO or 20 µM cisplatin and 10 µM SB203580. Total protein 
lysates were prepared and immunoblotted. Detection of phosphorylated HSP27 (P-HSP27) 
controlled effective p38 inhibition. IASPP staining validated the presence of iASPP 
knockdown. HSC70 staining served as a loading control (kd = knockdown; SB203580 = p38-
specific inhibitor, CDDP = cisplatin) 
 
P38 is a MAPK kinase that is known to be activated by phosphorylation in response to DNA 
damage. Following, active p38 can phosphorylate and therefore activate the p53-family to 
induce apoptosis (Bulavin, Saito et al. 1999; Sanchez-Prieto, Sanchez-Arevalo et al. 2002).  
Moreover, it had been recently found, that p38 can phosphorylate p300 at serine 1834, 
thereby contributing to the activation of p300 after DNA damage (Poizat, Puri et al. 2005; 
Wang, Han et al. 2013). Concluding, modulation of p38 activity in iASPP knockdown cells 
might indeed contribute to the observed decrease in p300 level and function. Thus, we tested 
the effects of the p38 inhibitor SB203580 on p300 level in cisplatin-treated HCT116 
knockdown cells (Figure 3.17C).  
Interestingly, inhibition of p38 slightly amplified the effects of iASPP knockdown in cisplatin-
treated cells, thereby further decreasing p300 levels in iASPP knockdowns. We think, that 
this amplification is low but significant, as BRMS1, the ubiquitin ligase which mediates the 
reduction of p300 protein level, decreased in iASPP-depleted, SB203580-treated cells, as 
well. Thus, this decrease of BRMS1 partially compensated for diminished p300 level due to 
the inhibition of p38 in iASPP knockdown cells. 
Moreover we obtained a more pronounced effect of iASPP knockdown on TAp73 level after 
additional treatment with SB203580. This result underscores, that the diminished activity of 
p38 in iASPP knockdown cells is contributing to the diminished protein stability and function 




experiments, we will have to dissect the role of p38 in the functional interaction of iASPP, 
p300 and BRMS1 in more detail.  
Of note, cisplatin treatment of MV3 and Brown cells resulted in an accumulation of a lower 
running, iASPP-specific band (at around 80kDa) (Appendix Sup-6A). We hypothesized that 
in these DNA-damaged cells, iASPP seems to be subjected to caspase-cleavage. 
Accordingly, we could inhibit the generation of an iASPP-cleavage product by simultaneous 
treatment of the cells with cisplatin and the caspase-inhibitor Z-VAD (Appendix Sup-6A). In-
silico analysis of the iASPP protein sequence revealed a cleavage site for caspases at its N-
terminus (Appendix Sup-6B). As the N-terminus of iASPP determines its cytoplasmic 
localization, N-terminal cleavage of iASPP might modulate its sub-cellular localization and 
therefore function. Hence, p300 might be differentially affected by full-length iASPP and N-
terminal truncated iASPP. Concluding, we suggest that iASPP cleavage might represent 
another level of iASPP-mediated regulation of p300 protein level. However, we did not further 
analyse this mechanism. 
 
3.18. Inhibition of MKP-1 can re-establish p300 level and apoptosis in low-iASPP 
expressing cell lines. 
Phosphorylation of p38 is normally regulated by MKP-1 mediated de-phosphorylation 
(Franklin and Kraft 1997). Following, Wang and co-workers reported that MKP-1 is over-
expressed in breast cancer and could be associated with increased chemoresistance (Wang, 
Cheng et al. 2003). Moreover, Kundu and colleagues elucidated an over-expression of MKP-
1 in malignant melanoma tissue. Thus, treatment of melanoma cell lines with the MKP-1 
inhibitor tyrosine phosphatase inhibitor-3 (TPI-3) was able to sensitize melanoma cells for 
chemotherapeutical treatment (Kundu, Fan et al. 2010).  
We showed that modulation of p38 activity after knockdown of iASPP is likely to contribute to 
decreased stability and protein level of p300. Concluding, we hypothesized that inhibition of 
MKP-1 and therefore activation of p38 in low iASPP expressing melanoma cell lines could 
contribute to a re-establishment of p300 levels followed by enhanced chemosensitivity. 
As TPI-3 is not commercially available, we utilized the MKP-1/ MKP-3 dual inhibitor BCI and 
treated various melanoma cell lines with BCI alone or in combination with cisplatin. 
Following, cell lysates were immunoblotted and stained for p300 (Figure 3.18A). 
Interestingly, BCI treatment alone was already sufficient to elevate p300 protein levels in 
MV3 and A375 cells. Furthermore, BCI treatment induced apoptosis in MV3 and A375 cells 




previously BCI-treated melanoma cells validated a 2-6 times higher percentage of apoptotic 
cells as shown by analysis of the subG1 phase. (Figure 3.18B) Therefore, BCI treatment 
alone already constitutes a potent inducer of apoptosis in melanoma cell lines.  
 
 
Figure 3.18. MKP-1 inhibition leads to a re-establishment of p300 level and induction 
of apoptosis.  
A. BCI treatment elevates the level of p300 in MV3 and A375 cells. MV3 and A375 cells 
were treated for 20 h with 10 µM BCI, 10 µM cisplatin or 10 µM BCI and 10 µM cisplatin. 
Total cell lysates were prepared and immunoblotted. Phosphorylated p38 was stained as a 
control for MKP-1 inhibition. Detection of PARP1 cleavage served as a marker for the level of 















































































B. MKP-1 inhibition triggers apoptosis in melanoma cell lines. A375 and MV3 cells were 
treated for 24 h with DMSO or 10 µM BCI. Cells were fixed with Ethanol and subsequently 
stained with propidium iodide. Percentage of dead cells was assessed by FACS analysis and 
quantification of cells in subG1 phase. Same gate settings were applied for all analysed 
samples.  
 
3.19. P300 partially contributes to BCI- and cisplatin treatment-induced apoptosis in 
low iASPP-expressing melanoma cells. 
We hypothesized that BCI treatment mediated apoptosis induction partially derived from re-
establishment of p300 protein levels and activity. Therefore, we investigated the level of 
apoptosis induction after BCI and/or cisplatin treatment of control and p300 knockdown A375 
cells (Figure 3.19).  
 
Figure 3.19. BCI treatment-mediated apoptosis is partially dependent on the re-
stabilisation of p300 protein level. 
P300 was transiently knocked down using specific siRNA. Control knockdown cells were 
transfected in parallel using scrambled siRNA. 48 h post-transfection, cells were treated for 
20 h with 10 µM BCI, 10 µM cisplatin or 10 µM BCI and 10 µM cisplatin. Total cell lysates 
were prepared and immunoblotted. Phosphorylated p38 (p-p38) was stained as a control for 
MKP-1 inhibition. Detection of cleaved PARP1 served as a marker for the level of apoptosis. 
HSC70 staining served as a loading control. (BCI = MKP-1 inhibitor, CDDP = cisplatin)  
 
As shown before, control knockdown cells displayed high levels of apoptosis induction after 
treatment with cisplatin, BCI or a combination of BCI and cisplatin. In contrast, p300 
knockdown cells exhibited only low levels of PARP1 cleavage, especially in single treatments 
DMSO CDDP BCI +BCI
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of cisplatin and BCI. Thus, in A375 cells at least, apoptosis that is induced by BCI and 
cisplatin treatment is partially mediated by p300. Therefore, we claim that the MKP-1 inhibitor 
BCI can induce apoptosis in melanoma cells due to the re-establishment and re-activation of 
p300. It might be that MKP-1 inhibition does not only re-activate p38 but also re-constitute 
iASPP-p300 interaction or alternatively abolishes BRMS1-mediated degradation of p300. 
Future experiments will further investigate the molecular mechanism behind MKP-1 inhibitor-








4.1. iASPP constitutes a new regulator for p300 and TAp73 function by control of p300 
stability. 
One of the molecular causes for cancer development results from functional inactivation of 
tumour suppressor proteins, thereby contributing to chemoresistance and tumour 
progression (Hanahan and Weinberg 2000; Röckmann and Schadendorf 2003). P300 and 
CBP represent two histone acetyltransferase proteins that have been described to participate 
in chemotherapy-induced tumour cell apoptosis (Goodman, 2000; Kitagawa et al, 2008). 
Following, inactivation of p300/CBP-dependent tumour suppressor functions are frequently 
detected in cancer due to mutations or genomic aberrations of both gene loci (Blobel et al, 
2002; Chan et al, 2011; Gayther et al, 2000; Goodman 2000). Molecular basis of their tumour 
suppressor activities partially derives from their co-activator role for the tumour suppressor 
proteins p53 and TAp73 (Avantaggiati, Ogryzko et al. 1997; Zeng, Li et al. 2000; Costanzo, 
Merlo et al. 2002; Iyer, Chin et al. 2004). However, as p300 and CBP can mediate 
acetylation and therefore activation of oncogenic proteins as well, it still remains to be 
revealed, how p300/CBP activity is specifically regulated (Kalkhoven 2004; Bedford and 
Brindle 2012). Most importantly, modulation of these regulatory mechanisms of p300/CBP 
function might provide the basis for new anti-cancer therapy approaches. 
Direct interaction of iASPP, another co-factor of the p53-family, with p300 as well as with its 
downstream target protein TAp73 has been reported before (Robinson, Lu et al. 2008; 
Gillotin and Lu 2011). Functional consequences of these interactions remain elusive though. 
Therefore, we investigated the consequences of iASPP depletion on p300 and TAp73 
expression levels as well as on their function in chemotherapeutic drug-induced apoptosis. 
Most of the previously assigned functions of iASPP revealed an inhibitory role of iASPP on 
the function of its interaction partner. Surprisingly, we found that iASPP enhances the protein 
stability of p300 as well as it promotes the co-activator function of p300 in TAp73-mediated 
apoptosis induction (Figure 3.2 and Figure 3.3). Interestingly, we could only validate the 
interaction between iASPP and p300, as well as the resulting stabilization of p300, after 
cisplatin treatment of the cells (Figure 3.1 and Figure 3.2). Hence, iASPP-p300 complex 
formation in cisplatin-treated cells represents the molecular basis for iASPP-mediated 




as p38-mediated phosphorylation of p300, thus leading to conformational changes of p300 
that enable the interaction with iASPP then (see also section 4.6).  
Subsequently, we also found a new, though unexpected, pro-apoptotic role for iASPP in 
cisplatin- and Etoposide-treated HCT116 cells. In detail, iASPP depletion led to diminished 
recruitment of p300 and TAp73 to pro-apoptotic target gene promoters (Figure 3.4 and 
Figure 3.5). Consequently, we could detect diminished up-regulation of pro-apoptotic p73 
target genes in cisplatin-treated cells (Figure 3.6) as well as impaired induction of cisplatin- 
or Etoposide-mediated apoptosis in tumourigenic cell lines (Figure 3.7 and Appendix Sup-3). 
So far, the inhibitory role of iASPP in p53-mediated apoptosis induction has been implicated 
as its most important function (Bergamaschi, Samuels et al. 2003). However, endogenous 
iASPP expression in a variety of cell lines did not interfere with chemotherapy-induced, p53-
mediated apoptosis (Mantovani, Tocco et al. 2007; Laska, Vogel et al. 2010). Moreover, a 
molecular mechanism has not been revealed yet, to explain how iASPP over-expression 
impairs p53-mediated up-regulation of pro-apoptotic target genes, while p53-dependent 
induction of cell cycle arrest genes remains unaffected (Trigiante and Lu 2006; Espinosa 
2008). Hence, a role for iASPP in promotion or inhibition of apoptosis might be dependent on 
iASPP expression level and the cellular context. 
Furthermore, we could validate that iASPP constitutes a regulator of p300 protein level in 
cisplatin-treated primary MEF cells as well as in melanoma cell lines, thereby validating our 
previous findings (Figure 3.8 and Figure 3.9). Accordingly, the functional interaction of iASPP 
and p300 represents a new aspect in the regulation of p300 level, which seems to account 
for both, primary and tumourigenic cell lines. 
Interestingly, studies in iASPP knockout mice revealed a positive feedback-loop between p63 
and iASPP, that regulates skin homeostasis (Chikh, Matin et al. 2011; Notari, Hu et al. 2011). 
In MEF cells and keratinocytes, iASPP was able to increase the protein levels of ∆Np63 and 
TAp63 without altering the corresponding mRNA levels of total p63 (Chikh, Matin et al. 
2011). Follow-up studies discovered that two microRNAs are regulated by iASPP, thus 
controlling p63 protein levels. Nevertheless, repression of these microRNAs could not fully 
re-establish p63 level in iASPP-depleted keratinocytes. Concluding, these results show that 
iASPP can also enhance the protein stability of p63 in keratinocytes, similar to our findings 
that iASPP mediates increased protein stability of TAp73 in cisplatin-treated cells (Figure 
3.3).  
Moreover, p300 has been implicated as an important regulator of keratinocyte differentiation 




Pickard et al. 2010). Therefore, it can be claimed that the functional interaction of iASPP and 
p300 might also contribute to iASPP-dependent regulation of p63 level in keratinocytes and 
MEF cells. Strikingly, iASPP depletion and the following decrease in p63 expression level 
caused an increase in differentiation as well as inhibition of keratinocyte proliferation (Chikh, 
Matin et al. 2011). In contrast, previous studies described a loss of keratinocyte 
differentiation after knockdown of total p63 protein (Truong, Kretz et al. 2006). Hence, Chikh 
and colleagues suggested that iASPP can also act upstream of p63; and due to our findings, 
it might be speculated that iASPP regulates p63 function through direct control of p300 levels 
in keratinocytes (Chikh, Matin et al. 2011). 
A previous study of the cellular function of the ASPP-family member ASPP1 further 
underscores our findings (Vigneron, Ludwig et al. 2010). It was shown that in untreated as 
well as hydroxyurea-treated HCT116 und U2OS cells, ASPP1 increased the protein stability 
of YAP-1 and TAZ through direct interaction with the YAP-1/TAZ modifying kinase LATS1. 
However, the E3 ubiquitin ligase that mediated these effects remains elusive. Consequently, 
ASPP1 promoted the pro-survival role of nuclear YAP-1/TAZ complexes, thereby inhibiting 
apoptosis and senescence of the cells (Vigneron, Ludwig et al. 2010; Vigneron and Vousden 
2012). Of note, this function of ASPP1 depended on its sub-cellular localization. Cytoplasmic 
ASPP1 led to YAP-1/TAZ-dependent inhibition of apoptosis, whereas nuclear localization of 
ASPP1 promoted its previously described co-activator role of p53-mediated apoptosis 
induction. Concluding, the sub-cellular localization of iASPP might influence the regulation of 
p300 and TAp73 function in cisplatin-mediated apoptosis, as well. 
 
4.2. BRMS1 is required for p300 degradation in iASPP knockdown cells. 
As proteasomal degradation of p300 is mediated by specific E3 ubiquitin ligases, and iASPP 
knockdown leads to accelerated degradation of p300, we investigated the responsible E3 
ubiquitin ligase mediating these effects. We found that BRMS1, a recently identified E3 
ubiquitin ligase for p300 in lung cancer cells (Liu, Mayo et al. 2013), could degrade p300 and 
CBP in HCT116 cells (Figure 3.10). Further analysis of BRMS1 and iASPP double 
knockdown cells elucidated, that BRMS1 expression was required for accelerated 
degradation of p300 and CBP in iASPP-depleted, cisplatin-treated cells (Figure 3.11). 
Therefore, iASPP is likely to inhibit BRMS1-mediated degradation of p300 and CBP in 
cisplatin-treated HCT116 cells. 
We hypothesize, that iASPP-p300 interaction masks the interaction site for BRMS1, that is 




and p300 interaction is prevented and p300 protein is not degraded anymore. However, we 
still have to prove this hypothesis by investigating BRMS1 and p300 interaction in the 
presence and absence of iASPP and cisplatin treatment. This will be done in future co-
immunoprecipitations. Figure 4.1 summarizes our present working hypothesis.  
 
Figure 4.1. iASPP inhibits BRMS1-mediated degradation of p300. 
A. BRMS1 is required for p300 degradation in untreated cells. In normal proliferating 
cells, BRMS1 can interact with p300 (and CBP) followed by the proteasomal degradation of 
the proteins.  
B. iASPP-p300 interaction contributes to TAp73-mediated apoptosis induction after 
DNA damage. After cisplatin treatment or severe DNA damage in general, iASPP starts to 
bind to p300, probably due to post-translational modifications of p300 (for example 
phosphorylation by p38). Hence, BRMS1 dissociates from p300 protein and subsequently 
enhances its protein stability. Next, p300 becomes associated with TAp73, which leads to the 
acetylation and therefore activation of TAp73 protein. Subsequently, TAp73-mediated 
transcription of pro-apoptotic p73 target genes such as puma or pig3 is induced, ultimately 
leading to apoptosis induction. In this hypothesis, iASPP contributes to cisplatin-induced 































4.3. Sub-cellular localization of iASPP, BRMS1 and p300 can determine their functional 
interaction. 
Most studies showed a proteasomal degradation of p300 and CBP protein in the nucleus 
(Poizat, Sartorelli et al. 2000; Poizat, Puri et al. 2005; St-Germain, Chen et al. 2008). 
Moreover, as BRMS1 is mostly described as a nuclear protein as well (Hurst, Xie et al. 
2013), BRMS1-mediated degradation of p300/CBP could take place in the nucleus as well 
(Figure 4.2A). In contrast, iASPP is likely to be predominantly localized in the cytoplasm of 
the cells, as the N-terminus of iASPP leads to complete cytoplasmic localization of full-length 
iASPP (Slee, Gillotin et al. 2004). Therefore, direct interaction of iASPP and p300 in cisplatin-
treated cells might not fully explain, how iASPP can prevent the nuclear, BRMS1-mediated 
degradation of p300.  
 
Figure 4.2. Subcellular localization as a possible determinant for the functional 
interaction of iASPP and p300. 
A. BRMS1 mediates the degradation of p300 in the nucleus. In untreated cells, p300 is 
degraded by BRMS1 in the nucleus. IASPP cannot inhibit this degradation as it localizes to 
the cytoplasm. 
B. iASPP enhances the protein stability of p300 by cytoplasmic sequestration of 

























cytoplasmic sequestration though interaction with iASPP. Thus, p300 accumulates in the 
nucleus, probably due to its interaction with N-terminal, caspase-cleaved iASPP, and 
subsequently mediates the activation of TAp73 by acetylation. Finally, cisplatin treatment 
triggers p300-dependent apoptosis. 
 
Nevertheless, a direct interaction of BRMS1 and iASPP in cisplatin-treated cells represents 
an alternative hypothesis that can explain iASPP-mediated inhibition of p300 degradation. 
Therefore, an interaction between cytoplasmic iASPP and BRMS1 in cisplatin-treated cells 
could induce a cytoplasmic sequestration of BRMS1, which then anticipates BRMS1-
mediated, nuclear degradation of p300 (Figure 4.2B). Hence, we will have to elucidate if 
iASPP can directly interact with BRMS1 and if this interaction takes place in the nucleus or 
cytoplasm of the cell. Concluding, if cisplatin treatment does not alter the cytoplasmic 
localization of iASPP, we could explain the effects of iASPP knockdown on p300 protein 
stability by the fact that iASPP regulates the sub-cellular localization of BRMS1.  
To test this, we could perform localization studies of BRMS1 in cisplatin-treated control and 
iASPP knockdown cells by applying immunofluorescence staining. However, we cannot 
exclude a BRMS1-mediated cytoplasmic degradation of p300 and CBP at the moment. 
Therefore, we will also have to perform co-immunoprecipitation experiments of BRMS1, p300 
and iASPP using purified nuclear and cytoplasmic extracts of cisplatin-treated cells as input. 
This experiment will not only determine the localization of iASPP-p300 and BRMS1-p300 
complexes, but also validate or reject our current working hypothesis (Figure 4.1). Figure 4.2 
summarizes, how iASPP-mediated regulation of the sub-cellular localization of BRMS1 can 
control p300 level. 
Interestingly, it has been shown before that the sub-cellular localization of BRMS1 modifies 
its function (Slipicevic, Holm et al. 2012). In melanoma, they discovered that cytoplasmic 
localization of BRMS1 was associated with disease-free survival of patients, whereas nuclear 
localization of BRMS1 correlated with metastasis and poor survival rate of the patients. 
Accordingly, we found that BRMS1 mediates the proteasomal degradation of p300 in some 
but not all cisplatin-treated melanoma cell lines (Figure 3.14). Therefore, iASPP-mediated 
cytoplasmic localization of BRMS1 could lead to the promotion of the anti-metastatic 
functions of BRMS1 that are likely to be independent of p300 and CBP. Hence, in low 
iASPP-expressing melanoma cells, BRMS1 could become localized to the nucleus, thereby 
probably mediating the proteasomal degradation of p300/CBP. Consequently, nuclear 
BRMS1 could be responsible for the frequently detected low levels of p300 and CBP in 





However, another observation might also argue against an iASPP-mediated regulation of 
BRMS1 localization. In some of the analysed, cisplatin-treated melanoma cell lines we 
detected N-terminal truncated iASPP instead of the full-length protein (Appendix Sup-6A). 
The N-terminal truncation resulted from caspase cleavage of iASPP in the process of 
apoptosis induction (Appendix Sup-6A and Sup-6B). As the N-terminus of iASPP (consisting 
of amino acids 1-478) determines the cytoplasmic localization of full-length iASPP protein 
(Slee, Gillotin et al. 2004), N-terminal cleavage of iASPP at amino acid 296 might cut off a 
putative nuclear export signal. Thus, N-terminal truncated iASPP is getting localized to the 
nucleus. Similar results were obtained by Zhang and colleagues, who found a N-terminal 
truncated isoform of iASPP, called iASPP-SV, that predominantly localized to the nucleus 
(Zhang, Diao et al. 2007). Following, N-terminal cleavage of iASPP might induce its 
translocalization to the nucleus of cisplatin-treated cells, which then permits a complex 
formation between iASPP and nuclear p300 (Figure 4.2). Hence, nuclear localization of N-
terminal cleaved iASPP would exclude an iASPP-mediated sequestration of BRMS1 in the 
cytoplasm of cisplatin-treated cells. We did not immunoprecipitate iASPP from p300-protein 
complexes (we only immunoprecipitated iASPP and detected co-bound p300; Figure 3.1). 
Therefore we cannot exclude that N-terminal truncated iASPP is binding to p300 instead of 
full-length iASPP. We will have to test this by further co-immunoprecipitation studies in 
cisplatin-treated melanoma cell lines, in which we will precipitate p300 and subsequently 
detect co-bound full length or N-terminal truncated iASPP by immunoblotting. 
Nevertheless, sub-cellular localization of BRMS1 in melanoma cell lines has to be taken into 
consideration when describing BRMS1-mediated degradation of p300. We already showed 
that BRMS1 mediates the degradation of p300 and CBP in some of the analysed, cisplatin-
treated melanoma cell lines (Figure 3.14). However, differential localization of BRMS1 might 
imply that not all melanoma cell lines will display BRMS1-mediated degradation of p300/CBP 
after cisplatin treatment of the cells. Concluding, it will be interesting to reveal if there is a 
correlation between BRMS1 localization and total protein level of iASPP. Therefore 
localization of p300, BRMS1 and iASPP in untreated and cisplatin-treated HCT116 and 
melanoma cell lines needs to be investigated in future experiments.  
 
4.4. The pro- and anti-apoptotic function of iASPP depends on its interaction partners 
and external stimuli. 
We did not find a direct interaction of TAp73 with iASPP in untreated or cisplatin-treated 
HCT116 cells. However, p300 becomes associated with TAp73 and iASPP in cisplatin-




between TAp73 and iASPP. Moreover we showed reduced protein stability of TAp73 in 
iASPP-depleted, cisplatin-treated HCT116 cells, similar to the effects of iASPP depletion on 
p300 level (Figure 3.2). As a consequence, we could show that iASPP depletion results in 
diminished recruitment of TAp73 to the chromatin, followed by overlapping loss of p300 and 
TAp73 binding to genomic p73 target gene promoters (Figure 3.3 and Figure 3.4). Therefore, 
we conclude that these effects on TAp73 function are likely to be the result of impaired p300 
function in iASPP-depleted cells. 
However, it has to be noted, that other reports depicted an inhibitory role for iASPP with 
respect to TAp73 function (Bell, Dufes et al. 2007; Cai, Qiu et al. 2012). Bell and colleagues 
showed that a fragment derived from the C-terminus of p53, called 37AA, can interfere with 
iASPP-p73 complex formation in the osteosarcoma cell line SaOS-2. Consequently, 37AA 
partially promoted TAp73-dependent apoptosis induction that is likely to be mediated through 
a transcriptionally independent, mitochondrial pathway (Bell et al, 2007). Though different 
from our results, these findings do not necessarily have to contradict ours, as we suggest a 
pro-apoptotic role for iASPP in chemotherapeutic drug-induced, TAp73-mediated apoptosis. 
Previous publications failed to analyse the effects of iASPP expression after chemotherapy 
leading to active TAp73 (Bell, Dufes et al. 2007; Cai, Qiu et al. 2012). Therefore, iASPP 
might inhibit TAp73 function in untreated cells; though after DNA damage, we found that 
iASPP helps to activate the pro-apoptotic function of TAp73. 
 
4.5. iASPP specifically regulates the p300-specific function towards TAp73, while p53 
remains unaffected. 
Importantly, p300 can also function as a co-activator of p53 (Grossman 2001). Therefore, we 
also analysed p53 function in respect to its chromatin localization and DNA-binding affinities 
in iASPP-depleted, cisplatin-treated HCT116 cells (Figure 3.3). Surprisingly, p53 seemed to 
remain unaffected by the functional impairment of p300 that results from iASPP knockdown. 
This result is unexpected as it has been shown before that cisplatin treatment leads to p300-
mediated acetylation of p53 at lysine residue 382 (Gu and Roeder 1997; Sakaguchi, Herrera 
et al. 1998). Consequently, cisplatin-induced acetylation of p53 promotes an increase in 
p53`s protein stability and DNA-binding affinity (Luo, Li et al. 2004). Thus, impaired p300 
function should also affect the DNA-binding properties of p53. 
The molecular basis of this differential, iASPP-mediated effect on p53-family function might 
consist in the different binding sites that mediate the interaction of p300 with TAp73 and p53. 




p300 to TAp73 protein is mediated by its central located CH1 and CH2 regions (Zeng, Li et 
al. 2000; Burge, Teufel et al. 2009; Chen and Li 2011). Thus, iASPP may impede with only 
one of these interactions. 
Moreover, p53-p300 interaction might interfere with BRMS1-mediated proteasomal 
degradation of p300, as BRMS1 binds to the C-terminal located IBID domain of p300, as well 
(Liu, Mayo et al. 2013). Concluding, p53-associated p300 is likely to be fully protected from 
BRMS1-dependent degradation, thus making an iASPP-dependent regulation of BRMS1-
mediated degradation of p300 dispensable. In contrast, TAp73-associated p300 can be 
theoretically degraded by BRMS1. Therefore, iASPP-p300 interaction is likely to be 
indispensable for effective activation of TAp73 by p300.  
The structure of iASPP comprises a SH3 domain that is located at the C-terminus of the 
protein. SH3 domains preferentially recognize proline-rich regions of target proteins, hence 
leading to the interaction of a SH3 domain containing protein with a proline-rich region 
containing target protein (Alexandropoulos, Cheng et al. 1995; Kay, Williamson et al. 2000). 
Therefore, although binding sites of an iASPP-p300 interaction are not discovered yet, 
iASPP is likely to bind to the C-terminal located proline-rich region of p300. As a 
consequence, iASPP-p300 interaction will exclude simultaneously binding of BRMS1 or p53 
to p300 protein. This hypothesis would not only explain why iASPP depletion leads to 
impaired TAp73 function while p53 remains unaffected, it might also underscore our working 
hypothesis that BRMS1-p300 and iASPP-p300 interaction are mutually exclusive.  
Of note, we cannot exclude that iASPP knockdown affects p53 function in other cell lines or 
after different stimuli as well, as we do not know yet which domains of p300 are binding to 
iASPP. Therefore, we will have to over-express different p300 fragments and co-
immunoprecipitate these fragments with iASPP. Moreover, we will also have to detect 
acetylated p53 level, in different chemotherapeutic drug-treated cell lines, in the presence or 
absence of iASPP. Thus, we will elucidate if iASPP knockdown also affects the co-activator 
role of p300 in p53-mediated apoptosis in some cell lines. 
 
4.6. DNA damage constitutes a pre-requisite for functional interaction of p300, TAp73 
and iASPP. 
We showed that iASPP can only regulate the function of p300 and TAp73 after DNA damage 
(Figure 3.1 and Figure 3.2). We propose that the complex formation between iASPP and 
p300 as well as the one between p300 and TAp73 in cisplatin-treated cells represents a pre-




activate enzymes that cause post-translational modifications of p300 or iASPP. Hence, this 
post-translational modification might represent a pre-requisite for interaction of iASPP and 
p300, either through conformational changes of the proteins or by recruitment of additional 
co-factors to iASPP-p300 complexes. 
P38 constitutes one candidate protein that has been shown before to post-translationally 
modify p300 after DNA damage (Poizat, Puri et al. 2005; Ogiwara and Kohno 2012). Ogiwara 
and colleagues revealed that cisplatin treatment induced p38- and Akt-mediated 
phosphorylation of p300 at serine residue 1834, thus contributing to the activation of the 
protein (Ogiwara and Kohno 2012). Moreover, others have shown that p38 constitutes a 
protein that is getting activated by cisplatin-treatment, thus contributing to cisplatin-induced 
apoptosis induction (Sanchez-Prieto, Sanchez-Arevalo et al. 2002).  
Interestingly, iASPP knockdown only affected p300 and TAp73 function after cisplatin 
treatment. Therefore, and also due to the fact that p38 can modify p300 function, we 
investigated if p38 contributes to the functional interaction of iASPP and p300. 
Our preliminary data indicate, that over-expression of iASPP increases the level of 
phosphorylated p38 (Figure 3.17A), whereas iASPP knockdown decreases the activity of p38 
in melanoma cells (Figure 3.17B). Thus, iASPP is likely to regulate the activity of p38. 
Following, additional treatment of iASPP-depleted, cisplatin-treated HCT116 cells with the 
p38 inhibitor SB203580 seems to intensify the diminished protein level of p300 (Figure 
3.17C). In contrast, treatment with BCI, an inhibitor of the p38 dephosphatase MKP-1, could 
partially re-establish p300 protein level in low iASPP expressing melanoma cell lines. 
Concluding, we suggest that p38-mediated phosphorylation of p300 might contribute to the 
functional interaction of iASPP and p300. Additionally, it might also impede BRMS1-mediated 
degradation of p300. Following, we will have to analyse iASPP-p300 complex formation, in 
the presence or absence of p38 inhibitor. Moreover, BRMS1 knockdown in BCI-treated cells 
will elucidate if p38-mediated phosphorylation of p300 can modify BRMS1-p300 interaction. If 
so, it will be possible to equalize the p300 protein level in untreated cells to the protein level 
of p300 in BCI-treated cells by additional knockdown of BRMS1. 
In line with our hypothesis, researchers detected an over-expression of MKP-1 in some 
melanoma cells. Hence, MKP-1 over-expressing melanoma cell lines displayed increased 
chemoresistance which was abolished by treatment of the cells with the MKP-1 inhibitor TPI-
3 (Kundu, Fan et al. 2010). Thus, over-expression of MKP-1 or down-regulation of iASPP 




inactivation of p300. Consequently, we will have to test if the expression of iASPP and MKP-
1 activity is inversely correlating in melanoma tissue or not. 
However, we should also keep in mind that other post-translational modifications of p300 
might determine the functional interaction of p300 and iASPP. For example, it has been 
shown before, that ERK1 and ERK2 can phosphorylate p300. Moreover, the MKP-1 inhibitor 
BCI can inhibit the activity of the ERK1 and ERK2 dephosphatase MKP-3, as well (Molina, 
Vogt et al. 2009). Therefore, re-establishment of p300 level by BCI treatment can also derive 
from inhibition of MKP-3 rather than from inhibition of MKP-1 (Figure 3.18). Accordingly, 
MKP-3 over-expression has been detected in melanoma as well (Li et al, 2012). Following, 
we will have to dissect the molecular mechanism underlying BCI treatment-mediated re-
establishment of p300 level in melanoma cells. Knockdown experiments of p38, ERK1 or 
ERK2, followed by BCI-treatment of melanoma cells, will reveal if re-establishment of p300 
level depends on re-activation of p38, ERK1 or ERK2. 
 
4.7. Malignant melanoma are characterized by down-regulated iASPP expression. 
As iASPP enhances the co-activator function of p300 in cisplatin-induced, TAp73-mediated 
apoptosis induction, we concluded, that there have to exist tumours that display a down-
regulation in iASPP expression. As a consequence, low expression of iASPP could lead to 
functional inactivation of p300 and therefore possibly to chemoresistance and 
tumourigenesis as well. We re-analysed multiple gene expression studies of various cancer 
types that have been published before. Hence, statistical evaluation of 3 independent gene 
expression studies displayed a significant down-regulation of iASPP mRNA levels in 
malignant melanoma compared to normal skin tissue and benign nevi (Figure 3.12 and 
Appendix Sup-5). Therefore, our findings describe for the first time a cancer type that is 
associated with decreased iASPP expression, whereas other researchers have only detected 
an over-expression of iASPP in various tumour types (Zhang, Wang et al. 2005; Jiang, Siu et 
al. 2011; Li, Wang et al. 2011; Cao, Huang et al. 2013). Of note, these studies elucidated an 
increase of iASPP on protein level rather than on mRNA level (Cao, Huang et al. 2013). 
Another study failed to show significant differences in iASPP mRNA level of cancer tissue 
compared to normal tissue samples (Li, Wang et al. 2011).  
Protein level and mRNA level do not necessarily have to correlate. In order to validate our 
findings of down-regulated iASPP mRNA levels in malignant melanoma, we analysed the 
protein levels of iASPP in several untreated and cisplatin-treated melanoma cell lines (Figure 




treated melanoma cells, compared to other, tumourigenic cell lines. However, we lack a 
comparative analysis with melanocytes, that represent the origin cell type from which 
melanoma evolve (Elder 1999). Therefore it is difficult to conclude if iASPP protein levels are 
decreased in the process of melanocyte transformation or not. Nevertheless, analysis of 
iASPP protein level in melanoma cell lines compared to other cancer cell lines could validate 
an overall down-regulation of iASPP at protein level. 
Of note, Lu and colleagues reported that melanoma tissue and melanoma cell lines are 
characterized by high expression of nuclear cyclin B1/CDK1-phosphorylated iASPP (Lu, 
Breyssens et al. 2013). This hyperphosphorylated form could be detected as a slow-
migrating isoform of iASPP in denaturating polyacrylamide gels. Following, they stated that 
cyclin B1/CDK1-phosphorylated iASPP contributes to the frequently observed inactivation of 
p53 in melanoma, thus promoting chemoresistance (Avery-Kiejda, Bowden et al. 2011). So 
far, we could not detect a slower migrating isoform of iASPP in the melanoma cell lines we 
analysed (data not shown). However, their findings do not necessarily have to contradict our 
results. It might be, that iASPP is down-regulated in the majority of melanoma tumours. 
However those melanoma that still display high iASPP expression might harbour constitutive 
expression of cyclin B1/CDK1 instead. Constitutively active cyclin B1/CDK1 might then lead 
to a change in iASPP function, which would also imply a loss of its co-activator function for 
p300. Accordingly, over-expression of cyclin B1/CDK1 can be frequently detected in 
melanoma (Georgieva, Sinha et al. 2001; Stefanaki, Stefanaki et al. 2007; Avery-Kiejda, 
Bowden et al. 2011). On the other hand, we suggest that low iASPP expressing melanoma 
should have normal cyclin B1/CDK1 activity. However, we have not yet analysed this 
possible correlation of iASPP expression level and cyclin B1/CDK1 activity. 
 
4.8. Does cisplatin treatment of melanoma cell lines constitute a model for analysing 
chemoresistance in melanoma? 
We suggest that low iASPP expression in melanoma contributes to a functional inactivation 
of p300 and therefore promotion of chemoresistance. Following, we could detect in some of 
the low iASPP-expressing melanoma cell lines down-regulated p300 protein level after 
treatment of the cells with cisplatin (Figure 3.13B). Nevertheless, protein level of p300 did not 
correlate with the overall induction of cisplatin-induced apoptosis as shown by detection of 
PARP1 cleavage (Figure 3.13B). Interestingly, clinical studies revealed that in-vivo, 
melanoma have a low response rate (~10%) to cisplatin (Bhatia, Tykodi et al. 2009). 
Therefore, cisplatin is only used in combination with other chemotherapeutic drugs for 




detect strong cisplatin-induced apoptosis in most of the melanoma cell lines, it might be that 
2D cultures of melanoma cell lines do not correctly reflect the in-vivo situation of malignant 
melanoma. Therefore, we should investigate the function of iASPP and p300 in the 
development of chemoresistance in 3D cell culture or in xenograft mouse models using 
stable iASPP or p300 knockdown melanoma cell lines. These experiments would reflect the 
situation in melanoma patients more realistically. 
Furthermore, we suggest to exchange cisplatin with dacarbazine, one of the few FDA-
approved chemotherapeutical drugs for treatment of malignant melanoma (Serrone and 
Hersey 1999; Finn, Markovic et al. 2012). Dacarbazine represents an alkylating agent that 
triggers DNA damage by adding an alkyl group to DNA, hence inducing pro-apoptotic 
pathways that can be compared to those that are induced by cisplatin treatment 
(Bergamaschi, Gasco et al. 2003; Marchesini, Bono et al. 2007; Sanada, Hidaka et al. 2007). 
Therefore, it will be interesting to investigate the impact of iASPP, p300 and BRMS1 
expression on dacarbazine-induced apoptosis in melanoma cell lines. It is not clear though, if 
dacarbazine can be applied in cell culture experiments or if it needs to be metabolised in the 
liver to become activated (Reid, Kuffel et al. 1999; Lev, Onn et al. 2004).  
 
4.9. Functional inactivation of p300 represents a possible mechanism that contributes 
to melanoma progression and metastatic transformation. 
Our preliminary data of p300 knockdown experiments in the melanoma cell line A375 
suggest that p300 has a crucial role in chemotherapy-induced apoptosis of melanoma cell 
lines (Figure 3.19). This might be explained by the co-activator role of p300 in p53-, or 
TAp73-mediated apoptosis after DNA damage (Costanzo, Merlo et al. 2002; Ianari, Gallo et 
al. 2004; Iyer, Chin et al. 2004). As TAp73 expression is mostly not detectable in melanoma, 
functional inactivation of p300 might contribute to the frequently observed inactivation of p53 
then (Tsao, Zhang et al. 1999; Bardeesy, Bastian et al. 2001; Alla, Engelmann et al. 2010).  
In line, some researchers discovered that functional inactivation of p53 in integrin-αV over-
expressing melanoma cells is caused by the integrin-dependent functional inactivation of 
p300 (Bao and Stromblad 2004). They showed that integrin-αV prohibited p300-mediated 
acetylation of p53 at lysine residue 382, due to an integrin-dependent proteasomal 
degradation of the p300 protein. Accordingly, over-expression of integrin-αV can be 
frequently detected in melanoma and correlates with tumour growth, cell survival, cell 





Investigation of the proto-oncogene DEK in melanoma further underscores a possible role for 
p300 in determining the chemosensitivity of malignant melanoma. DEK constitutes a 
chromatin-remodelling factor that has been shown to be frequently over-expressed in 
melanoma due to chromosome 6p amplification (Santos, Zielenska et al. 2007; Khodadoust, 
Verhaegen et al. 2009). Interestingly, DEK over-expression leads to inhibition of DNA 
damage-induced apoptosis in melanoma, and this partially derives from DEK-mediated 
inhibition of the HAT activity of p300 (Ko, Lee et al. 2006; Wise-Draper, Allen et al. 2006; 
Khodadoust, Verhaegen et al. 2009).  
In summary, integrin-αV as well as DEK over-expression can cause a functional inactivation 
of p300 in melanoma. As a consequence, the tumour suppressive function of p300 is 
impaired, thus contributing to p53 inactivation-dependent chemoresistance. Both studies 
validate p300 as a possible re-activation target in melanoma therapy. It might be worth to 
investigate if integrin-αV or DEK over-expression is present in those melanoma that retain 
normal iASPP level. Accordingly, low iASPP expression in melanoma could then correlate 
with moderate integrin-αV and DEK expression. Concluding, this correlation analysis would 
underscore our hypothesis that low iASPP expression might be a cause of functional 
inactivation of p300 in melanoma.  
 
4.10. Treatment of low iASPP expressing melanoma with the p300 activator CTB fails 
to re-establish p300 level and function. 
Recently, small molecules have been extracted from natural substances that specifically 
modulate the HAT activity of p300 and CBP (Balasubramanyam, Swaminathan et al. 2003). 
CTB [N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxybenzamide] is a p300-activating 
substance that had been extracted from anacardic acid. Dissection of its binding properties 
showed that CTB enhances the HAT activity of p300 through conformational changes of the 
protein (Mantelingu, Kishore et al. 2007; Devipriya, Parameswari et al. 2010).  
We investigated, if we could increase or re-establish p300 function in different cell lines by 
applying CTB alone or in combination with cisplatin. CTB treatment of MEF cells resulted in 
elevated expression of p300 as well as increased induction of cisplatin-mediated apoptosis 
(Figure 3.15). This finding motivated us to try CTB treatment in melanoma cells. However, 
CTB alone in combination with cisplatin could not re-establish p300 levels in low iASPP-
expressing melanoma cells or iASPP knockdown HCT116 cells (Figure 3.16). One reason for 
this failure might derive from impaired expression of iASPP. We could show that iASPP does 




contributes to both the regulation of p300 level and function, CTB-mediated re-activation of 
p300 will not compensate for diminished p38 activity.  
Moreover, as CTB was shown to bind to the HAT domain rather than to the C-terminus of 
p300, we suggest that CTB treatment cannot abrogate BRMS1-mediated degradation of 
p300 in cisplatin-treated, iASPP knockdown cells. Following, CTB will bind p300 and partially 
activate the HAT domain, but it will fail to increase p300 expression on protein level. 
Concluding, we suggest that CTB treatment of tumourigenic cell lines alone or in combination 
with other drugs does not constitute a reasonable therapeutically approach for re-activation 
of p300.  
 
4.11. iASPP expression levels in melanocytes and melanoma may regulate the specific 
function of p300 in melanoma. 
The function of p300 in melanocytes and melanoma development has not been intensively 
investigated. However, knockdown of p300 in melanocytes and melanoma cell lines resulted 
in cellular senescence due to inhibition of Cyclin E expression (Bandyopadhyay, Okan et al. 
2002). Moreover, chemical inhibition of its HAT activity in melanoma cell lines resulted in 
both cell growth arrest and cellular senescence (Yan, Eller et al. 2013). Cellular senescence 
has been implicated as a tumour suppressive function of cells, thus abrogating uncontrolled 
proliferation of cells. Therefore, loss of p300 might trigger oncogene-driven cellular 
senescence in melanocytes and nevi. As a consequence, senescence prevents melanocyte 
transformation and subsequently the development of melanoma (Michaloglou, Vredeveld et 
al. 2005). In line with this argumentation, p300 might represent a proto-oncogene in 
melanocytes, and functional inactivation of p300 might contribute to the suppression of 
melanocyte transformation. 
However, cellular senescence also implicates a low rate of apoptosis induction after 
treatment of the cells with chemotherapeutical drugs. Due to their quiescent status, 
senescent cells tolerate chemotherapeutical-drug induced DNA-damage, thereby failing to 
induce apoptosis after chemotherapy treatment (Achuthan, Santhoshkumar et al. 2011). 
Consequently, senescent cells might survive chemotherapy, followed by re-establishment of 
tumour cell proliferation and re-occurrence of tumours at a later time point. Therefore, loss of 
p300 function and following cellular senescence might promote chemoresistance and 
formation of metastasis in melanoma. Concluding, p300 might also be proclaimed as a 




Concluding, this possible proto-oncogenic and tumour suppressive role of p300 is likely to be 
cell context-dependent. P300-related co-factors might influence these functions of p300, and 
we suggest that iASPP represents such a regulatory switch for p300 function. IASPP could 
promote the tumour suppressive role of p300 in melanoma whereas it could suppress the 
proto-oncogenic functions of p300 in melanocytes and some subtypes of melanoma.  
Summing up our findings, we showed that iASPP is regulating the protein stability and 
function of p300. Consequently, iASPP can promote TAp73 activation as well as TAp73`s 
pro-apoptotic role in cisplatin-induced apoptosis by regulation of p300 protein level. 
Moreover, iASPP expression is down-regulated in melanoma and might constitute a 
biomarker for the chemosensitivity of tumours. It still needs to be revealed if re-activation of 
p300 might be a new therapeutical approach for treatment of malignant melanoma, that 
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Appendix Sup-1. iASPP knockdown leads to an overlapping loss of p73 and p300  target site binding in 
cisplatin-treated HCT116 cells.
For chromatin immunoprecipitation HCT116 knockdown cells were treated for 8 h with 20 µM cisplatin prior to
chromatin harvest. Chromatin immunoprecipitations were performed using a p73- as well as p300-specific
antibody. For control, an IgG reaction was performed in parallel. The data is represented as the % of input sample



















Appendix Sup-2. iASPP and p73 knockdown leads diminished induction of pro-apoptotic p73 target genes 
in cisplatin-treated HCT116 cells.
For RNA extraction cells were treated for 12 h with 20 µM cisplatin.
A. Gene expression of additional p73 target genes in cisplatin-treated iASPP knockdown cells.
For details see Figure 3.6.
B. P73 knockdown leads to a similar reduction in the mRNA levels of p73 target genes.
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Appendix Figure Sup-3. iASPP and p73 knockdown leads diminished induction of pro-apoptotic p73 target 
genes and apoptosis in Etoposide-treated HCT116 cells.
IASPP and p73 knockdown cells were generated by pooling 3 different shRNA constructs for iASPP or p73
knockdown. Control knockdown was performed using shRNA for the luciferase gene. For RNA extraction and cell
cycle analysis, cells were treated for 24 h with 30 µM Etoposide.
A. Gene expression analysis of p73 target genes in Etoposide-treated iASPPand p73 knockdown cells.
Bax, noxa, puma and fas mRNa level were analysied using gene-specific primer. HPRT1 served as a reference
gene for normalization of the Ct values. Depicted are the relative mRNA level as the mean log ratio.
B. IASPP and p73 knockdown contributes to the apoptosis induction after Etoposide treatment.
Etoposide-treated control, iASPP and p73 knockdown cells were fixed with Ethanol and stained with Propidium
iodied. Cell cycle profiles were generated by FACS analysis. For quantification of the % of dead cells, subG1 phase
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Appendix Sup-4. BRMS1 knockdown modifies the gene expression of a subset of p300/ p73 target genes.
BRMS1 was transiently depleted using two different siRNAs and a scrambled siRNA as a control. 36 h after
transfection, cells were treated for 8 h with 20 µM cisplatin. After RNA extraction and cDNA synthesis, the gene
expression of various p73/ p300 target genes was analysed. Represented is puma and fas as p300 and p73 co-
regulated, pro-apoptotic target genes. Rad51 and cyclin E represents genes that are transcriptionally regulated by








Appendix Sup-5. Down-regulation of iASPP mRNA level in two additional gene expression
studies of malignant melanoma.
The figure displays the gene expression level of iASPP in multiple malignant melanoma samples
compared to normal skin tissue and benign nevus samples of two independently performed
microarray analysis (Riker et al, 2008; Haqq et al, 2005). These studies underscore the previously
evaluated study of Talantov and colleagues; Figure 3.12), thereby confirming down-regulation of
iASPP in the process of melanoma development.
Appendix Sup-5
Gene expression of iASPP in normal skin, 
benign nevus and melanoma (Haqq et al, 2005)
Gene expression of iASPP in normal skin
and cutaneous melanoma (Riker et al, 2008)
Normal skin Melanoma






































Appendix-Sup-6. IASPP is cleaved by caspases in some melanoma cell lines.
A. iASPP is subjected to caspase-cleavage in MV3 and Brown cells.
MV3 and Brown cells were treated for 24 h with 20 µM cisplatin. To proof cleavage of iASPP by caspases, cells
were treated in parallel for 24 h with 40 µM Z-Vad or 40 µM Z-Vad and 20 µM cisplatin. Moreover cells were treated
for 4 h with 10 µM MG132 or 10 µM MG132 and 20 µM cisplatin to visualize proteasomal degradation processes of
p300 and iASPP. Protein lysates were prepared and immunoblotted. Detection of cleaved caspase 3 served as a
control for effective inhibition of caspases by Z-Vad. Actin staining controls equal loading of the samples. (CDDP =
cisplatin, zVAD = caspase inhibitor, MG132 = proteasome inhibitor)
B. In-silico analysis of the iASPP sequence detects a N-terminal caspase cleavage site.
The iASPP protein sequence was analysed with the CutDB program
(http://cutdb.burnham.org/relation/show/21917). A caspase-cleavage site was detected at position 295 (sequence:
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